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ABSTRACT
The prevalences of obesity (body mass index  30 kg/m2) and its concomitant comorbidities, 
metabolic syndrome, sleep related breathing disorders and other diseases are increasing 
worldwide and in Norway. A moderate weight reduction through dietary change and 
increased physical activity is recommended to decrease risk. Pharmacological therapy is an 
adjunct to behaviour change. To guide clinical treatment, a better understanding of 
measurement errors in the reported diet and physical activity of patients with obesity-
associated comorbidities and the effects of dietary interventions in this group including anti-
obesity drug is needed.  
This thesis is based on three cross-sectional studies and two randomized, controlled 
trials. In a population of obese subjects with metabolic risk factors, energy intake was 
underreported by 500 kcal and 1000 kcal according to a dietary interview and dietary records, 
respectively. Thus, in a majority of obese subjects dietary advice to achieve moderate energy 
restriction cannot be based on dietary assessments. ActiReg® is a monitor that can be used to 
estimate total energy expenditure and physical activity. Despite an underestimated of 100 
kcal, the ActiReg® method gave a valid estimate of total energy expenditure compared to the 
doubly labelled water method, which is the gold standard. These results may indicate that 
energy restriction 500 kcal to1000 kcal below measured total energy expenditure is an 
approach that can be used in counselling for weight reduction. With regard to physical 
activity, obese subjects seeking treatment spent a mean of 26 minutes per day in moderate 
physical activity before advice for weight loss was given. This is close to the recommended 
levels but for weight loss and maintenance purposes the level of physical activity has to be 
increased.  
A simple intervention to increase intake of vegetables and fruit was tested in subjects 
with sleep related breathing disorders. A behavioural group program that emphasized a 500 g 
increase in the daily intake of vegetables and fruit resulted in better weight loss, decreased 
systolic and diastolic blood pressure and increased plasma levels of lipid soluble antioxidants 
compared to usual care controls after three months. The influence of orlistat on eating 
behaviour and dietary intake was studied in a long-term weight maintenance trial. After 
weight loss achieved with the use of a very low energy diet for eight weeks, treatment with 
orlistat did not influence eating behaviour or fat intake other ways than placebo. Subjects that 
chose to take orlistat after the end of the study when the use was optional had higher than 
recommended intake of fat and this may hamper the effect of the drug.  
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1 INTRODUCTION 
1.1 The health consequences of obesity 
The prevalence of overweight (body mass index [BMI] of 25-29.9 kg/m2) and obesity (BMI  
30 kg/m2) is increasing (Soowon and Hopkin, 2006) and it is estimated that about 315 million 
people worldwide are obese (James, 2004). Scandinavian countries are no exception (Ulset et 
al., 2007). The prevalence of obesity has been doubled in Norway during the last 20 years and 
one of five adults is obese. In both men and women the highest prevalence of obesity is seen 
in age above 60 years (Ulset et al., 2007).  
Obesity has been associated with increased risk of cardiovascular disease, type 2 
diabetes, sleep related breathing disorders (SRBD), fatty liver, dyslipidaemia (elevated serum 
triglycerides and apolipoprotein B, decreased high density lipoprotein [HDL], increased small 
dense low density lipoprotein [LDL]), hypertension and thromboembolic disease as well as 
mortality due to certain forms of cancer (colonic, uterine, ovarian, gall-bladder). In addition 
obesity is associated with increased morbidity due to conditions such as osteoarthritis, 
gallstones, bladder dysfunction, polycystic ovary syndrome, asthma, lymphoedema, 
psychological problems, low social status and low levels of physical activity (Coppack et al., 
2005). In Norway, it has been shown that an elevation in BMI of one unit increased the 
relative risk of fatal coronary heart disease by 6% (Håheim et al., 2007). This is shown in 
figure 1.  
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Figure 1. Crude rate ratios of cardiovascular heart disease mortality according to BMI 
quintiles during long-term follow up. From Håheim LL et al. Predictiveness of body mass 
index for fatal coronary heart disease in men according to length of follow-up: a 21-year 
prospective cohort study. Scand J Publ Health 2007;35:4-10. 
 
 
 
 
This dissertation focuses specifically on obese individuals at high risk of cardiovascular 
disease associated with SRBD and metabolic syndrome. 
 
1.1.1 Sleep related breathing disorders  
SRBD are an increasingly common cause of morbidity and mortality among overweight and 
obese individuals. SRBD are characterized by repetitive collapse (apnea) or partial collapse 
(hypoapnea) of the upper airway during sleep (Barvaux et al., 2000). This results in pauses in 
breathing while sleeping and intermittent transient hypoxia. SRBD include habitual snoring, 
increased upper airway resistance syndrome and obstructive sleep apnea. It is estimated that 
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one of five adults in Western countries has at least mild disease and one of 15 has at least 
moderate disease (Caples et al., 2005). The apnea-hypo apnea index (AHI) is a commonly 
used measure of SRBD (Young, 2005) and an AHI  5 indicates the presence of obstructive 
sleep apnea. There is a graded increase in the prevalence of SRBD with increasing body 
weight (Young, 2005). SRBD have been associated with hypertension and an increased risk 
of cardiovascular disease (CVD) (Lavie, 2004; Stradling, 2004). Sympathetic over-activity, 
increased oxidative stress, insulin resistance and a pro-thrombotic state are some of the 
mechanisms thought to mediate the relation between SRBD and CVD (Shamsuzzaman et al., 
2002; Fletcher, 2003; Lavie, 2003; Punjabi et al., 2004). The exact independent relation of 
SRBD to CVD is still not clear. However, there is widespread acceptance for the idea that 
concomitant factors such as pervasiveness of male gender, age, central obesity, hypertension, 
diabetes and dyslipidemia contribute to the increased risk of CVD among patients with SRBD 
(Newman et al., 2001).  
Studies have consistently shown that a 3% reduction in weight improves symptoms of 
AHI by about 1% (Young et al., 2002). Such moderate weight loss is important and can 
facilitate treatment of SRBD and lower associated risks, but additional treatment with nasal 
continuous positive airways pressure (CPAP) is necessary for most individuals to improve 
sleep quality (Barvaux et al., 2000). 
 
1.1.2 Metabolic syndrome  
Metabolic syndrome is a constellation of interrelated risk factors that promote the 
development of atherosclerotic CVD and diabetes type 2 (Grundy et al., 2005). The definition 
of metabolic syndrome varies (Alberti and Zimmer, 1998; National Cholesterol Education 
Program, 2002; International Diabetes Federation, 2005). Almost all attempts to characterise 
metabolic syndrome include abdominal obesity, atherogenic dyslipidaemia, elevated blood 
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pressure and disturbance of carbohydrate metabolism. The definition of metabolic syndrome 
given by the International Diabetes Federation emphasises the importance and essentiality of 
abdominal obesity, which is measured by waist circumference in clinical practice. 
In 2005 the American Heart Association/National Heart, Lung, and Blood Institute 
published a Scientific Statement regarding the diagnosis and management of metabolic 
syndrome. The goal of treatment is to reduce the overall risk for clinical atherosclerotic 
disease by modification of the underlying risk factors (obesity, physical inactivity and 
atherogenic diet) through life style changes. For treatment of obesity a goal of 7-10% weight 
reduction is recommended (Grundy et al., 2005). Though the concept of metabolic syndrome 
has been debated in the literature (Grundy, 2006; Reaven, 2006), there is broad agreement 
that obese subjects with established cardiovascular risk factors are a high-risk group for CVD 
and type 2 diabetes, and that weight reduction addresses one of the most important causes of 
increased risk. 
1.1.2.1 Weight reduction and metabolic syndrome 
 
A weight reduction of 7-10% gives clinically relevant benefits for subjects with metabolic 
syndrome or its components. Weight loss of this size has been shown to reduce the incidence 
of type 2 diabetes (Tuomiletho et al., 2001; Knowler et al., 2002) and ameliorate elevated 
blood pressure (Apple et al., 2003). In addition reductions in serum triglycerides and increases 
in HDL-cholesterol have been shown (Dattilo and Kris-Etherton, 1992). It has to be noted that 
during weight loss HDL-cholesterol is reduced, while the increase in seen when weight is 
stabilized after weight loss (Dattilo and Kris-Etherton, 1992).  
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1.1.2.2 Anthropometric risk factors for metabolic syndrome 
Accumulation of adipose tissue in the abdominal region has been shown to predict increased 
risk for CVD independent of BMI (Rexrode et al., 1998; Rexrode et al., 2001) and waist 
circumference may predict increased risk for CVD better than waist-to-hip ratio (Ketel et al., 
2007). The World Health Organization BMI classification of obesity (WHO, 1998) as shown 
in table 1 is limited by not taken take distribution of body fat into consideration. An additional 
measurement of waist circumference and waist-to-hip ratio is recommended to assess the 
distribution of body fat in the abdominal region (Grundy et al., 2005). Assessment of body 
composition by dual energy x-ray absorptiometry (DEXA) is a more sophisticated method to 
measure body composition and distribution. When compared to computer tomography 
scanning this method gives valid estimates of total and abdominal fat mass in obese subjects 
(Glicman et al., 2004). 
 
Table 1. Body mass index classification of overweight and obesity (WHO, 1998)  
BMI CLASSIFICATION 
25.0-29.9 Overweight 
30.0-34.9 Obesity grade 1 
35.0-39.9 Obesity grade 2 
>40.0 Obesity grade 3 
 
      
1.2 Body weight regulation  
1.2.1 The homeostatic regulation of body weight 
To reduce obesity-associated morbidities sustained weight reduction is paramount. One major 
obstacle is that maintenance of weight loss is difficult to achieve due to redundant 
mechanisms of body weight regulation that counteract negative energy balance (Knecht et al., 
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2008). Within a narrow individually defined range appetite and energy balance are tightly 
regulated to maintain body weight or adiposity by homeostatic mechanisms (Speakman, 
2004).  
The homeostatic mechanisms involve hormones secreted from adipose tissue, 
endocrine glands and enteroendocrine cells which all converge at the vagus nerve, brainstem 
and hypothalamus to modulate complex interactions of neurotransmitters and central appetite-
regulating peptides (Lenz and Diamond, 2008). The hypothalamic arcuate nucleus contains 
orexigenic (appetite increasing) neuropeptid Y and agouti-related peptid neurons as well as 
anorexigenic pro-opiomelanocortin and cocaine-stimulated and amphetamine-stimulated 
transcript peptide producing neurons. These peptides interact with receptors in other areas of 
the hypothalamus, nucleus tractus solitarius and area postrema to regulate meal size and 
energy balance (Valassi et al., 2008). Figure 2 illustrates the homeostatic regulation of 
appetite. 
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Figure 2. The homeostatic regulation of appetite. From Lenz A, Diamond FB Jr. Obesity: the 
hormonal milleu. Curr Opin Endocrinol Diabetes Obes 2008;15:9-20. 
 
 
Moreover, cognitive, hedonic, and emotional neural processes are also involved in energy 
intake (EI) and energy balance (Zheng and Berthoud, 2007). As an example, increased levels 
of leptin that was primarily thought to selectively modulate activity of neuropeptid Y and pro-
opiomelanocortin neurons, also acts on neurons in the gut involved in meal termination (Lenz 
and Diamond, 2008) and on neurons involved in the taste, smell and visual perceptions on 
food (Zheng and Berthoud, 2007). In obesity, leptin resistance and decreased levels of gut 
peptide involved in meal termination and suppression of appetite have been demonstrated 
(Lenz and Diamond, 2008).  
The complex regulation of body fat stores is not a major focus of this dissertation. 
However, understanding that any attempt to lower established fat stores leads to 
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compensatory mechanisms, both in the short term and in the long term, to restore body fat 
stores is essential to any clinical approach to overweight and obesity. 
1.2.2 The roles of physical activity and diet 
1.2.2.1 Physical activity  
The cornerstone of treatment for obesity is to help individuals make changes in dietary and 
physical activity habits. Behaviour change requires long-term support and the acquisition of 
behavioural skills. Numerous studies have been performed using a variety of approaches to 
initiate and maintain weight loss in individuals by modifying their behaviour. Medication (see 
below) has been used as an adjunct to some approaches. In general these studies show that 
weight loss programs achieve only modest success. For example in a recent meta-analysis 
Franz et al. found that regardless of the type of intervention (i.e. diet, physical activity, 
medication) weight loss achieved within the first few months of treatment plateaus at 
approximately six months (Franz et al., 2007). However, achieving changes in people’s 
patterns of physical activity and diet remains the central goal of all treatment programs, due to 
salutary effects of moderate activity and a varied, balanced diet on health and longevity 
(Heilbronn et al., 2006). 
In meta-analysis, increasing the amount of exercise of about 30 minutes per day 
contributed to approximately 2 kg weight loss after one year (Franz et al., 2007). Despite a 
small effect on body weight loss per se physical activity has other well-established health 
benefits. Physically active women and men of all ages have a lower mortality rate compared 
to inactive individuals (Pedersen, 2007). Moreover, exercise alone or in combination with 
weight loss and dietary interventions has been shown to reduce the incidence of diabetes type 
2 (Tuomiletho et al., 2001; Knowler et al., 2002) and improve metabolic risk factors 
associated with metabolic syndrome (Couillard et al., 2001; Kraus et al., 2002; Boulé et al., 
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2005; Shaw et al., 2006). In addition, studies consistently have shown that subjects 
participating in high levels of physical activity have improved weight loss maintenance 
compared to subjects with lower levels of physical activity (Johannsen et al., 2007; Franz et 
al., 2007; Jakicic et al., 2008).  
In 2007 the American College of Sports Medicine and American Heart Association 
updated their guidelines for physical activity and public health. It was recommended that all 
healthy adults should engage in a minimum of 30 minutes of moderate endurance physical 
activity on five days each week as well as activities that maintain and increase muscular 
strength and endurance a minimum of two days each week (American College of Sports 
Medicine and American Heart Association, 2007). Moreover, for individuals that achieve this 
level of activity but remain overweight, a further increase in physical activity was stated to be 
a reasonable component of strategies to lose weight (American College of Sports Medicine 
and American Heart Association, 2007). This is an area where adherence is a challenge. To be 
able to design appropriate exercise prescriptions in a clinical setting, a quantified assessment 
of the activity pattern of obese individuals is needed. 
 
1.2.2.2 Diet 
Dietary change seems to play a larger role in the achievement of initial weight loss than 
physical activity. Recent meta-analyses showed that randomized controlled trials comparing 
dietary counselling-based weight loss programs with usual care interventions produced a 
mean net weight loss of approximately 5 kg after one year, of which about half was 
maintained after three years (Dansinger et al., 2007; Franz et al., 2007). The optimal dietary 
macronutrient composition for weight loss purposes has not been clearly demonstrated (Franz 
et al., 2007). Studies comparing various dietary compositions for the purpose of weight loss 
have given divergent results (Dansinger et al., 2005; Gardner et al., 2007). Some authors 
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found that dietary composition did not seem to influence weight loss (Dansinger et al., 2005). 
Others have reported superior effects of a low carbohydrate diet during one year of treatment 
(Gardner et al., 2007). A meta-analysis showed that carbohydrate-reduced diets achieved 
greater initial weight losses but no difference between diets could be demonstrated after one 
year (Nordmann et al., 2006).  
Lowering the glycaemic index and load of the diet is a much touted and popular 
approach to weight loss, however, conflicting reports have appeared (Thomas et al., 2007; 
Aston et al., 2008). A recent meta-analysis showed that diets emphasising carbohydrates with 
a low glycaemic index improved weight loss by about 1 kg compared to higher glycaemic 
carbohydrates (Thomas et al., 2007). On the other hand, a well-controlled study in which most 
foods were provided to participants found no advantage of a diet with a low glycaemic index 
on weight loss, dietary intake or appetite ratings (Aston et al., 2008). Evidence does exist 
indicating that short-term weight loss and maintenance is improved when low fat protein 
sources of energy replace carbohydrates (Halton and Hu, 2004; Paddon-Jones et al. 2008). For 
improved long-term weight maintenance a reduction in fat intake has been shown to be 
effective in a number of studies (Howard et al., 2006; Phelan et al., 2006; Jakicic et al., 2008). 
However, in a well-controlled dietary intervention study a low-carbohydrate diet and a 
Mediterranean diet were superior to a low fat diet after two years (Shai et al., 2008). In this 
regard, it has to be noted that the low carbohydrate diet was not energy-restricted while the 
two other diets were restricted.   
Despite a wide diversity of studies and opinions regarding the optimal amounts of fat 
and carbohydrate in weight reducing diets, a number of dietary regimens have been tried that 
emphasise an increased intake of vegetables and fruit (de Souza et al., 2008). Table 2 shows 
some beneficial effects of vegetables and fruit.  
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Table 2. Beneficial effects of increasing intake of vegetables and fruit  
Energy density  
Fibre  
Vitamin C, folate  
Potassium, magnesium  
Antioxidants (i.e. carotenoids)  
Hunger  
 
   
Vegetables and fruit are rich in fibre, have low energy density and may reduce hunger (Ello-
Martin et al., 2007). As an example, a randomized, clinical trial found that women given 
dietary advice to reduce fat and increase intakes of vegetables and fruit lost 1.5 kg more 
weight and reported less feelings of hunger, compared to women that were given advice to eat 
a low fat diet without increasing intake of vegetables and fruit (Ello-Martin et al., 2007).  
 
1.2.3 The role of eating behaviour 
Appetite is regulated by a complex interplay between physiological and psychological 
mechanisms. Psychological and behavioural factors such as dietary restraint, disinhibition, 
hunger and binge eating have been found to influence energy intake and body weight. Dietary 
restraint is defined as the tendency to consciously restrict food intake either to prevent weight 
gain or to promote weight loss by control over energy intake and types of food eaten (Pirke 
and Laessle, 1993). Disinhibition is the tendency to overeat in the presence of palatable foods 
or other disinhibitors such as emotional distress (Lowe and Maycock, 1988). Hunger has been 
technically defined as the susceptibility to perceived body symptoms that signal the need for 
food (Lowe and Maycock, 1988). Other psychological and behavioural factors as anxiety, 
depression, and social and cultural environments are not further discussed here. 
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Binge eating has been identified as a common problem among obese subjects seeking 
obesity treatment. Table 3 shows the diagnostic criteria for the binge eating disorder 
(American Psychiatric Association, 1994).  
While the disorder has been reported with a prevalence of 30% among participants in 
weight loss programmes in earlier studies (Spitzer et al., 1992; Spitzer et al., 1993), more 
recent studies have reported prevalences of less than 10% (Vamado et al., 1997; de Man 
Lapidoth et al., 2006). However, in these studies about 20% of the participants reported binge 
eating without endorsing all criteria necessary to warrant a diagnosis of the disorder (Vamado 
et al., 1997; de Man Lapidoth et al., 2006). Obese subjects that do not meet all of the 
diagnostic criteria may binge eat less regularly. High scores for disinhibition and hunger have 
been associated with a high intake of fatty foods (Lindroos et al., 1997) and with a greater 
binge eating severity (Foster et al., 1998). During binge eating the energy intake per episode 
may be of thousands kcalories and high palatable, fatty foods are preferred (Marcus, 1993).  
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Table 3. The American Psychiatric Association DSM-IV-TR diagnosic criteria for binge 
eating disorder 
A. RECURRENT EPISODES OF BINGE EATING 
 An episode of binge eating is characterized by both of the following: 
1. Eating in a discrete period of time (e.g., within any two-hour period), an amount of 
food that is definitely larger than most people would eat in a similar period of time 
under similar circumstances. 
2. A sense of lack of control over eating during the episode (e.g., a feeling that one 
cannot stop eating or control what or how much one is eating). 
B. THE BINGE EATING EPISODES ARE ASSOCIATED WITH THREE (OR MORE) OF 
THE FOLLOWING: 
1. Eating much more rapidly than normal 
2. Eating until feeling uncomfortably full 
3. Eating large amounts of food when not feeling physically hungry 
4. Eating alone because of being embarrassed by how much one is eating 
5. Feeling disgusted with oneself, depressed or very guilty after overeating 
C. MARKED DISTRESS REGARDING BINGE EATING IS PRESENT 
D. THE BINGE EATING OCCURS, ON AVERAGE, AT LEAST TWO DAYS A WEEK 
FOR SIX MONTHS 
Note: The method for determining frequency differs from that used for Bulimia 
Nervosa; future research should address whether the preferred method of setting a 
frequency threshold is counting the number of days on which binges occur or counting 
the number of episodes of binge eating 
E. THE BINGE EATING IS NOT ASSOCIATED WITH THE REGULAR USE OF 
INAPPROPRIATE COMPENSATORY BEHAVIOUR (e.g., purging, fasting, excessive 
exercise etc.) and does not occur exclusively during the course of Anorexia Nervosa or 
Bulimia Nervosa. 
 
Increasing dietary restraint, and decreasing disinhibition, hunger and binge eating 
episodes are important interventions for improved weight maintenance after weight loss 
(Clark et al., 1994; Foster et al., 1998; Cooper et al., 2003; Vogels et al., 2005; Bulik et al., 
2007). To improve eating behaviour, standard behaviour therapy is widely used in lifestyle 
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modification for obesity (Stunkard and Berthold, 1985; Fabricatore, 2007). Table 4 shows 
elements of standard behaviour therapy used in obesity treatment. 
 
Table 4. Elements of standard behavioural therapy used in obesity treatment   
 Can be delivered in individual sessions or in group sessions for 60 to 90 min 
 The sessions are usually in pre-determined order 
 Treatments are time-limited and problem-oriented 
 Treatments are present and future-focused  
o Involve stimulus control 
Shopping (i.e. shop after eating, shop from a list)  
Involve making exact plans (i.e. plans for how to eat regularly, exercise 
or eat less in parties) 
o Involve skills for changing eating behaviour (i.e. eat slowly, do not eat when 
bored, sad or while watching TV) 
o Involve handling with reward (i.e. plan rewards other than eating for specific 
behaviour) 
o Involve self monitoring (i.e. diet diary, step counting, body weight) 
o Involve realistic goal setting for eating behaviour, exercise and weight  
o Involve problem-solving issues and prepare for relapse 
o Involve handling with dysfunctional thoughts (i.e. think about progress not 
shortcomings, have rational restatements of negative thoughts) 
o The patient is educated in basic nutrition (healthful eating pattern), body 
weight regulation, health effects on modest weight loss and physical activity 
   
1.2.3.1 Questionnaires used to assess eating behaviour 
The Three Factor Eating Questionnaire (TFEQ) (Stunkard and Messicks, 1985) and the Binge 
Eating Scale (BES) (Gormally et al., 1982) are recognized instruments to assess eating 
behaviour. The TFEQ is a 51-item instrument, which contains three subscales measuring 
dietary restraint, disinhibition and hunger. It consists of 36 closed questions with a forced, 
false/true answer format and 15 with a 4-point “Likert” scale (Stunkard and Messicks, 1985). 
Using a Likert scale, the participants are asked to respond to the most appropriate alternative 
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of almost never, seldom, usually or almost always. Examples of questions used for the 
assessment of the eating behaviours assessed in the TFEQ are shown in table 5.  
 
Table 5. Examples of questions to measure the eating behaviors dietary restraint, disinhibition  
and hunger             
Eating
behaviour
Questions Scale 
Dietary 
restraint 
How frequent do you avoid “stocking up” 
on tempting foods? 
Almost never, seldom, usually 
or almost always 
 
Disinhibition When I feel anxious, I find myself eating. False or true 
 
Hunger I am usually so hungry that I eat more 
than three times a day. 
False or true 
 
 
The BES consists of 16 sets of 3-4 statements relating to binge eating behaviour and the 
subject is asked to endorse the one item of each set which best describes the eating behaviour.  
 
1.2.4 The role of pharmacological treatment  
Drug treatment may be used as an adjunct to diet changes to improve treatment outcomes in 
subjects with BMI >30 or subjects whose BMI is in the range of 27-29.9 and who also have 
metabolic risk factors (Lau et al., 2007). The anti-obesity drugs orlistat, sibutramine and 
rimonabant are all approved in Europe for long-term treatment of obesity (Rucker et al., 
2007). Here the focus will be on the pancreatic lipase inhibitor, orlistat.   
Due to the pharmacological action of the drug, it has been thought that orlistat may 
have a policing influence on food intake. About 30% of dietary fat is not metabolised, but 
excreted in the faeces (Guerciolini, 1997). If the dietary intake of fat is higher than about 30% 
of energy, abdominal symptoms including oily spotting, faecal incontinency and flatus may 
ensue. In double blind, randomized placebo controlled trials including more than 10 000 
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participants treatment with orlistat was shown to enhance weight reduction by 2.9 kg (95% CI 
2.5 -3.2) (Rucker et al., 2007). Moreover, orlistat has been shown to reduce the incidence of 
diabetes (Torgerson et al., 2004) and improve weight maintenance after weight loss 
(Richelsen et al., 2007). 
The effect of anti-obesity drugs is likely to be counteracted by compensatory changes 
in food intake and energy expenditure to maintain a stable body weight over time, unless 
changes in lifestyle are made simultaneously (Speakman, 2004). However, the motivation to 
maintain lifestyle changes may be attenuated by the use of a drug known to reduce the 
intestinal absorption of fat. Subjects that are taking an active, effective drug may be less likely 
to be restrictive and comply with dietary recommendations than subjects taking placebo. Diet 
pills are often advertised with appetite suppressing, fat and carbohydrate blocking, 
metabolism boosting, fatigue reducing and fat burning properties. As an example an extract of 
a cactus was promised to induce a weight loss of 17.5 kg during four weeks. Due to the fibre 
component of the extract, malabsorption should occur. Weight loss was promised without any 
change in diet or physical activity. Some subjects might hope for weight loss independent of 
efforts to change lifestyle, while others might use pills as a tool to achieve changes in diet and 
physical activity. Thus, a better understanding of how a pill like orlistat affects eating 
behaviours and dietary intake during weight loss and maintenance, could be helpful to 
improve the clinical management of obesity. 
1.3 Self report of dietary intake – the problem of underreporting 
In nutritional research, in dietary counselling and in evaluation of the nutritional effects of the 
intervention data of dietary intake is needed. This is an area of research that is fraught with 
difficulties due to the tendency of human beings in Westernized societies to underreport their 
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energy intake. Dietary assessment methods may be retrospective such as the food frequency 
questionnaire (FFQ) and the 24-hour recall or prospective such as the dietary record (DR). 
In general, the strength of the FFQ is its ability to assess the usual long-term intake 
and also to capture the intake of infrequently consumptions during the time period assessed. 
On the other hand, retrospective methods are subject to error because of poor recollection of 
past diet and difficulty estimating portion sizes. In the quantitative, prospective DR, all foods 
and beverages consumed are measured. However, DRs may be prone to reporting errors 
because of altered food choice and under-eating (Trabulsi and Scoeller, 2001). In this regard 
both the retrospective and the prospective dietary assessment instruments are thought to have 
uncorrelated errors, as well as a correlated error of underreporting.
Given the widespread tendency of misreporting, it is important to use biomarkers that 
have errors independent of the reported intake errors to validate the data. During weight 
stability, total energy expenditure (TEE )(Kniplis et al., 2001) and urinary nitrogen excretion 
(Bingham and Cummings, 1985) are established biomarkers for energy and protein intake, 
respectively. In addition plasma carotenoids (Al-Delaimy et al., 2005) are concentration 
biomarkers that reflects the reported intake of fruit and vegetables. 
 
1.3.1.1 Validation of reported dietary intake against total energy expenditure 
A measurement of TEE by the doubly labelled water (DLW) method is considered as the gold 
standard in free-living individuals (Coward and Prentice, 1985; Schoeller, 1988; Livingstone 
and Black, 2003). The method involves the administration of water containing enriched 
quantities of stable isotopes of deuterium and oxygen-18. An exact dose of the DLW is given 
to the subject and the concentration of the isotopes is measured in urine specimens. The 
concentration of the deuterium is eliminated in water. Most of the oxygen-18 is eliminated 
from the body in the form of water, but some is also eliminated in the form of carbondioxid. 
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The elimination rate of the oxygen-18 is therefore steeper than the rate for deuterium. The 
difference in eliminating rate between these two isotopes is a measure of carbondioxid 
production an indirect measure of the metabolic rate.  
Despite the superior measurement of TEE, the usefulness of the DLW method in a 
clinical setting is limited by its high cost and technical complexity. TEE may also be 
estimated based on resting metabolic rate (RMR) and assessments of physical activity. 
Physical activity has been assessed by a number of questionnaires and different kinds of 
accelerometers. In the present ones, the ActiReg® method is used. ActiReg® is not an 
accelerometer, but an electromechanical monitor which records the main body positions 
(stand, sit, bent forward and lie) together with motion of the trunk and/or one leg each second. 
Figure 3 and 4 shows the ActiReg® monitor.  
 
Figure 3. The ActiReg® unit. 
 
The picture shows the close-up of the Actireg® unit. The apparatus has two pairs of position 
and motion sensors connected by cables to a battery operated storage unit. 
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Figure 4. The Actireg® during registration. 
 
The picture shows a person wearing the Actireg®. One pair of sensors is placed on the chest 
(sternum) while the other is placed on the right thigh. The sensors are attached to the skin 
with medical tape. The storage unit is placed in a small bag fixed to an elastic belt worn 
around the waist.  
 
 
 
 
 
 
 
 
 
 
An estimate of RMR is an important part of the ActiReg® method to calculate TEE. RMR 
can be calculted by equations or measured by direct or indirect calorimety. Indirect 
calorimetry is based on the fact that when food is oxidized in the body, oxygen is used and 
carbondioxid is produced in proportion to the heat generated. Thus, measuring the volume of 
oxygen consumption and carbondioxid production, the energy expended can be calculated 
(Haugen et al., 2007).  
A validation of the ActiReg® method against the DLW method in obese subjects is 
important for the usefulness of the method in a clinical setting. Furthermore,  
all established methods used in the dietary assessments rely on the subjects’ self-reported 
intake. It has been shown that the report of dietary intake is influenced by a number of 
variables such as gender, age, BMI, socioeconomic status, physical activity, smoking status, 
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psychological factors, cultural context, dieting and eating behaviour (Livingstone and Black, 
2003).  Thus, a better understanding of the accuracy of reported intake data might be helpful 
to improve dietary counselling and evaluate effects of dietary interventions for sustained 
weight reduction. 
2 AIMS AND RESEARCH QUESTIONS 
The overall purpose of this doctoral dissertation is to inform clinical interventions promoting 
behaviour change (including diet and physical activity) for the purpose of weight reduction 
and the maintenance of weight loss in obese subjects with high risk of CVD. The dissertation 
focuses on assessment and lifestyle issues including the accuracy of dietary report and energy 
expenditure data, assessment of physical activity patterns, effects of dietary change and 
medication for weight loss. The independent scientific contributions consist of three papers 
using a cross-sectional design (of which two are validation studies) and three papers reporting 
two randomized controlled clinical trials. The individual aims of each paper are stated in their 
introductions. As this dissertation focuses on more general aspects of assessment and 
counselling, the research questions are specified below.  
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Research questions: 
1. What is the accuracy of dietary intake data reported by obese subjects with 
components of metabolic syndrome? Paper 1   
2. Does recording of physical activity obtained by ActiReg® contribute to a valid 
estimate of total energy expenditure in obese subjects with components of metabolic 
syndrome? Paper 2   
3. What is the level of physical activity at baseline in obese subjects with components of 
metabolic syndrome who are seeking treatment for weight loss? Paper 3 
4. What is the effect of dietary intervention to increase intake of vegetables and fruit on 
weight loss and CVD risk factors in obese subjects with SRBD?  Paper 4  
5. How does orlistat affect eating behaviour and dietary intake when used for long-term 
weight maintenance in obese subjects with components of metabolic syndrome? 
Papers 5 and 6 
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3 MATERIALS AND METHODS
3.1 Subjects 
Table 6 shows an overview of the study population and design of the studies. 
Table 6. An overview of the study population and design of the studies  
Paper  N Population Design  
Paper 1 and 2 
 
 
 
 
 
 
Paper 3 
 
 
 
Paper 4 
 
50 
 
 
 
 
 
 
130 
 
 
 
138 
Non-smoking men 
and women with 
components of 
metabolic syndrome 
(all subjects were 
included in Paper 3) 
 
Men and women with 
components of 
metabolic syndrome 
 
Men and women with 
sleep related 
breathing disorders 
 
Cross-sectional, 
validation studies 
 
 
 
 
 
Cross-sectional study 
 
 
 
Randomized, 
controlled, 
intervention trial 
Paper 5 
 
 
 
 
Paper 6 
306 
 
 
 
 
44 
Men and women with 
components of 
metabolic syndrome 
 
 
The Norwegian 
sample of the men 
and women with 
components of 
metabolic syndrome 
in the SMOMS trial 
(40 of the subjects 
were included in 
Paper 3) 
Randomized, double-
blinded, clinical trial 
(The SMOMS multi-
center trial) 
 
Controlled, 
intervention study 
 
3.1.1 Obese subjects with components of metabolic syndrome  
The participants in Paper 1 and 2 were 27 women and 23 men, all non-smoking and aged 24 
to 64 years with a mean BMI of 36 kg/m2 (range 31-48). They were recruited by newspaper 
advertisement or referral to the Department of Preventive Cardiology at Ullevål University 
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Hospital. Inclusion criteria were two or more risk factors for metabolic syndrome according to 
the National Cholesterol Education Program: glucose  6.1 mmol/L or HDL-cholesterol  
1.03 mmol/L for males or  1.29 mmol/L for females or serum triglycerides  1.69 mmol/L or 
waist circumference > 102 cm for males or > 88 cm for females or systolic blood pressure  
130 mm Hg and diastolic blood pressure  85 mm Hg. Exclusion criteria were body weight > 
135 kg, current dieting, cigarette smoking, history of eating disorder or other chronic diseases, 
drug or insulin treated diabetes mellitus and abuse of drugs or alcohol. In Paper 1, one subject 
did not complete the DR.     
Paper 3 included 68 women and 62 men aged 24 to 64 years with a mean BMI of 37 
kg/m2 (range 30-50) and 2 components of metabolic syndrome according to criteria of the 
National Cholesterol Education Program (National Cholesterol Education Program, 2002). 
The 27 women and 23 men participating in the validation studies (Papers 1 and 2) were part 
of this sample as were 19 women and 21 men in Paper 6. All participants were recruited by 
newspaper advertisement or referral to the Department of Preventive Cardiology at Ullevål 
University Hospital.  
In Paper 5 the participants were 149 men and 157 women aged 19 to 64 years with a 
mean BMI of 38 kg/m2 (range 30-45) of which 197 (64.4%) remained in the study after three 
years. They were recruited from nine clinical research centres in Denmark, Finland, Norway, 
and Sweden in response to newspaper advertisements to participate in the Scandinavian 
Multicenter study of obese subjects with the Metabolic Syndrome (SMOMS). The main 
results from the study have been published (Richelsen et al., 2007). The inclusion criteria 
were abdominal obesity (waist circumference > 92 cm for females and > 102 cm for males) 
and at least one of the following metabolic risk factors: impaired fasting glucose (> 6.1 
mmol/L and < 7.1 mmol/L), diet treated type 2 diabetes, dyslipidaemia (HDL-cholesterol < 
1.1 mmol/L for females and 0.9 mmol/L for males) or triglycerides > 2.0 mmol/L. Subjects 
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were excluded if they had clinically relevant conditions that might affect the outcome of the 
trial (i.e. weight change of more than ± 4% for the last two months before inclusion, 
pregnancy, lactation, chronic diseases, weight loss surgery, bulimia, fat soluble vitamin 
deficiencies, abuse of drugs or alcohol).  
In Paper 6 the subjects were the Norwegian participants in the SMOMS trial 
(Richelsen et al., 2007). Fifty-two subjects were randomized after weight loss, 44 subjects 
were examined after one year and 33 subjects were examined two months after the end of the 
trial. 
 
3.1.2 Obese subjects with sleep related breathing disorders 
The subjects in Paper 4 were 138 men and women diagnosed with SRBD of which 95 men 
and 30 women completed the study. The participants were consecutively referred from the 
Ear, Nose and Throat Department at Ullevål University Hospital or from primary care 
physicians to the Department of Preventive Cardiology for weight reduction. Their diagnosis 
was established by polysomnography in a sleep laboratory. They were aged between 28 and 
72 years and had a mean BMI of 37 kg/m2 (range 27-55). Exclusion criteria were any major 
non-cardiac disease expected to reduce life expectancy and abuse of drugs or alcohol. 
 Fifty of the subjects in Paper 4 tested the reproducibility of the FFQ. The 
reproducibility data are not published but will be briefly discussed in this overview.   
 
3.2 Design of the studies  
3.2.1 Papers 1 and 2 
Papers 1 and 2 were methodological, validation studies using cross-sectional design initiated 
by Serena Tonstad and Mette Svendsen. In paper 1 we compared EI to TEE. EI data were 
obtained by a dietary interview based on a FFQ and by DR. TEE was measured by the doubly 
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labelled water (DLW) method. Accuracy was seen as the expected EI/TEE of 1.00. Subjects 
were classified as under reporters and non-under reporters by how much the EI/TEE ratio 
deviated from 1.00 by calculating the 95% confidence interval (CI) of the EI/TEE ratio 
according to the equation by Black & Cole, 2000:  
95%CI = 2· (CVTEE)2 +(CV2EI/d).  
For the coefficient of variation (CV)TEE for repeated measurements for energy measurements 
by the DLW method 8% was used (Black & Cole, 2000). CVEI is the within-subject CV for 
daily intake of energy and 23% was used (Bingham, 1987). The number of days was 90 for 
the FFQ and three for the DR.  
In paper 2 TEE was calculated by the ActiReg® method based on a registration of 
physical activity and measured RMR. This result was compared to TEE measured by the 
DLW method.  
 
3.2.2 Paper 3 
Paper 3 was a cross-sectional study reporting the physical activity patterns of obese patients 
with components of metabolic syndrome before advice for change in diet or physical activity 
for weight loss purposes was given. Recording of physical activity with ActiReg® is 
described.  
 
3.2.3 Paper 4 
This is a randomized, controlled clinical trial initiated by Serena Tonstad and Mette 
Svendsen. The effects of an increased intake of vegetables and fruit were studied in subjects 
with SRBD. All subjects received dietary advice for weight loss before randomization. 
Subjects in the intervention group were given dietary counselling in a behavioural treatment 
program in eight sessions.   
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3.2.4 Papers 5 and 6 
In paper 5, the effect of orlistat on dietary restraint, disinhibition, hunger and binge eating was 
examined in a randomized, multicentre clinical trial initiated by Aila Rissanen and supported 
by the manufacturer of orlistat. Subjects that achieved a weight loss of 5% during eight 
weeks of treatment with a liquid very low energy diet (VLED) were randomized to orlistat or 
placebo treatment for three years. The subjects were monitored monthly for the first 18 
months and then every third month for the rest of the study.  
In paper 6, dietary intake data was compared between Norwegian participants in the 
SMOMS study randomized to orlistat or placebo before the VLED, one year after 
randomization and in subjects that chose to take orlistat or not two months after the end of the 
trial.  
3.2.5 Assessments of dietary intake 
The main dietary assessment method in this overview is the FFQ used as a semi-structured 
interview lasting for 1 to 2 hours (Paper 1, 4 and 6). In the interview the subject reported the 
frequencies and the estimated amount of 174 food items and beverages that have been 
consumed over the last three months. Portion sizes were estimated with the used of an atlas of 
food portions, photographs, household measurements and ordinary models of sweets and 
snacks. In Paper 1, the dietary assessments were done immediately after the assessments of 
energy expenditure. In Paper 4, the dietary assessments were done at baseline and after three 
months of intervention. In Paper 6, the dietary intake was assessed before the VLED, one year 
after randomization to orlistat or placebo and two months after the end of the trial. The same 
registered dietician (Mette Svendsen) performed all the dietary interviews. 
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In Paper 1 weighed dietary records for three non-consecutive days were obtained 
about one month before the measurement of TEE. In Paper 6, a 24-hour dietary recall was 
conducted one year after randomization. The same dietician (Mette Svendsen) performed all 
the dietary recalls. Portion sizes were estimated with use of the same tools as for the FFQ. 
The results of the questionnaires, DRs and recalls were coded manually and energy and 
nutrient calculations were done with the same software program (Mat på data 3.0, 1996).   
  
3.2.6 Measurement of energy expenditure and physical activity  
3.2.6.1 The doubly labelled water method 
In paper 1 and 2 the doubly labelled water method was used to assess total energy 
expenditure. The participants ingested 0.05 g deuterium-labelled water and 0.10 g oxygen-18-
labelled water per kg body weight and this dose was planned to enrich body water by 
approximately 350  (delta per million) for deuterium and 60  (delta per million) for oxygen-
18. Urine samples for analysis of the elimination of the isotopes were collected at day 2, 3, 4, 
8, 13, 14 and 15 after ingestion of the isotope-enriched water at day 1. The analyses were 
done in triplicates with a mass spectrometer (Thermoquest Finnigan MAT, Bremen, 
Germany). The elimination rates for the isotopes were calculated by the multipoint method 
(International Dietary Energy Consultancy Group, 1990). The difference between the 
elimination rates of the isotopes was used as an indirect measure of carbondioxid production. 
The analyses and calculations were done at the Sahlgrenska Academy in Gøteborg, Sweden.  
 
3.2.6.2 The ActiReg® method 
In paper 2, 3 and 6 TEE was estimated by the ActiReg® method. A specially developed 
computer program (ActiCalc32®) was used to calculate TEE. The calculation model is based 
on the estimated energy cost of the body position and activity combined with the number of 
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position changes each minute. Table values (Food and Agricultural Organization/World 
Health Organization/united Nations University, 1985) for energy expenditure during different 
activities were used in according to corrected values for weight bearing activities. The 
corrected values for weight bearing activities were calculated from oxygen expired during a 
standardized, walking test on a treadmill at six different intensities (1-6 km/h) done at the 
National School of Sports, Oslo (Paper 2). The physical activity patterns are expressed as 
physical activity ratios (PAR) as is the ratio of energy expenditure to RMR. TEE is calculated 
by summarizing the calculated energy expenditure for each minute of the measurement 
period.   
In Paper 2 the subjects recorded physical activity by the ActiReg® method during the 
first seven days of the DLW measurement period. In this overview not only TEE, but also the 
physical activity level (PAL) value (i.e. the ratio of TEE to RMR) will be discussed. Dr. Bo-
Egil Hustvedt, University of Oslo, was responsible for the calculations of the calibrated 
values.  
 In Paper 3, physical activity patterns were assessed by an ActiReg® recording 
performed continuously for a mean of four days. Time spent on different levels of physical 
activity categorised as PAR levels was calculated using the ActiCalc32® program. Based on 
table values a PAR of 1.0-1.5 corresponded to lying down standing and sitting (Food and 
Agricultural Organization/World Health Organization/united Nations University, 1985) and 
based on the results of the treadmill test (Paper 2), a PAR 1.6-6.0 corresponded to strolling 
and walking and a PAR >6 corresponded to brisk walking and jogging at a speed of more than 
4.5 km/h.   
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3.2.6.3 The resting metabolic rate 
In Paper 2 we measured RMR indirectly with a standard portable ventilated hood system 
(Deltatrac® Metabolic Monitor; Datex Instrumentarium Corp., Helsinki, Finland). The 
measurements and calculations were done after standardized procedures (Wooley, 2006). Dr. 
Bo-Egil Hustvedt, University of Oslo, performed the RMR measurements and calculations. 
RMR may also be estimated by several equations (Paper 2). In Paper 3 and 6, the Mifflin 
equation was used to calculate RMR (Mifflin et al., 1990):  
RMR (kcal) women: 9.99 · weight (kg) + 6.25 · height (cm) – 4.92 · age - 161  
RMR (kcal) men: 9.99 · weight (kg) + 6.25 · height (cm) – 4.92 · age + 5 
 
3.2.7 Assessment of eating behaviour 
We used the TFEQ to assess the eating behaviours restraint, disinhibition and hunger in 
Papers 1 and 5. Binge eating was assessed with the BES in Paper 5. Scores were calculated 
and the ranges for possible scores were 0-21 for dietary restraint, 0-16 for disinhibition 0-14 
for hunger and 0-46 for BES (Gormally, et al., 1982). Higher scores reflect a greater tendency 
to exhibit the particular eating behaviour characteristics.  
3.2.8 Laboratory measurements 
Fasting serum lipids and glucose were analysed at the Clinical Chemical Department of 
Ullevål University Hospital (Papers 1 and 4) or centrally for all the sites participating in 
SMOMS (Medilab, Copenhagen, Denmark) in Papers 5 and 6. In Paper 4 serum folate was 
analysed at the Clinical Chemical Department of Ullevål University Hospital and plasma 
carotenoids and the ferric reducing antioxidant power were analyzed in batches at the Institute 
for Nutrition Research, University of Oslo, Oslo. 
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3.2.9 Anthropometric measurements 
Physicians at the Department of Preventive Cardiology performed the baseline measurements 
of weight, height, and waist- and hip circumference with standardized tools in Papers 1-4. The 
measurements were done by the same registered dietician (Mette Svendsen) for the rest of the 
study periods. In Paper 5 these measurements were done by the responsible staff at the 
different SMOMS sites.  
Waist was measured with the subject unclothed, midway between lower costa and 
crista (Papers 5 and 6) or at the level of the umbilicus (Paper 4) while the subject was 
standing. Hip circumference was measured at the level of the greater trochanter. BMI was 
calculated as weight in kg divided by height in square meters. Blood pressure was measured 
by physicians or staff with a mercury or digital blood pressure monitor. After the subjects sat 
quietly for 5 minutes, blood pressure was measured in the right arm with an appropriately 
sized cuff. 
Body composition was determined by DEXA in Paper 1, 2 and 3 at Spesialistsenteret 
Pilestredet Park, Oslo. The responsible physician was Johan Halse, a specialist in 
endocrinology. 
 
3.2.10 Interventions 
The intervention in Paper 4 was for subjects to increase the daily intake of vegetables and 
fruit to 400 g and 300 g, respectively. The overall goal was to replace vegetables and fruit for 
more energy dense food items to achieve energy deficiency. In Papers 5 and 6 weight loss 
was achieved with a commercially available VLED ( 800 kcal per day) administered for 
eight weeks. The dietary recommendations for the weight maintenance phase of the trial were 
to follow a diet consisting of <30% of energy from fat and to decrease the intake of saturated 
fat to <10% of energy while allowing for a small amount of unsaturated fat from fatty fish and 
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plant sources. The subjects were advised to increase their intake of fibre from vegetables, 
legumes, fruits and whole meal bread, to choose low fat diary products and lean meat or 
chicken instead of minced meat and sausages, and to reduce their intake of cakes/biscuits, ice 
cream, chocolate, sugar containing beverages and alcohol when re-introducing foods after 
they finished the VLED. 
In Papers 4, 5 and 6, the dietary and behavioural interventions were mostly done in 
group sessions. All participants were given individual dietary advice before randomization in 
Paper 4 and the following sessions in the intervention group were done in groups with 10-18 
subjects. In the group sessions practical implementations of increasing the daily intake of 
vegetables and fruit were focused. The subjects were given homework exercises and their 
experiences were discusses in the groups. Table 7 shows the contents of the sessions.  
 
Table 7. The contents of the sessions. 
Sessions Theme of the session Practical exercise at 
the sessions 
Homework exercise 
1. 
 
 
 
 
 
 
The scientific 
background for the 
recommendation to 
increase vegetables 
and fruit for health 
and weight loss 
purpose 
Exhibition showing 
the weight of some 
vegetables and fruit 
 
 
 
 
2. 
 
 
 
 
 
 
 
 
 
 
 
Goal 
 
 
How to increase 
intake of vegetables 
and fruit? 
Increase intake of 
vegetables to dinner 
and lunch 
Use fruit in stead of 
sweets, desserts and 
snacks 
If necessary, use 
vegetables for the 
evening meal 
Make plans to 
increase intake of 
vegetables and fruit 
Make an eating plan 
with regular meals 
and snacks 
 
 
 
 
 
 
 
 
 
Try to eat 400 g 
vegetables and 300 g 
fruit 
Use the eating plan  
 
 
Eat vegetables to the 
dishes 
 
Make fruit available 
 
 
Make salads or soups 
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3. 
 
 
 
4. 
The plate model that 
includes 50% of the 
plate to be filled with 
vegetables 
Increase the 
variability of 
vegetables and fruit 
No forbidden 
vegetables and fruit 
Use the vegetables 
and fruit of the 
season 
Use beans and lentils 
to increase satiety 
Use small amounts of 
oils and dressings to 
increase taste 
Make plans to use the 
plate model for lunch 
and dinner 
 
Shopping in a 
vegetable and fruit 
store  
 
Make shopping lists 
Prepare salads for 
lunch 
 
The group make  
their own recipe book 
Participate in 
cooking-course 
5. 
 
 
 
 
 
 
 
 
 
 
 
 
6. 
 
 
 
 
 
7. 
 
 
 
 
8. 
Healthy eating; 
reduce intake of fatty 
diary and meat 
products, eat more 
fish, lean meat and 
chicken, use low fat 
diary products, use 
small amounts of oils, 
dressings and nuts, 
use whole-meal or rye 
bread, reduce intake 
of sweets, desserts 
and snacks 
How to eat in parties? 
 
 
 
 
 
How to eat during 
holidays? 
 
 
 
Body weight 
regulation 
Realistic goal setting 
of 7-10% weight 
reduction  
The group evaluted 
their dietary intake 
based on a 24-hour 
recall 
 
 
 
 
 
 
 
 
 
Talk about how to 
deny politely 
Make plans for 
restricting cakes 
Plan to eat much 
vegetables 
Plan to eat regularly 
meals 
Plan to increase 
physical activity 
When and how to do? 
Write the weight goal 
that you: 
Hope to achieve 
Will be satisfied with 
Will not be satisfied 
with 
Record your dietary 
intake for at least a 
week 
 
 
 
 
 
 
 
 
 
 
Bring fruits as a gift 
Make sure that salads 
and vegetables will be 
served 
 
 
 
 
Prepare to do your 
physical activity in 
any circumstances 
Think about what you 
have achieved, how 
does it feel in terms of 
eating healthy, 
easiness to move, 
pains 
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In papers 5 and 6, the subjects were offered dietary and behavioural therapy in groups for the 
first 18 months of the study and for the next 18 months the subjects met individually with a 
dietician. At the group session’s exhibitions were used to illustrate the amount of fat in foods. 
Subjects were taught to read food labels, make a plan for mealtimes and plan menus. Subjects 
were instructed to use a plate model for hot meals. They were asked to use this model at 
different occasions including social eating and eating at restaurants. The subjects were asked 
to assess eating behaviour and plan specific strategies to avoid pitfalls. The behavioural 
program otherwise included features such as goal setting, stimulus control and cognitive 
restructuring (Melin & Rössner, 2003). In studies 5 and 6, the subjects that achieved a weight 
loss of more than 5% during the VLED, were randomized to orlistat 120 mg three times per 
day or to matching placebo three times per day.  
 
3.2.11 Statistical analyses 
In all papers descriptive data were presented as means (SD) or as medians with interquartile 
ranges for not normally distributed data. Mean and median differences between groups were 
tested with the unpaired Student’s t-test and the Mann-Whitney rank test for normally 
distributed and skewed variables. Differences within the groups were tested with the paired t-
test or Wilcoxon signed rank test as appropriate. The Chi squared test was used in 
comparisons of categorical variables. Pearson’s correlation coefficients were calculated for 
normally distributed variables and Spearman’s rank correlation coefficients were calculated 
for skewed variables.  
In paper 1, simple regression analyses were conducted and factors that were 
statistically significant in the univariate analysis were entered into a multiple regression 
analyses to identify the most important factors correlated to reported accuracy of energy 
intake. In Paper 2, the agreement of the results obtained by the methods was tested by the 
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method of Bland Altman. In Paper 3, serum triglycerides and the amount of time spent at 
PAR >6 were log-transformed because of skewness. Variables that were significantly 
correlated with minutes per day spent at PAR>6 were entered into a multiple regression 
analysis and adjusted for confounders.  
In Paper 4, we conducted multiple regression analyses to identify factors that 
determined weight change in all subjects as follows: To test for group homogeneity, we did a 
multiple regression analysis including the exposure factor (x1), treatment variable (x2) and the 
product variable of x1 and x2. When the product variable was found to be significant in the 
multiple regression analysis, the slopes of association were claimed to be different between 
treatment groups. In such a case simple regression analysis between change in weight and the 
exposure factor was done within each treatment group. Group homogeneity was tested for the 
presence of diabetes or CVD, use of antihypertensive or lipid-lowering medication, smoking 
habits and gender. The tests for homogeneity showed heterogeneity between the control and 
intervention group only in regard to use of antihypertensive medication. Because of the 
heterogeneity, use of antihypertensive medication was not included in the final multiple 
regression analysis. 
In Papers 1 and 4, energy density was calculated for the whole diet minus drinks 
(coffee, tea, milk, juice, soft drinks and alcoholic beverages).  
In Paper 5, analysis of variance using least square means with changes in weight as 
covariates was done to test the possible difference between the orlistat and placebo group with 
regard to changes in scores for eating behaviour at the measured time-points. Changes were 
calculated as the difference in scores between screening and subsequent measurements. To 
test the interaction effect between genders F-tests from ANCOVA were used. To test the 
association between eating behaviour and change in weight at month 33, we conducted 
multiple regression analyses with change in weight as the dependent variable and BMI at 
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screening, age, gender, treatment and the changes in scores for restraint, disinhibition, hunger 
and binge eating, respectively, as four separate independent variables. Analyses were done 
using the observed values (for which the data are shown), last observation carried forward 
values and for the completers. The statistician (Fredrik Hansson) performed the statistical 
procedures in Paper 5.  
 Statistical tests were considered significant at P <0.05. Statistical analyses were 
performed using the Stat View 5.0.1 software in Papers 1, 3, 4, and 6. SPSS for windows 
(version 13.0.0) software was used in Paper 2 and SAS software (version 9.1.3) was used in 
Paper 5.  
 
4 REVIEW OF THE PAPER RESULTS  
I. Accuracy of food intake reporting in obese subjects with metabolic risk factors.  
Mette Svendsen and Serena Tonstad.   
We examined the determinants of reporting accuracy and explored which specific 
foods and eating behaviours were associated with underreporting. The DLW method 
was used to estimate TEE. Fifty women and men with a BMI of 36 kg/m2 participated 
in a dietary interview based on a FFQ and completed weighed DR. TEE did not differ 
between underreporters (one-half of the sample) and non-underreporters. The accuracy 
was assessed by the ratio EI/TEE as is expected to be 1.00. The EI/TEE was 0.68 in 
underreporters and 1.01 in non-underreporters according to the FFQ. According to the 
DR the accuracy was 0.57 in underreporters and 0.85 in non-underreporters. 
Underreporters had lower median intakes of sweets/desserts/snacks than non-
underreporters according to both methods. According to the FFQ, reported intake of 
bread and sweets/desserts/snacks were determinants of accuracy. According to the DR, 
sweets/desserts/snacks and dietary restraint were determinants of accuracy.  
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II. Validation of ActiReg® to measure physical activity and energy expenditure 
against doubly labelled water in obese persons. 
Bo-Egil Hustvedt, Mette Svendsen, Arne Løvø, Lars Ellegård, Jostein Hallén and 
Serena Tonstad. 
In this study we compared TEE estimated by the DLW method and TEE calculated 
from a seven-day recording of physical activity with ActiReg® in 50 obese subjects. 
We also compared RMR measured by indirect calorimetry and estimated by 
standardized equations. TEE estimated by the DLW method was 3322 kcal (SD 590 
kcal) and total energy expenditure calculated from ActiReg® was 3219 kcal (SD 540 
kcal), an underestimation of about 4%. RMR derived from standard equations based 
on weight, age and sex were overestimated while the RMR based on fat-free mass 
values in addition was underestimated. 
III. Physical activity patterns of obese subjects with a high metabolic risk profile. 
Mette Svendsen, Bo Egil Hustvedt and Serena Tonstad. 
In this study we assessed physical activity patterns of 130 treatment seeking obese 
women and men with components of metabolic syndrome and examined the 
association between cardiovascular risk factors and time spent on moderate intensity 
physical activity. Physical activity was measured continuously with ActiReg® for a 
mean of four days. Time spent on physical activity was categorized as PAR levels 
expressed as the ratio of energy expenditure of different activities to RMR. The 
subjects daily spent a mean of 1065 minutes lying, standing and sitting (PAR 1.0-1.5), 
348 minutes strolling and walking (PAR 1.6-6.0), and 26 minutes brisk walking and 
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jogging (PAR >6.0). The time spent on brisk walking and jogging was inversely 
associated with total cholesterol and triglycerides explaining about 6% and 8%, 
respectively of the variation in the lipid levels after adjustment for age and sex.  
IV. The effect of an increased intake of vegetables and fruit on weight loss, blood 
pressure and antioxidant defence in subjects with sleep related breathing 
disorders.
Mette Svendsen, Rune Blomhoff, Ingar Holme and  Serena Tonstad. 
The effect of an increased intake of vegetables and fruit with regard to weight loss, 
blood pressure and antioxidant defence was studied in a randomized, controlled trial in 
138 obese subjects with SRBD. The intervention to increase the intake of vegetables to 
400 g per day and fruit to 300 g per day was conducted in a group based behaviour 
program. After three months, the intervention group achieved a 2% better weight loss 
and reduced systolic (-7 mmHg) and diastolic (-4 mmHg) blood pressure (mean 
difference between the groups), compared to the control group. A doubling in the 
intake of fruit and vegetables resulted in increased concentrations of plasma -
carotene and -carotene, with no change in antioxidant defence measured with the 
ferric reducing antioxidant power assay. In a multiple regression analysis the change 
in intake of vegetables was a significant contributor to the change in weight.  
V. Effect of orlistat on eating behaviour among participants in a three-year weight 
maintenance trial. 
Mette Svendsen, Aila Rissanen, Bjørn Richelsen, Stephan Rössner, Fredrik Hansson
and  Serena Tonstad.
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We studied the effect of orlistat on dietary restraint, disinhibition, hunger and binge 
eating and assessed the relation between changes in eating behaviour and weight 
maintenance in 306 abdominally, obese subjects included in the SMOMS trial. This 
was a three-year clinical trial of orlistat or placebo following an eight-week VLED. 
Compared to screening, dietary restraint was increased and disinhibition, hunger and 
binge eating were decreased in the orlistat and in the placebo group. These changes 
were similar in both groups with the exception of the hunger score. This score was 
reduced more in the placebo than in the orlistat group at the end of the study. In 
multivariate analyses scores for restraint, disinhibition and binge eating were 
associated with weight loss after adjustment for BMI, gender, age and treatment. 
VI. The long-term influence of orlistat on dietary intake in obese subjects with 
components of metabolic syndrome.
Mette Svendsen, Merete Helgeland and Serena Tonstad. 
In this study we assessed dietary intake in the Norwegian participates in the SMOMS 
trial. A dietary interview based on a FFQ was conducted in 44 subjects before weight 
reduction and after one year of treatment with orlistat or placebo. Two months after 
the end of the trial, dietary intake was assessed in 33 subjects that remained in the trial. 
At one year, dietary intake did not differ between the orlistat and placebo group. 
Energy percent from fat was reduced and energy percent from carbohydrate was 
increased within both groups. Two months after the end of the trial when the use of 
orlistat was optional, energy percent of fat was 32.6% in subjects that chose to take 
orlistat and 27.7% in subjects not taking orlistat.  
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5 DISCUSSION 
5.1 General discussion 
Conservative therapy for weight loss and maintenance consists of changes in diet, physical 
activity and eating behaviour. Pharmacological therapy is an adjunct to changes in lifestyle. 
This discussion will focus on these four elements of the clinical management of obesity.  
 Assessments of dietary intake  
 Measurements of energy expenditure and physical activity  
 The effect of an increased intake of vegetables and fruit  
 The influence of an anti-obesity drug on eating behaviour and diet 
In this section methodological considerations and a discussion of the results will precede 
implications for treatment. 
 
5.1.1 Methodological considerations  
5.1.1.1 Assessment of dietary intake 
In Paper 1 we validated reported EI against TEE measured by the DLW method, as is the gold 
standard. When using TEE as an objective measure of EI, we assume that the subjects were in 
energy balance over the measurement period of 14 days. The measurement period was 
according to standard procedures (International Dietary Energy Consultancy Group, 1990) but 
may still be too short to measure long-term energy expenditure. Weight changes during the 
study were minor and were not adjusted for (International Dietary Energy Consultancy 
Group, 1990).  
Another methodological issue in Paper 1 was that the subjects recorded food intake for 
only three days about one month before the measurement of TEE. This was to reduce the 
burden on the participants. Ideally, the DR should have been performed during the 
measurement period. Usually a seven-day record is recommended for a valid estimate on 
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energy intake (Bingham, 1987). A longer period of recording may have increased the reported 
energy intake due to less day-to-day variability, especially within the non-underreporting 
group. However, within the underreporting group that showed a higher dietary restraint, a 
longer recording period may have been out weighted by more underreporting (Trabulsi and 
Schoeller, 2001).  
Men and women were almost equally represented in the study. Due to the high cost of 
the method, the study population was small and we do not have a non-obese control group. 
The FFQ method has recently been shown to better capture obesity related reporting than 24-
hour dietary recalls (Lissner et al., 2007). 
 
5.1.1.2 Measurement of energy expenditure 
In Paper 2, we compared TEE measured by the DLW method and by the ActiReg® method. 
A methodological consideration in this study was the difference in measurement period. To 
reduce the burden of the subjects, the ActiReg® recordings were only done during the first 
seven days of the DLW measurement period. The subjects may have been more active during 
the ActiReg® recording compared to the whole measurement period. If this was the case, 
more underestimation of TEE by ActiReg® compared to TEE measured by the DLW method 
would have been expected.  
 Another methodological issue is the PAR levels we used to summarize TEE. Data is 
sparse on energy expenditure during various intensities of weight bearing activities in the 
obese. The PAR level approach has been assumed to compensate for differences in BMI. 
However, table values are based on measurement in normal weight subjects (Food and 
Agricultural Organization/World Health Organization/United Nations University, 1985) and 
increasing PAR with increasing body weight has been shown (Kuriyan et al., 2006). In Paper 
2 we reported that walking faster than 4.5 km/h corresponded to a PAR>6 as is higher than 
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reported in normal- and overweight subjects (Food and Agricultural Organization/World 
Health Organization/united Nations University, 1985; Kuriyan et al., 2006). If using normal 
weight PAR levels for weight bearing activities, the underestimation of TEE by the ActiReg® 
method compared to TEE measured by the DLW method would have been about 15% (Paper 
2). Thus, using higher PAR levels in the obese seems appropriate. 
  
5.1.1.3 Registration of physical activity 
In paper 3, we assessed physical activity patterns with the ActiReg® method. The study was 
cross-sectional and cannot be used to determine causality. We used an objective measurement 
of physical activity, but the study has some methodological considerations. As discussed 
above, we used PAR>6 for walking with a speed higher than 4.5 km/h. If the higher energy 
cost of weight bearing activities in the obese had not been taken into consideration, time spent 
on PAR>6 would have been lower.    
We measured physical activity for only four days. In the updated recommendations 
from the American College of Sports Medicine and American Heart Association, five days a 
week was identified as a minimum level of physical activity (American College of Sports 
Medicine and American Heart Association, 2007). Although the measurement period was 
within the recommended number of days for adults (Troiano, 2005), ideally the measurement 
period should have been for five days. It is a possibility that the subjects increased their 
physical activity in a shorter period of recording. Indeed, a higher PAL was seen among our 
subjects compared to the observed PAL in the studies that used ActiReg® for seven days 
(Mattiessen et al., 2008; Kurtze et al., 2007). Moreover, we did not separate between vigorous 
and moderate intensity. If some of the activity recorded was of vigorous intensity, then the 
calculated time spent on PAR>6 should have been higher. It has to be argued that in the 
NHANES 2003-2004 the time spent on vigorous physical activity was less than one minute 
 50
per day (Troiano, 2008). The level of physical activity at vigorous intensity probably would 
have been low, but this was not measured in our study. We also accumulated all bouts of time 
spent on PAR>6. In the 2007 recommendations it is clearly stated that the minimum length of 
the short bouts used to accumulate physical activity has to be at least 10 minutes (American 
College of Sports Medicine and American Heart Association, 2007). This may have been of 
minor influence because in the NHANES 2003-2004 the results of calculating bouts minutes 
per day were similar to the overall minutes per day (Metzger et al., 2008). Another 
consideration in this study was that we used estimated RMR based on the Mifflin equation 
instead of a measurement of RMR. Ideally, the RMR should have been measured, but when 
calculating PAL and PAR levels the RMR is both in the numerator and in the divider and the 
error in RMR will be outweighed.  
 
5.1.1.4 The effect of an increased intake of vegetables and fruit 
In the randomized, controlled dietary intervention study (Paper 4) we examined the effect of a 
dietary intervention during three months. Long-term adherence to dietary interventions is 
paramount in the clinical management of obesity. This study did not assess the long-term 
adherence to the diet because the study was a part of a longer study involving a three months 
weight loss period and a one-year weight maintenance period with orlistat. Only the three-
month period is reported here (the result of the one year maintenance period will be reported 
elsewhere). Ideally the weight loss period should have lasted for six months (Franz et al., 
2007), but three months was chosen because the control group had to wait for treatment. The 
subjects in the control group were waiting-list controls and we wanted to offer them treatment 
as soon as possible. Another consideration by the study design was that the treatments had 
unequal intensity between the intervention and the control group. However, the treatment 
offered to the control group reflected a usual setting of individual therapy with a dietician. 
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 This study showed that the recommended amounts of vegetables and fruit were 
feasible to achieve in a daily life setting where subjects had to plan, purchase and prepare 
their own food. More than one-half of the subjects reported consumption of the recommended 
amount of vegetables and fruit. However, overreporting of fruit and vegetables in the 
intervention group may occur. We did not validate the energy intake data as will be discussed 
in the next section, but we used carotenoids as biomarkers for the reported intake of 
vegetables and fruit. -chryptoxanthin, -carotene and lycopene have been shown to predict 
intake of citrus fruit, carrots, and tomato products, respectively (Al-Delaimy et al., 2005). 
Indeed, we found reported intake of vegetables associated with -carotene and intake of fruit 
associated with -chryptoxanthin. Moreover, the concentrations of -carotene, zeaxanthin and 
lycopene after three months in the intervention group were in line with the concentrations 
reported after increasing intake of vegetables and fruit by 450 g in a well-controlled feeding 
study (Brevik et al., 2004) (data not shown). Thus, based on the results of the carotenoid 
analyses we assume that the reported intake of vegetables and fruit showed adherence to the 
dietary intervention. The lower concentrations of some of the carotenoids may reflect 
differences in intake; not all vegetables and fruit are rich in the various carotenoids.  
  We used the ferric reducing antioxidant power assay to evaluate the effect of the 
dietary intervention on antioxidant defence and found no effect on antioxidant capacity. The 
lack of effect may be due to the fact that this assay is better suited for measurements of 
antioxidant status in plant products than in biological samples (Ghiselli et al., 2000). 
Carotenoids are lipid-phase antioxidants and are important to prevent and repair lipid 
peroxidation (Karlsen, 2008). Indeed, vegetables such as broccoli, carrots, onions and 
tomatoes that are high in carotenoids also contain compounds that may induce endogenous 
antioxidant effect (Blomhoff, 2005). Thus, the increased intake of vegetable and fruit may 
have improved the antioxidant capacity of the subjects in the intervention group due to the 
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increase in plasma concentrations of plasma - and - carotenoids despite no change in the 
ferric reducing antioxidant power assay. 
The sample size and statistical power calculations were based on the assumed 
difference in weight between the intervention and control group. Unfortunately, the sample 
size was too small for us to perform sub-group analyses of subjects treated or not treated with 
CPAP.  
 
5.1.1.5 The influence of orlistat on eating behaviour and diet 
In paper 5, the influence of orlistat on eating behaviour was examined in more than three 
hundred obese subjects about equal distributed between genders. Thus, the statistical power 
was good. The subjects were followed for three years in a placebo controlled trial and the 
completion rate was relatively high. We were able to prospectively measure changes in eating 
behaviour at several time-points. However, we did not have any measurement of the eating 
behaviour at randomization, when the olistat or placebo treatment started. It was not clinically 
relevant to assess eating behaviour after an eight-week, liquid VLED before ordinary diets 
was restarted. 
Eating behaviour was measured with the validated questionnaires TFEQ and BES (in 
Paper 1 the TTEQ was used). An important consideration is how questions that are not 
answered are handled. We scored unanswered questions as zero, meaning that the subject got 
a low score on the eating behaviour. If the subject rejected to answer the question because of 
embarrassment or neglect, the score on the eating behaviour would have been too low. 
Another consideration is that the Norwegian questionnaires were translated for the purpose of 
the SMOMS study. The translation was not back translated. 
 In Paper 6, dietary intake was assessed during long-term follow up after weight loss. 
We measured TEE to validate the intake data and showed that underreporting was obvious in 
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both groups. Only retrospective dietary methods are reported in this study and the 
underreporting could be due to difficulties with remembering all food eaten or estimating 
portion sizes. However, these subjects also recorded their diet for several times during the 
study (Richelsen et al., 2007) and were well aware of the eating habits.  
 Another consideration of the study was that we did not measure RMR. Ideally it 
should have been measured, but the recording was done when the subjects were supposed to 
be in energy balance before weight reduction and during weight maintenance. 
 
 
5.1.2 The accuracy of reported dietary intake  
We found that at the group level energy intake was under reported by 17.6% with the FFQ 
method and by 29.6% with the DR method (Paper 1). Tables 8 and 9 show that the difference 
between energy intakes estimated by the dietary methods and measured energy expenditure 
was 575 kcal (2.4 MJ) by the FFQ and 982 kcal (4.1 MJ) by the DR method. To achieve a 
weight loss of 0.5-1.0 kg per week, an energy deficit of about 500-1000 kcal (2.1-4.2 MJ) is 
recommended. Based on these findings it seems like self-reported dietary intake data may be 
of limited value for the purpose of counselling for energy deficient diets (tables 8 and 9). 
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According to the FFQ, underreporters had a ratio of EI/TEE below 0.83 and non-
underreporters had a ratio equal or above 0.83. The corresponding numbers for the DR were a 
ratio of EI/TEE below 0.69 for underreporters and equal or above 0.69 for non-
underreporters. About half of the subjects were classified as underreporters by both methods. 
However compared to the expected EI/TEE = 1.00 in weight stable subjects the FFQ showed 
superior accuracy compared to the DR (EI/TEE = 0.824 and EI/TEE = 0.704 according to the 
FFQ and DR, respectively, P=0.0003). Table 8 shows that according to the FFQ, EI was in 
accordance with TEE among the non-underreporters. Thus, it seems like the FFQ method 
better capture energy intake compared to three days of DR and a minority of subjects are able 
to report adequately by the method. 
To further validate the dietary intake data we used the excretion of urinary nitrogen as 
a biomarker for the dietary intake of protein (Svendsen and Tonstad, 2008). Subjects were the 
23 men and 27 women participating in the validation study in Paper 1. The subjects collected 
24-hour urinary samples for three non-consecutive days. Completeness was ascertained using 
the para-aminobenzoic-acid method (Bingham and Cummings, 1983; Johansson et al., 1999). 
As seen in table 8 and 9, underreporters of total energy also underreported energy from 
protein with both dietary methods. However, the underreporting of energy from protein was 
smaller than the underreporting of total energy. The less underreporting of energy from 
protein than total energy may indicate a bias toward more underreporting of carbohydrate, fat, 
or alcohol. Unfortunately, biomarker-type measurement does not exist for other nutrients than 
protein. The protein data cannot be generalized to other nutrients. However, data suggest that 
under-reporters of energy also reports consuming less of all food groups but that the degree of 
underreporting can vary between foods (Krebs-Smith et al., 2000). This large-scale study 
found that low energy reporters omitted foods from their reports and substantially 
underreported portion sizes of many foods. This may have been the case in our study too, as 
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evidenced by a general underreporting of portion sizes and a specific underreporting of bread, 
sweets, desserts and snacks.  
The results of our study showing the problem underreporting of dietary intake in the 
obese are in accordance with a number of other studies (Hill et al., 2001; Trabulsi and 
Schoeller, 2001; Subar et al., 2003). Thus, the results are generalisable to obese, middle-aged 
subjects that are non-smoking and highly motivated. It has to be mentioned that the subjects 
knew that the energy expenditure would be measured and they had been recording their 
dietary intake prior to the dietary interview. They may have been more aware of their dietary 
intake and eating habits and reported more accurately than subjects usually seen in a clinical 
setting. These results may be less generalisable to a smoking, obese population that are not as 
aware of the eating habits.  
 
5.1.3 The validity of energy expenditure estimated by ActiReg®   
In Paper 2 we showed that energy expenditure calculated by the ActiReg® method was 
underestimated by 103 kcal (431 kJ) compared to TEE measured by the DLW method. The 
study highlights the importance of considering the increased energy expended during weight-
bearing activities in obese subjects. As seen in Paper 2, calculation of TEE with normal PAR 
levels the underestimation of TEE by the ActiReg® method was 507 kcal (2.1 MJ).  
The small underestimation of TEE seen by the ActReg® system may be due to the fact 
that the energy expenditure of activities such as arm movements (i.e. snow shuffling), 
carrying loads, walking upstairs, muscle strength training, swimming and cycling or spinning 
is not captured. In light of the small underestimation it seems like activity measured by 
ActiReg® is closely in accordance with activity levels measured by the DLW in other studies 
(Tooze et al., 2007; Goris and Westerterp, 2008). In our study, PAL level assessed by the 
AciReg® method was 1.80 which is slightly higher than the mean PAL of 1.74 in obese 
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subjects reported by Goris and Westerterp in a recent review (Goris and Westerterp, 2008). In 
the OPEN study TEE measured with the DLW method was 2728 kcal (11.4 MJ) in obese 
women and 3576 kcal (15.0 MJ) in obese men (Tooze et al., 2007). According to the 
ActiReg® method, TEE was 2944 kcal (11.5 MJ) in women and 3541 kcal (14.9 MJ) in men. 
This may indicate that the ActiReg® method better capture energy expenditure in women 
than in men.  
Energy expenditure at rest accounts for most of the expended energy during the day. 
RMR can be measured or predicted by various equations. In Paper 2 we used the formula 
adopted from Schofield in the FAO/WHO/UNU Report (Food and Agricultural 
Organization/World Health Organization/united Nations University, 1985), Mifflin (Mifflin et 
al., 1990), Cunningham (Cunningham, 1991) and Müller (Müller et al., 2004). Calculation of 
RMR using all these formulas was significantly different from the RMR measured by indirect 
calorimetry. In accordance with other studies performed among obese subjects (Frankenfiled 
et al., 2005), the Mifflin formula showed best agreement with the measured RMR. At the 
group level the predicted RMR by the Mifflin formula was 1889 kcal (SD 245 kcal), 
indicating overestimation by 4.6% (mean difference between predicted RMR and measured 
RMR was 87 kcal [364 kJ]). At the individual level the predicted RMR (Mifflin) was 
significantly correlated to measured RMR (r=0.876 [95%CI 0.815, 0.937]). The Cunningham 
formula underestimated RMR by 266 kcal (1.1 MJ) and it has to be noted that this formula is 
used in impedance measurements to estimate RMR.  
We concluded in Paper 2, that ActiReg® may be used to measure TEE in obese 
subjects on two premises: RMR should be measured, and the increased energy expenditure 
during weight-bearing activities in obese subjects should be considered. Ideally a 
measurement of RMR should be performed in a clinical setting where predictions of RMR are 
widely used. A concern about predicting RMR is that a possible adoption of energy efficiency 
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reduces RMR. In a number of studies it has been shown that RMR is reduced during energy 
deficient states (Rosenbaum et al., 2003; Westerterp, 2003; Stiegler and Cunliff, 2006; Martin 
et al., 2007). A small but well-designed study by Martin et al. showed a mean reduction in 
RMR of 91 kcal (382 kJ) per day compared to controls who were not energy restricted after 
adjustment for fat free mass (Martin et al., 2007). However, recent studies have shown that 
during weight maintenance the reduction in RMR is explained by altered body composition 
(Das et al, 2003; Hunter et al., 2008). Hunter et al. reported no decrease in REE adjusted for 
fat free mass and fat mass during four weeks of weight maintenance after weight reduction 
(Hunter et al., 2008). In line with this, no change in RMR was seen in subjects after gastric 
bypass when change in fat mass and fat free mass were accounted for (Das et al., 2003). It 
seems like RMR is reduced during energy deficient states but when new equilibrium states are 
achieved no reduction in RMR is seen. This means that RMR may be predicted in weight 
stable individuals. Using the Mifflin formula an overestimation of about 5% in RMR may be 
expected.  
The study population was the same as in Paper 1 and the results are generalisable to 
middle-aged, non-smoking, highly motivated, obese subjects that are moderately active (see 
below). The results may be less generalisable to smoking, younger or older adults or subjects 
with a weight above 135 kg. It has to be noted that recording of physical activity with the 
ActiReg® method require motivated participants. Being monitored for several days and 
having irritating cables attached to the body are some of the barriers to easy use of this 
method. 
 
5.1.4 The level of physical activity before weight loss was initiated  
In Paper 3 we found that obese subjects were moderately physically active for about 26 
minutes per day. This amount is close to the recommended 30 minutes of physical activity 
 60
given by the American College of Sports Medicine and American Heart Association 
(American College of Sports Medicine and American Heart Association, 2007). It is also 
almost in accordance to the activity found in the NHANES 2003-2004 (Troiano et al., 2008). 
In this study PA was monitored for at least four days in almost 5000 US subjects of whom 
30% were obese. The main results of the study were that males were more physically active 
than females, that physical activity declines with age and that only 5% of adults obtained 
physical activity at the recommended level (Troiano et al., 2008). In contrast, we found that 
about one-third of obese subjects seeking treatment for weight loss was physically active for 
more than 30 minutes per day. This may indicate that the excess weight does not exclude 
moderate physical activity. The overall PAL during the day was 1.85 that is slightly higher 
than the PAL of 1.71 reported in 138 Danish subjects (Matthiessen et al., 2008) and the PAL 
of 1.68 reported in 93 overweight, young Norwegian men (Kurtze et al., 2007).  
To initiate weight reduction or maintain weight loss even more physical activity is 
probably necessary (Ross et al., 2000; Slentz et al., 2004; Stiegler and Cunliff, 2006; 
Johannsen et al., 2007; Catenacci et al., 2008). Obese men that spent 60 minutes per day on 
brisk walking achieved about a 7% reduction in body weight (Ross et al., 2000). Likewise, the 
Studies of Targeted Risk Reduction Interventions through Defined Exercise showed that 
physical activity corresponding to 4-5 km of daily walking had salutary effects on body 
weight (Slentz et al., 2004). Assuming a speed of 4.5 km per hour, our subjects would have 
had to walk for 60 minutes per day to reach this level of activity. Adherence to 60 minutes or 
more of physical activity may be a challenge. In a recent study only 12 of 202 subjects 
maintained a daily physical activity level of more than 60 minutes per day for 18 months 
(Tate et al., 2007).  
In addition, individual variations in the effect of an exercise-induced weight loss 
program may occur (King et al., 2008). This was shown in a study of 35 obese men and 
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women that participated in a well-controlled exercise program for 12 weeks. The mean weight 
loss was 3.7 kg (SD 3.6 kg) as was predicted by the increase in energy expenditure. However, 
when dividing the subjects in two groups according to their actual versus predicted weight 
loss, it was seen that some individuals (compensators) compensated the energy expended 
during exercise with increased efficiency of energy expenditure and increased energy intake. 
The compensators lost about 1.5 kg of weight compared to 6.3 kg lost by non-compensators. 
In compensators RMR was reduced whereas EI at a test meal and subjective hunger ratings 
were increased. In non-compensators EI was decreased and change in hunger ratings were not 
reported (King et al., 2008). Thus, prescriptions of exercise may benefit from considering 
dietary and behavioural therapy and vice versa.  
A recent review concluded that changes in physical activity appear to result in less 
weight loss than expected (Stiegler and Cunliff, 2006). This may be due to reduced RMR 
during energy deficient states (Rosenbaum et al., 2003; Stiegler and Cunliff, 2006; Martin et 
al., 2007) and more energy efficient muscle contractility (Rosenbaum et al., 2003). With 
regard to weight reduction an increase in TEE and overall PAL is necessary. In a recent study 
it was shown that overall PAL decreased in the energy restricted group with no such decrease 
in the energy restricted plus exercise group (Martin et al., 2007). Thus there are good reasons 
to increase the level of overall physical activity both during energy deficient states and during 
weight maintenance. Indeed, a high level of physical activity has been shown among subjects 
that sustained weight loss for long-term (Jakicic et al., 2008; Catenacciet al., 2008). 
Participation in physical activity for 48 minutes per day was reported among the 25% of 
subjects that maintained a weight loss of more than 10% during two years of follow-up 
(Jakicic et al., 2008). Likewise, the National Weight Control Registry found that subjects 
having successfully maintained a weight loss of at least 13.6 kg for more than one year 
participated in 60 to 75 minutes of moderate physical activity per day. However, the standard 
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deviation was high suggesting a wide range in the amount of performed physical activity 
(Catenacci et al., 2008).  
The result of our study showing that the subjects participated in moderately physical 
activity for 26 minutes per day at least four days of the week may be generalised to middle-
aged obese men and women with risk factors for metabolic syndrome. The study was small 
but the results are is in line with the 27 minutes of physical activity monitored in a subgroup 
of more than 2000 healthy subjects aged 20 to 69 years in the NHANES 2003-2004 study 
(Troiano, 2008).  
 
5.1.5 The effect of increasing intake of vegetables and fruit on weight loss and 
cardiovascular risk factors
In paper 4 targeted dietary counselling to increase the intake of vegetables and fruit 
contributed to weight reduction and decreased systolic and diastolic blood pressure in subjects 
with SRBD but had no effect on blood lipids or antioxidant status measured with the ferric 
reducing antioxidant power assay. The dietary intervention resulted in a doubled intake of 
vegetables and fruit in the intervention group compared to the control group. Energy density, 
energy percent of fat and energy percent of saturated fat were decreased and energy percent of 
carbohydrate, fibre, potassium, magnesium, vitamin C, folate, -tocopherol and -carotene 
were all increased in the intervention group compared to control group. The multiple 
regression analysis indicates that increased intake of vegetables contributed to the weight loss 
of about 1 kg per month. A similar monthly weight reduction was seen in the PREMIER 
clinical trial (Appel et al., 2003). The PREMIER study lasted for six months, included adults 
with above optimal levels of blood pressure and tested the effect of established 
recommendations for blood pressure reduction (weight loss, sodium restriction, increased 
physical activity and limited alcohol intake) compared to the effect of these recommendations 
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plus the DASH diet rich in fruit, vegetables and low fat diary products. In the PREMIER 
study, both interventions reduced blood pressure compared to the control group. In the group 
that included the DASH diet, the reduction in systolic and diastolic blood pressure was 4 and 
3 mmHg, respectively (Appel et al., 2003). Like ours, the study was conducted in a clinical 
setting and no food was provided.   
It seems like a dietary and behavioural intervention to increase intake of vegetables 
and fruit was effective with regard to weight loss, blood pressure reductions and increased 
concentrations of plasma antioxidants, but had no effect on serum lipids. This may be due to 
the obesity status of the participants. In a feeding study Lefevre et al. showed that the 
reduction in LDL cholesterol decreased as the percentage of body fat, BMI and insulin 
increased (Lefevre et al., 2005). In addition, the intervention could have been more tailored to 
favourable effects on lipid levels. The subjects in this study were included on the basis of 
their diagnosis of SRBD but they also experienced a high metabolic risk profile including 
components of the metabolic syndrome. In dietary treatment of the metabolic syndrome it is 
recommended to decreased intake of saturated fat to less than 7% of total energy (Grundy et 
al., 2005). Indeed, the intake of fatty meat product decreased and the intake of lean meat 
products increased in the intervention group compared to the control group (data not shown). 
However, given the beneficial effect on apolipoprotein-B and triglyceride containing lipids 
including more protein in the diet (Furtado et al., 2008), maybe targeted advice to increase the 
intake of low-fat diary products, legumes and nuts may have been beneficial. To decrease 
intake of saturated fat also more emphasis should have been given to reduction of the intake 
of buns, cakes, biscuits, ice cream, chocolate and snacks. Very low fat diets however, are not 
preferable in individuals with depressed HDL-cholesterol and elevated triacylglycerol 
concentrations. An eating pattern like the Mediterranean-style diet, which is rich in fibre and 
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has moderate amounts of unsaturated fat, has been shown to reduce metabolic risk factors 
(Esposito et al., 2004). 
The reported dietary intake of saturated fat decreased, especially in the intervention 
group. However, the energy intake was underreported. In this study we did not validate the 
energy intake data by measured TEE, but EI can be validated as suggested by Goldberg et al. 
(Goldberg et al., 1991). With this technique recorded EI is compared with presumed energy 
expenditure (i.e. EI is expressed as a multiple of RMR). Using the Mifflin formula to 
calculate RMR, the EI/RMR showed underreporting in both groups at baseline (EI/RMR= 
1.40 in the control group versus EI/RMR=1.38 in the intervention group) and after three 
months (EI/RMR= 1.38 in the control group versus EI/RMR=1.29 in the intervention group). 
This may have been expected, given the above discussion. In addition, unpublished data with 
regard to the reproducibility of the FFQ as was tested in 50 subjects with SRBD participating 
in two dietary interview separated by one month, showed more underreporting at the second 
interview compared to the first (EI at the first FFQ was 2551 kcal and EI at the second FFQ 
was 2329 kcal). Moreover, participation in a weight-loss program may further increase 
underreporting (Johnson et al., 2005). Taken the underreporting into consideration, the intake 
of saturated fat may have been higher than reported. 
 Conducting a dietary intervention in subjects diagnosed with SRBD, gave some 
unexpected challenges. Despite CPAP treatment, many of the subjects were tired, exhausted 
and felt asleep during the sessions. Not all subjects managed to do their homework exercises 
and issues that were important for the subjects were discussed in the group when they came 
up. As an example the subjects wishes for new recipes and tips for variation of the diet 
preceded the visit to the vegetables and fruit store, as was a success. The behavioural 
treatment program was group based, but at every visit the subjects were weighed individually. 
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This time was used to briefly assess individual barriers to the intervention. If suitable, the 
barriers were discussed more broadly in the group sessions.   
About generalisability, this study included patients diagnosed with SRBD and 
consecutively referred to the Department of Preventive Medicine. The majority of the subjects 
used CPAP. The results of this study may be less generalisable to subjects with SRBD not 
treated with CPAP. The study also included a small number of women due to pervasiveness 
of SRBD in male gender. However, a number of other trials have investigated the effect of an 
increased intake of vegetables and fruit in women (Apple et al., 1997; Howard et al., 2006; 
Ello-Martin et al., 2007). After three years, the Women’s Health Initiative Dietary 
Modification Trial showed that weight loss was achieved with a decrease in intake of fat and 
increased intake of vegetables and fruit. Furthermore, the DASH trial that included both 
women and men, showed reduction in diastolic blood pressure (Apple et al., 1997).  
 
5.1.6 The influence of orlistat with regard to eating behaviour and dietary intake 
5.1.6.1 Eating behaviour 
In Paper 5 we found no substantial differences between the effect of orlistat or placebo on 
eating behaviour measured with the TFEQ and BES during three years of weight maintenance 
following a VLED. We observed that the placebo group showed a lower score for hunger 
after 33 months, but this difference in hunger may be of minor clinical relevance given the 
overall reduction in hunger in both groups. Golay et al have recently reported this. They 
followed 55 severely obese subjects for five years after a six-week in-hospital weight loss 
program and found emotional liability, depression and anxiety rather than hunger as reasons 
for overeating. Moreover, the subjects that regained weight during follow up reported higher 
rates of behaviour disorder, psychological difficulties and a poor dietary structure (Golay et 
al., 2004).  
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All subjects in our study were instructed to take orlistat or placebo to their main meals. 
In this regard orlistat may be important to enable subjects to have a regular meal structure. 
The optimal meal structure has not been established for weight loss and weight maintenance. 
However, most of the successful weight maintainers in the National Weight Control Registry 
reported regularly eating breakfast every day of the week (Wyatt et al., 2002). A regular meal 
plan may be important in preventing impulsive eating and over-eating episodes. Over-eating 
tendency was a good predictor for energy intake in Type 2 diabetes patients followed for four 
years (Van Strien and Van der Laar, 2008) and impulsivity has been associated with 
disinhibition (Yeomans et al., 2008). Moreover, in a retrospective study in 535 women 
habitual disinhibition was the strongest correlate of weight gain during 20 years (Hays and 
Roberts, 2008). A reduction in disinhibition together with an increased score for restraint has 
been taken to be an expression of successful dieting (Yeomans et al., 2008). In our study we 
found that increased score for restraint and decreased scores for disinhibition and binge eating 
were associated with changes in weight in the orlistat group. It can be speculated that orlistat 
have influenced these eating behaviours in a subgroup of individuals prone to overeat in 
response to different disinhibitors. 
In multivariate analyses, increased restraint and decreased disinhibition and binge 
eating were predictors of sustained weight maintenance in all participants adjusted for BMI, 
age, gender and treatment. Thus, changes in eating behaviour in the orlistat group are mostly 
due to quantified eating behaviour similar to the way placebo operates. In fact, dietary 
restraint increased and disinhibition, hunger and binge eating decreased during the VLED 
period. It seems like the weight reduction itself contributed to these changes in eating 
behaviour and that these changes sustained whether or not taken an active anti-obesity drug. 
This may be due to the dietary and behavioural treatment program as was organized both in 
group and in individual sessions and included weight monitoring, dietary diaries, skills 
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training, problem solving issues, relapse prevention and dealing with emotional states. These 
were the same elements emphasized in the Look AHEAD study an intervention study that is 
designed to determine the effect of weight reduction on cardiovascular morbidity and 
mortality in overweight subjects with type 2 diabetes (Wadden et al., 2006).  
The results of our study are generalisable to men and women with metabolic risk 
factors that have achieved an initial weight loss and use orlistat treatment for weight 
maintenance in a behaviour modification program. The results may be less generalisable to 
subjects with eating disorders.  
  
5.1.6.2 Dietary intake 
In paper 6 we have two findings. First, the use of orlistat did not lead to a lower fat intake 
compared to placebo in obese subjects consuming a low fat diet and participating in a 
structured program for weight loss maintenance. Second, subjects that chose to take orlistat 
when its use was optional did not comply with the dietary fat recommendations.  
One concern about the use of an-antiobesity drug is that the use will attenuate the motivation 
to maintain dietary changes. Like others (Hill et al., 1999; Franson and Rössner, 2000), we 
did not find differences in dietary intake between the orlistat and placebo groups. The orlistat 
group reduced their dietary intake of fat and increased their intake of carbohydrates just like 
the placebo group and both groups reported to consume a low fat diet. In this regard, the use 
of orlistat seems not to influence the dietary intake when the subjects are participating in a 
behavioural treatment program and follow dietary recommendations. In these subjects, the 
pharmacological effect of the drug will improve weight loss and maintenance (Richelsen et 
al., 2007; Rucker et al., 2007).  
In contrast, the subjects that chose to take orlistat when it’s use was optional may have 
been aware that they will not or can not adhere to the dietary recommendations and this may 
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hamper the effect of the drug (Ullrich et al., 2003; Golay et al., 2005). In our study, these 
subjects achieved an initial weight loss of more than 5%, they participated in a behavioural 
treatment program and were scheduled for 30 visits with a dietician during three years of 
follow up. In addition they were weighed at the visits and monitored their diet on four 
occasions. Despite of this treatment program the subjects were not able to sustain the dietary 
recommendations that were given. These subjects may need follow-up by a psychologist or 
specialist in behavioural therapy to work with other barriers of weight loss. Other dietary 
composition approaches may also have been more beneficial for these subjects. A recent 
study showed that weight loss was sustained for two years in three dietary regimens: 3 kg by a 
low fat diet, 4 kg by a Mediterranean diet and 5 kg by a low carbohydrate diet (Shai et al., 
2008). It may be easier for some subjects to reduce carbohydrate than fat. May be better 
individualized tailoring of different diets based on preferences and experiences in the nutrition 
counseling could increase compliance with dietary interventions. Enhanced compliance may 
also be achieved by more focus on self-monitoring of weight. Consistent daily or weekly self-
monitoring of weight has been reported to be beneficial for weight maintenance (Wing et al., 
2006; Butryn et al., 2007). 
The use of the VLED may be questioned. However, the method has been 
recommended for weight loss purposes, providing the diet is followed by a 1-2 years 
integrated weight maintenance programme consisting of lifestyle interventions involving 
dietary change, nutrition education and behavioural therapy (Astrup & Rössner, 2000) as was 
given in the SMOMS trial (Richelsen et al., 2007). Given the overall result of the SMOMS 
trial, the method seems safe and effective and improvement in weight maintenance may be 
achieved with the use of orlistat. It has to be mentioned that the subjects were followed 
weekly during the VLED period and behavioural treatment were included in the sessions. The 
subjects were recommended to consume the VLED portion at regular meal times and eat 
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vegetables in the amounts of 100 kcal per day. After the VLED period, the subjects were very 
restrictive and interested to make change in their diet to sustain weight reduction. During the 
long-term follow up, the diet deteriorated slightly. This was observed despite an obvious 
underreporting of dietary intake. Two months after the end of the trial, the reported intake of 
saturated fat was above the recommended level of 10% of energy in the orlistat group.  
The study population in this study was small and care must be taken with regard to 
generalisability of the three years data. More research is needed on dietary intake of subjects 
that chose to take an anti-obesity drug for long-term weight maintenance after weight loss. 
 
5.2 Implications for treatment 
A majority of obese subjects with metabolic risk factors underreported dietary intake to such a 
degree that dietary counselling with the aim of energy restriction was difficult. This may be a 
general underreporting of portion sizes and a more specific underreporting of sweets, desserts 
and snacks. Hence, it seems important to ask pointedly about these items in dietary 
interviews. The dietary interview based on a FFQ provided more accurate data than the DR. 
This may be due to the fact that FFQ reflected dietary intake during the last three months and 
included holidays. Moreover, restrained eating behaviour did not influence reporting accuracy 
according to the FFQ. Thus is seems like long-term assessments of dietary intake better 
capture irregular eating occasions that increase energy intake in the obese.   
A measurement of TEE with the ActiReg® method gives a valid estimate of TEE 
despite a small underestimation. Improvements of the ActiReg® system with regard to 
actually calculating energy used during vigorous exercise, carrying loads and resistance 
training activities are needed. In obesity research a measurement of RMR is preferable in 
assessments of TEE especially in subjects that are not weight stable. Given the poor reporting 
accuracy of dietary intake among the obese, prescribing energy restriction 500 kcal to1000 
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kcal below TEE is another approach that can be used. In this approach individually meal plans 
based on the subjects’ food preferences may be prescribed at the correct energy intake.  
Obese subjects performed moderate physical activity for 26 minutes at least four days 
of the week, before advice for weight loss was given. This level of physical activity is almost 
in accordance with recommended levels for health benefits. For weight loss and maintenance, 
the amount of exercise probably has to be more than doubled. However, the individual 
variation in level of physical activity is high and an objective assessment of physical activity 
may be a tool for tailoring exercise prescriptions.  
A doubling of the intake of vegetables and fruit induced weight loss, decreased blood 
pressure and increased carotenoid concentrations in obese subjects with SRBD. The subjects 
participated in a behavioural treatment program conducted of a registered dietician. Minor 
weight loss was seen in the control group that only were seen at a usual care practice by the 
same dietician. This implies that dietary interventions to increase intake of vegetables and 
fruit in free-living obese subjects are achievable when the subjects are offered a behavioural 
treatment program of eight sessions during three months.   
In motivated subjects a substantial, initial weight loss was achieved with a VLED in a 
behavioural treatment program. Orlistat did not influence eating behaviour or dietary intake 
other ways than the placebo did during long-term weight maintenance after a VLED for eight 
weeks. Some subjects that chose to take orlistat may be aware that they do not or cannot 
follow dietary recommendations and this may hamper the effect of the drug. In these subjects 
various dietary interventions, more intensive programs including consistent self-monitoring, 
additional psychological therapies, other anti-obesity drugs or surgery need to be considered. 
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6 CONCLUSIONS 
1. A majority of obese subjects with metabolic risk factors underreported dietary intake 
to such a degree that dietary advice to achieve moderate energy restriction cannot be 
based on dietary assessments. The mean difference between reported energy intake 
and energy expenditure was about 500 kcal and 1000 kcal as measured by the FFQ 
and the DR, respectively.  
2. Despite a small underestimation of 100 kcal, measurement of TEE with the ActiReg® 
method gives a valid estimate of TEE in obese subjects with metabolic risk factors 
when RMR is measured and the increased energy during weight bearing activities is 
considered. This is a non-invasive way of measuring TEE that may deserve further 
clinical study and application. 
3. Obese subjects seeking treatment spent a mean of 26 min per day in moderate physical 
activity measured with ActiReg® before advice for weight loss was given. This 
suggests that for weight loss and maintenance purposes the level of physical activity 
has to be increased.  
4. Targeted dietary advice to increase the daily intake of vegetables and fruit given in a 
behavioural group program for three months resulted in better weight loss, decreased 
systolic and diastolic blood pressure and increased plasma levels of lipid soluble 
antioxidants (-carotene, -carotene) in the intervention group compared to controls. 
5. When included as part of a behavioural program for weight loss maintenance orlistat 
did not influence dietary restraint, disinhibition or binge eating in other ways than 
placebo. Hunger was reduced more in the placebo group than in the orlistat group, but 
this seems not to be of clinical importance giving the overall reduction in hunger in 
the orlistat group.  
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6. When included in a dietary treatment program orlistat did not influence dietary intake 
of fat differently than placebo. Subjects that chose to take orlistat after the end of the 
program had higher than recommended intake of fat and this may hamper the 
effectiveness of the drug.  
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Accuracy of food intake reporting in obese subjects with metabolic risk factors
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The aim of the present study was to determine the accuracy of reported energy intake according to a food-frequency questionnaire (FFQ) and dietary records
(DR) in obese subjects with metabolic syndrome risk factors. Subjects were twenty-three men and twenty-seven women with mean BMI of 35·7 (range
30·5–43·8) kg/m2 who participated in a dietary interview based on a FFQ and completed weighed DR. Total energy expenditure was measured with the
doubly labelled water method. Total energy expenditure, measured RMR and physical activity level did not differ between under-reporters (50% of the
sample) and non-under-reporters. Under-reporters had lower median intake of sweets, desserts and snacks than non-under-reporters (100 v. 161 g/d
(P¼0·0008) and 61 v. 128 g/d (P¼0·0002) according to the FFQ and DR, respectively). The DR also showed lower energy density (6·7 (SD 1·3) v. 7·9
(SD 1·6) kJ/g; P¼0·0064), lower intake of sugary drinks (0 v. 167 g/d; P¼0·0063) and higher scores for dietary restraint (9·0 (SD 5·0) v. 6·1 (SD 3·5);
P¼0·0285) in under-reporters. Energy density was associated with accuracy according to the FFQ (Spearman’s rank correlation coefﬁcient (RS) 0·406;
P¼0·0034) and the DR (RS 0·537; P,0·0001). In multivariate analysis, consumption of bread and sweets, desserts and snacks measured by the FFQ
was positively associated with accuracy (R 2adjusted 0·46 (95% CI 0·32, 0·70)). According to the DR, consumption of sweets, desserts and snacks was
also associated with accuracy, as was dietary restraint (inversely) (R 2adjusted 0·67 (95% CI 0·54, 0·83)). In obese subjects with metabolic risk factors,
intake of sweets, desserts and snacks, bread and dietary restraint were determinants of reporting accuracy.
Energy intake: Under-reporting: Eating behaviour: Doubly labelled water
In 2001, the National Cholesterol Education Program deﬁned the
metabolic syndrome as a constellation of at least three of ﬁve risk
factors (increased waist circumference, hypertriacylglycerolaemia,
low HDL-cholesterol, high blood pressure, and high fasting
glucose) that increase the risk of CHD and recommended that
the metabolic syndrome should be a target of risk-reduction
therapy after the primary target, level of LDL-cholesterol, is
met (Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults, 2001). One of the primary
methods of risk reduction is weight loss. Studies have shown
that even a modest degree of weight loss induced by dietary
and lifestyle change in individuals with characteristics of the
metabolic syndrome is associated with clinical beneﬁts
(Tuomilehto et al. 2001). However, counselling for weight loss
is hampered by the difﬁculty in obtaining accurate dietary data
(Lissner, 2002). The development of the doubly labelled water
(DLW) method to estimate total energy expenditure (TEE) has
led to general acceptance of the notion that dietary self-reporting
substantially underestimates energy intake (EI), and data have
accumulated for nearly two decades showing that obese
individuals are more likely to under-report than others (Prentice
et al. 1986, 1996; Braam et al. 1998; Hill & Davies, 2001).
Studies on the accuracy of dietary self-reporting have con-
sidered a number of factors in addition to a high BMI that may
inﬂuence the likelihood of under-reporting. These include sex,
age, socio-economic status, eating behaviour and dieting, physical
activity, non-smoking, psychological factors and the cultural con-
text as reviewed recently (Livingstone & Black, 2003). Under-
reporting is accentuated when repeated assessment of dietary
intake is conducted (Caan et al. 2004). Furthermore, certain
foods and nutrients are more likely to be under-reported than
others, primarily carbohydrates, fats, snacks, and foods or
drinks that are considered to be unhealthy (Bingham et al.
1995; Heitmann & Lissner, 1995; Poppitt et al. 1998; Tonstad
et al. 1999; Goris et al. 2000; Hill & Davies, 2001). Such selec-
tive under-reporting may lead to spurious associations between
dietary components and biological markers or risk factors
(Lissner et al. 1998). Poor accuracy of dietary data may be
more pronounced and may mislead public policy, in particular
when subjects at high risk for disease are considered, for example,
individuals with the metabolic syndrome, as indeed has been
demonstrated recently (Rosell et al. 2003). In this study, under-
reporters had a higher prevalence of the metabolic syndrome
than other subjects and associations between the diet and the
components of the metabolic syndrome differed between
under-reporters and the remaining subjects (Rosell et al. 2003).
The aim of the present investigation was to examine the deter-
minants of self-reporting of energy in a sample of obese men and
women with the metabolic syndrome or at least two of its risk fac-
tors and to explore the speciﬁc foods, eating patterns and
behaviour that are associated with under-reporting using the
DLW method to estimate TEE. The overall goal was to inform
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the dietary advice that is appropriate for this group of individuals.
Because cigarette smoking may confound the relationship
between nutrient intakes and under-reporting (Dallongeville
et al. 1998), we chose to include only non-smokers in the study.
Subjects and methods
Subjects
Fifty non-smoking, obese men and women with a mean age of
43·2 (SD 10·3; range 24–64) years and a mean BMI of 35·7
(SD 3·3; range 30·5–43·8) kg/m2 and two or more risk factors
for the metabolic syndrome according to the National Cholesterol
Education Program (glucose $6·1mmol/l or HDL-cholesterol
#1·03mmol/l for males or #1·29mmol/l for females or serum
triacylglycerols $1·69mmol/l or waist circumference .102 cm
for males or .88 cm for females or systolic blood pressure
$130mmHg and diastolic blood pressure $85mmHg) were
recruited by newspaper advertisement and referral to the Depart-
ment of Preventive Cardiology at Ulleva˚l University Hospital
(Oslo, Norway). Subjects were screened via blood chemistry
and a medical examination done by a physician to assess risk fac-
tors and eligibility to the study. Fifteen subjects had two risk fac-
tors, twenty-seven subjects had three risk factors and eight
subjects had four risk factors; thus 60% had the full metabolic
syndrome. Exclusion criteria were body weight .135 kg, current
dieting, cigarette smoking, history of eating disorder or chronic
disease, suspected non-compliance due to abuse of drugs or alco-
hol, drug- or insulin-treated diabetes mellitus, migraine requiring
intermittent medication, use of thyroxin, diuretics or weight-redu-
cing agents and use of inhaled or oral b-agonists or corticoster-
oids. The educational level of each subject was determined
according to the number of years of education and categorised
as completed primary school, high school or a university
degree. The Ethical Committee (region 1 in Norway) approved
the protocol and all participants gave their written informed
consent. The study was conducted between October 2001 and
October 2003.
Measurements
Height was measured with a standardised wall measuring stick
scale to the nearest 0·5 cm. Subjects were weighed (in underwear)
with a digital weight (SECA, Hamburg, Germany) to the nearest
0·1 kg. Weight was measured at the screening and baseline visits
and on day 1 and day 15 of the DLW measurement period.
Weight changes during the DLW period were calculated as the
difference between day 15 and day 1 and weight changes
during the 3-month study as the difference between day 15 of
the DLW period and baseline. Waist was measured in the stand-
ing position at the level of umbilicus (unclothed) and hip circum-
ference was measured at the level of the greater trochanter. Body
composition was determined by dual-energy X-ray absorptiome-
try (Lunar Expert 1116; Lunar Corp., Madison, WI, USA). The
measurement was done in 15min. The CV for the dual-energy
X-ray absorptiometry measurements was 3–4%. RMR was
measured with a standard portable ventilated hood system (Delta-
tracw Metabolic Monitor; Datex Instrumentarium Corp.,
Helsinki, Finland). The Deltatracw was calibrated by automatic
standard gas calibration at the start of each measurement. The
subjects slept at home the night before the measurement. On
the day of the measurement the subjects took a taxi to the site.
The subjects fasted during the last 12 h before the measurement
and were instructed not to eat or drink anything but water on
the day of the measurement. After changing clothes and mounting
the equipment, the subjects relaxed for 30min in the recumbent
position before the head was covered with the canopy. Measure-
ments were done at 1min intervals for 20–25min. A mean value
of at least a 10min period at a stable level of energy expenditure
was deﬁned to be the RMR.
Doubly labelled water method
Energy expenditure by the DLW method was measured over a
period of 14 d and used as a measure of habitual energy expendi-
ture. Sample analyses and calculation procedures have been
described in detail elsewhere (Slinde et al. 2003). First a baseline
urine sample was collected for the determination of the back-
ground isotope enrichment (day 1). Then a weighed mixture of
2H-labelled and oxygenated water, corresponding to 0·05 g 2H-
labelled water and 0·10 g 18O-labelled water/kg body weight,
was ingested. The percentage enrichment of the waters was
99·9% for 2H and 10·0% for 18O. The dose was planned to
enrich body water with approximately 350 parts per thousand (d
per mil) for 2H and 60 parts per thousand (d per mil) for
18O. Urine samples were collected from the second voiding
during day 2, day 3, day 4, day 8, day 13, day 14 and day 15.
The mean time interval between drinking dose and the ﬁrst
post-dose urine sample was 22 (SD 3; range 12–30) h. The partici-
pants were instructed to collect the urine spot, register exact void-
ing time and freeze the samples at home. Participants were called
every voiding day to ensure compliance with the procedure.
When the samplings were completed, the urine samples were
stored at 2758C until transportation to the laboratory on dry ice.
Analysis of the isotopic enrichment was determined in tripli-
cates with a Thermoquest Finnigan MAT Delta plus isotope-
ratio mass spectrometer with a water/H2-CO2 equilibrating
device (Thermoquest Finnigan MAT, Bremen, Germany). The
precision deﬁned as standard error in triplicate samples is 0·26
for 3H and 0·10 for 18O. Tap water was collected and analysed
for background measurements and all TEE calculations were cor-
rected for the content of isotopes in the drinking water. TEE was
calculated by the multi-point method using linear regression as
suggested by the International Dietary Energy Consultancy
Group (1990). All elimination curves were checked for major
or diverging residuals. The CV for the elimination constants
was on average 3·2% for hydrogen and 2·7% for oxygen. The
mean No:Nd ratio was 1·033 (SD 0·008; range 1·007–1·049). We
used the relationship between pool size of 2H (Nd) and pool
size of 18O (No) as a quality measurement for the DLW. The
mean food quotient (FQ) determined from the food-frequency
questionnaire (FFQ) was 0·85 (SD 0·016; range 0·81–0·89). The
individual No:Nd ratio and FQ of the participants were used in
the calculation of the energy equivalence of the produced CO2
as suggested by the International Dietary Energy Consultancy
Group (1990).
Food-frequency questionnaire
A FFQ was used as the basis of an interview with a registered die-
titian (M. S.), lasting between 1 and 2 h. The FFQ was designed to
assess the food intake during the last 3 months and based on two
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previously developed FFQ (Lindroos et al. 1993; Andersen et al.
1999). The questionnaire elicited frequencies and consumption of
174 individual food items or constellations of items grouped
together according to the typical Norwegian meal pattern. Speciﬁ-
cally the consumption of soft drinks and alcoholic beverages,
sweet baked goods, cookies, cakes, ice cream, desserts, sweets,
chocolate and snacks as nuts, potato crisp and popcorn were
asked for. The FFQ also included twenty-one summary questions
and seven dietary supplement questions. An atlas of food portions
as well as photographs, household measurements and ordinary
models of sweets and snacks was used to estimate portion sizes.
Particular attention was given to extra layers of bread spread,
food eaten during cooking, fat used in frying and extra portions
of dinner and dinner leftovers. The FFQ interview was done
immediately following the DLW measurement period.
Weighed dietary records
Participants were provided with food scales and instructed to
weigh each individual food item using a digital scaled weight
and provide notes on ingredients of composite dishes with
approximate quantities. When weighing was not appropriate, the
subject used household measurements and pictures to record por-
tion sizes. Forty-nine subjects completed dietary records (DR) for
three non-consecutive days. One male subject was not able to
complete the DR due to personal problems. The records were
done with 3–4 d between each recording and all days of the
week were about equally represented. On average the DR were
completed a mean of 34 (SD 25) d before the DLW measurements.
We assessed eating frequency by counting the number of eating
occasions recorded in the DR. An eating occasion was deﬁned as
a food or snack (solid or liquid) containing energy with an inter-
val of .1 h separating the occasions (Farshchi et al. 2005).
Assessment of eating behaviour
Forty-nine subjects completed the Norwegian version of the
Three Factor Eating Questionnaire. One male refused to ﬁll in
the questionnaire. The Three Factor Eating Questionnaire was
developed to measure cognitive and behavioural components of
eating (Stunkard & Messick, 1985). The scale contains subscales
for restraint (possible scores 0–21), disinhibition (0–16) and
hunger (0–14). The restraint subscale assesses the intent to con-
trol food intake to achieve and maintain a desired body weight.
The disinhibition scale assesses overeating in response to a var-
iety of situations associated with loss of control of food intake,
while the hunger subscale assesses subjective feeling of hunger
and food cravings.
Deﬁnition of under-reporters and non-under-reporters of energy
Subjects were identiﬁed as under-reporters, accurate reporters and
over-reporters of energy based on the 95% conﬁdence limits (CL)
of the expected EI:TEE ratio of 1·00. The 95% CL between the
two measurements were calculated from the published equation
(Black & Cole, 2000):
95%CL ¼ ^2 £ pððCVTEEÞ2 þ ðCV2EI=dÞÞ:
CVTEE for repeated measurements for energy measurements by
the DLW method was 8% (Black & Cole, 2000). CVEI is the
within-subject CV for daily intake of energy and 23% was used
(Bingham, 1987). The number of days was 90 for the FFQ and
3 for the DR.
According to this calculation, subjects were classiﬁed as under-
reporters, accurate reporters and over-reporters, depending on
how much EI:TEE deviated from the expected ratio of 1·00. Sub-
jects deﬁned as accurate-reportersFFQ had an EIFFQ:TEE ratio
within the 95% CL (0·83, 1·17), under-reportersFFQ had an EIFFQ:
TEE ratio below the lower CL (,0·83) and over-reportersFFQ had
an EIFFQ:TEE ratio above the upper CL (.1·17). Accurate-
reportersDR had an EIDR:TEE ratio within the 95% CL (0·69,
1·31), under-reportersDR had an EIDR:TEE ratio below the lower
CL (,0·69) and over-reportersDR had an EIDR:TEE ratio above
the upper CL (.1·31). According to the FFQ, two males and
two females were classiﬁed as over-reporters; while, according
to the DR, one female was an over-reporter. Because the
number of over-reporters was minor, accurate reporters and
over-reporters were grouped as non-under-reporters.
Calculations and statistics
The FFQ and the DR were coded manually for calculations of
total energy, energy density, energy-yielding nutrients and food
items with a computer program based on the Norwegian food
composition table (Rimestad et al. 1995; National Association
for Nutrition and Health, 1996). Because of the low median
intake of speciﬁc foods, we grouped food items into the following
categories: fruit, berries, juice and jam; milk; bread; vegetables;
boiled potatoes, rice and pasta; fatty meats, minced meat and sau-
sages; chicken and meat with less fat; ﬁsh and ﬁsh products; oil,
butter and margarine; fatty cheese; sweets, desserts and snacks;
sugary drinks. The calculated dietary intake of energy assessed
by FFQ and DR was compared directly to the estimated TEE
from the DLW measurement. Energy density was calculated for
the whole diet minus all drinks (coffee, tea, milk, juice, soft
drinks and alcoholic beverages).
The results are presented as means and standard deviations, or
medians with interquartile ranges (IQR) for non-normally
distributed data. Mean and median differences were tested with
the unpaired Student’s t test and the Mann–Whitney signed
rank test, respectively.
Anthropometrics, daily intake of nutrients and food and eating
scores for restraint, disinhibition and hunger were correlated with
the EI:TEE ratio calculated by the FFQ and the DR. Pearson’s
correlation coefﬁcients were calculated for normally distributed
variables and Spearman’s rank correlation coefﬁcients (RS)
were calculated for skewed variables. Simple regression analyses
were conducted to assess the relation of reporting accuracy to
percentages of energy from protein, fat, and carbohydrate and
food intakes to determine whether there was selective under-
reporting. Factors that were statistically signiﬁcant in the univari-
ate analysis were entered into a multiple regression analysis to
identify the most important factors correlated to reported accu-
racy of EI. Because the intake of food is reﬂected in the calcu-
lated diet composition, we chose to enter the reported intake of
food instead of diet composition in the multivariate regression
analyses.
The tests were considered signiﬁcant at P,0·05. Statistical
analyses were performed using the StatView 5.0.1 software
(SAS Institute Inc., Cary, NC, USA).
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Results
Characteristics of participants according to sex are shown in
Table 1. Subjects had high concentrations of triacylglycerols,
diastolic blood pressure and waist circumference in accordance
with the inclusion criteria. Restraint and hunger scores were simi-
lar for men and women, but women scored higher than men on
the disinhibition factor.
Eating characteristics of under-reporters and non-under-
reporters
Relative to TEE, both men and women under-reported EI in both
dietary assessment methods. EI among male subjects was under-
reported by 14·1 (SD 18·9; range 236·0 to 41·6) % according to
the FFQ and by 27·9 (SD 14·4; range 23·1 to 51·7) % according
to the DR compared with the measured TEE. Female subjects
under-reported EI by 20·6 (SD 24·1; range 235·2 to 62·9) and
31·0 (SD 22·0; range 244·6 to 69·0) % according to the FFQ
and the DR, respectively. No signiﬁcant difference by sex was
seen in the reported EI relative to TEE. More than 50% of the
subjects were classiﬁed as under-reporters of EI according to
both methods (Table 2).
Anthropometrics, energy expenditure, energy density, daily
intakes of energy-yielding nutrients and foods and scores for
eating behaviour in under-reporters and non-under-reporters
according to the FFQ and DR are shown in Tables 3 and 4, and
Tables 5 and 6, respectively. Eating frequency assessed by the
DR is also shown in Table 6. According to the DR, under-repor-
ters had a lower energy density of the diet and reported a lower
intake of ‘sweets, desserts and snacks’ and sugary drinks, as
was reﬂected in a higher percentage of energy from protein and
a lower percentage of energy from sugar among under-reporters
compared with non-under-reporters. However, the reported absol-
ute amount of protein was lower in under-reporters compared
with non-under-reporters according to both dietary assessment
methods (92·2 (SD 23·0) v. 117·2 (SD 30·9) g; P¼0·0018 accord-
ing to the FFQ and 80·7 (SD 23·7) v. 97·5 (SD 20·0) g; P¼0·0116
according to the DR). Energy-adjusted intake of sweets, desserts
and snacks (median) was lower among under-reporters than non-
under-reporters, respectively (7·7 (interquartile range (IQR) 4·9–
10·9) v. 11·0 (IQR 7·6–14·7) g/MJ; P¼0·0275) according to the
DR. According to the FFQ the same trend was seen, although
not statistically signiﬁcant (11·1 (IQR 7·0–13·7) v. 12·2 (IQR
9·9–14·8) g/MJ; P¼0·2256). Sweets, desserts and snacks intake
was inversely related to percentage energy from protein according
to the FFQ (RS 20·51; P¼0·0004) and the DR (RS 20·48;
P¼0·0008). According to the DR, the energy density of the diet
was associated with sweets, desserts and snacks (RS 0·553;
P¼0·0001) and according to the FFQ the association was not sig-
niﬁcant (RS 0·272; P¼0·573).
No signiﬁcant differences were seen in eating behaviour scores
in under-reporters compared with non-under-reporters, with the
exception of restraint scores, which were higher in under-repor-
ters than non-under-reporters according to the DR (Table 5).
During the DLW period, the mean weight change in all partici-
pants was 0·1 (SD 1·0; range 23·6 to 1·8) kg. No signiﬁcant
weight difference was seen between under-reporters and non-
under-reporters (0·01 (SD 0·97) v. 0·22 (SD 1·11) kg; P¼0·4768
according to the FFQ and 0·01 (SD 1·12) v. 0·29 (SD 0·82) kg;
P¼0·3299 according to the DR). There was no signiﬁcant differ-
ence in the weight change between under-reporters and non-
under-reporters in the entire 3-month period of the study (1·24
(SD 1·56) v. 1·49 (SD 1·57) kg; P¼0·5769 according to the FFQ
and 1·50 (SD 1·50) v. 1·21 (SD 1·65) kg according to the DR).
Reporting accuracy
The relationship of reporting accuracy to anthropometrics, energy
density, diet composition, intakes of food and eating behaviour
scores is shown in Table 7. According to the FFQ, reporting accu-
racy was inversely correlated to the percentage energy from pro-
tein and positively to the percentage energy from sugar and the
energy density of the diet. Accuracy was positively associated
with the intake of the following: sweets, desserts and snacks;
fatty cheese; bread; milk; oil, butter and margarine. Scores for
restraint were inversely and scores for hunger were positively
Table 1. Characteristics of participants*
(Mean values and standard deviations)
Men (n 23) Women (n 27)
Mean SD Mean SD P
Age (years) 44 10 42 11 0·5543
Height (m) 1·82 0·07 1·69 0·06 ,0·0001
Weight (kg) 115·1 13·8 104·5 12·1 0·0058
BMI (kg/m2) 34·6 2·9 36·6 3·4 0·0290
Tissue fat (%) 41·5 7·5 53·3 5·6 ,0·0001
Waist (cm) 118·4 10·0 106·4 9·4 ,0·0001
Hips (cm) 110·0 7·6 117·6 9·6 0·0036
Waist:hip ratio 1·1 0·1 0·9 0·1 ,0·0001
Systolic blood pressure (mmHg) 128 11 123 15 0·1824
Diastolic blood pressure (mmHg) 85 8 85 10 0·9143
Total cholesterol (mmol/l) 6·2 1·1 6·2 1·3 0·9217
LDL-cholesterol (mmol/l) 3·8 0·7 4·1 1·1 0·4256
HDL-cholesterol (mmol/l) 1·1 0·2 1·3 0·3 0·0044
Triacylglycerols (mmol/l) 2·7 1·6 1·9 0·8 0·0184
Glucose (mmol/l) 5·4 0·6 5·3 0·5 0·8167
*Differences between sexes were tested with unpaired t tests.
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associated with accuracy. According to the DR, the percentage
energy from protein and scores for restraint were inversely corre-
lated to accuracy, while the percentage energy from fat, energy
density, eating frequencies, intakes of ‘sweets, desserts and
snacks’, sugary drinks, ‘fatty meat, minced meat and sausages’,
and fatty cheese and hunger were positively associated with accu-
racy. Reporting accuracy was not signiﬁcantly correlated to edu-
cational level (R 0·156; P¼0·2781).
The multiple regression analysis of the reporting accuracy of
energy according to the FFQ is shown in Table 8. ‘Sweets, des-
serts and snacks’, energy density, fatty cheese, bread, ‘oil,
butter and margarine’, and restraint were entered into the
model. ‘Sweets, desserts and snacks’ and bread (R2adj 0·46 (95%
CI 0·32, 0·70)) were signiﬁcant predictors. The multiple
regression analysis of the reporting accuracy of energy according
to the DR is shown in Table 9. ‘Sweets, desserts and snacks’,
energy density, sugary drinks, restraint, eating frequency and
hunger were entered into the multivariate model and ‘sweets, des-
serts and snacks’ and restraint were signiﬁcant predictors of the
variation in the reporting accuracy of energy (R2adj 0·67 (95%
CI 0·54, 0·83)). Eating frequency was positively correlated to
sweets, desserts and snacks (RS 0·54; P¼0·0002) and sugary
drinks (RS 0·30; P¼0·0360). Individual items in the category of
sweets, desserts and snacks showed the same trends as the
entire category (data not shown).
Discussion
The present study focused on subjects with the metabolic syn-
drome or two risk factors for the metabolic syndrome. The
reported consumption of sweets, desserts and snacks was lower
among under-reporters than non-under-reporters and showed a
signiﬁcant association with reporting accuracy according to both
methods of dietary assessment (FFQ and DR) in the multiple
regression analyses. In addition, bread consumption assessed by
the FFQ was a signiﬁcant contributor to reporting accuracy. Diet-
ary restraint was an additional signiﬁcant contributor to accuracy
assessed by DR.
About half of this obese population with metabolic risk factors
under-reported EI. This ﬁnding is in accordance with the Observ-
ing Protein and Energy Nutrition (OPEN) study that included 484
subjects of whom 142 had BMI $30 kg/m2, and 57% of the
Table 2. Percentage of participants classiﬁed as under-reporters, accurate reporters and over reporters of energy intake by
the food-frequency questionnaire and the dietary records
Food-frequency questionnaire (n 50) Dietary records (n 49)
Percentage Male (n) Female (n) Percentage Male (n) Female (n)
Under-reporters of energy 56 12 16 53 11 15
Accurate reporters of energy 36 9 9 45 11 11
Over-reporters of energy 8 2 2 2 0 1
Table 3. Anthropometry, energy expenditure, energy intake, energy density, macronutrient composition and
eating scores in under-reporters (UR) and non-under-reporters (non-UR) according to the food-frequency
questionnaire*
(Mean values and standard deviations)
UR (n 28) Non-UR (n 22)
Mean SD Mean SD P
Tissue fat (%) 49·1 8·7 46·2 9·0 0·2489
Waist:hip ratio 1·0 0·1 1·0 0·1 0·8777
BMI (kg/m2) 36·3 3·6 35·0 2·7 0·1522
Total energy expenditure (kJ/d) 14 038 2464 13819 2524 0·7594
RMR (kJ/d) 7606 898 7452 1178 0·6016
Physical activity level† 1·84 0·17 1·86 0·21 0·7401
Energy intake (kJ/d) 9573 2571 13938 3723 ,0·0001
Energy intake:total energy expenditure 0·68 0·12 1·01 0·18 ,0·0001
Energy density (kJ/g) 6·49 1·06 7·35 2·13 0·0699
Diet composition (% energy)
Fat 34·5 3·9 35·5 5·9 0·4793
Protein 16·3 2·4 14·8 2·4 0·0287
Carbohydrate 45·2 5·5 46·6 7·0 0·4349
Sucrose 5·4 2·9 8·6 8·3 0·0698
Alcohol 2·7 2·9 2·3 4·5 0·7038
Eating scores‡
Restraint 8·5 4·8 6·3 3·9 0·0929
Disinhibition 8·1 3·2 8·2 3·2 0·9180
Hunger 5·3 2·9 6·0 3·4 0·4625
*Differences between UR and non-UR were tested with unpaired t tests.
†Physical activity level is calculated by dividing total energy expenditure by RMR.
‡The results of one male were missing.
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obese participants were classiﬁed as under-reporters of energy
according to the FFQ (Subar et al. 2003). In the present study,
men under-reported EI by 14% and women by 21% according
to the FFQ. According to the DR, men and women under-reported
EI by 28 and 31%, respectively. In comparison, Goris et al.
(2000) found a 37% under-reporting of energy by male subjects
with a BMI similar to that of subjects in the present study.
A novel ﬁnding in the present study was that consumption of
bread according to the FFQ was a signiﬁcant contributor to accu-
racy. This ﬁnding may be partly explained by the association
between bread consumption and an irregular or frequent meal pat-
tern. In Norway bread-based meals are typically consumed two to
three times per d. In addition, bread is often consumed as a
between-meal snack. The extra bread eaten at irregular meals
and snacks may be forgotten or not reported. In contrast, con-
sumption of bread was not associated with accuracy measured
by DR. However, under eating may be a major problem with
DR as discussed below.
Consumption of sweets, desserts and snacks was robustly
associated with reporting accuracy, and was the only multivariate
determinant of accuracy in addition to bread consumption accord-
ing to the FFQ. These two variables explained almost half of the
multivariate variance in accuracy. Likewise, reported intake
of sweets, desserts and snacks was associated with accuracy
Table 4. Intake of food in under-reporters (UR) and non-under-reporters (non-UR) according to the food-fre-
quency questionnaire*
(Medians and interquartile ranges)
UR (n 28) Non-UR (n 22)
Food (g/d) Median IQR Median IQR P
Fruit, berries, juice and jam 246 140–387 305 78–614 0·6182
Milk 202 55–338 302 154–604 0·0451
Bread 152 114–180 213 125–286 0·0837
Vegetables 190 116–269 197 123–332 0·8298
Boiled potatoes, rice and pasta 153 119–210 190 119–208 0·4117
Fatty meat, minced meat and sausages 71 47–82 66 32–161 0·9820
Chicken and meat with less fat 69 43–103 68 28–93 0·5909
Fish and ﬁsh products 58 36–92 82 28–105 0·8298
Oil, butter and margarine 50 28–67 67 29–91 0·1112
Fatty cheese 24 9–48 35 18–72 0·1594
Sweets, desserts and snacks 100 64–135 161 121–196 0·0008
Sugary drinks 63 0–211 150 18–378 0·2146
IQR, interquartile range.
*Differences in reported intake of food in UR and non-UR were tested with the Mann–Whitney signed rank test.
Table 5. Anthropometry, energy expenditure, energy intake, energy density, macronutrient composition and
eating scores in under-reporters (UR) and non-under-reporters (non-UR) according to the dietary records*
(Mean values and standard deviations)
UR (n 28) Non-UR (n 22)
Mean SD Mean SD P
Tissue fat (%) 49·2 8·2 45·9 8·7 0·2613
Waist:hip ratio 1·0 0·1 1·0 0·1 0·7869
BMI (kg/m2) 36·4 3·2 35·0 3·4 0·1531
Total energy expenditure (kJ/d) 14 107 2791 13 613 2021 0·4866
RMR (kJ/d) 7598 990 7394 1022 0·4836
Physical activity level† 1·85 0·22 1·84 0·15 0·9143
Energy intake (kJ/d) 8071 1999 12 756 4112 ,0·0001
Energy intake: total energy expenditure 0·57 0·09 0·85 0·16 ,0·0001
Energy density (kJ/g) 6·70 1·34 7·90 1·59 0·0064
Diet composition (% energy)
Fat 34·8 6·5 36·2 5·5 0·4396
Protein 16·8 3·3 14·7 2·3 0·0151
Carbohydrate 46·3 7·5 46·6 6·2 0·9789
Sucrose 4·9 3·3 9·3 7·0 0·0063
Alcohol 1·3 2·8 2·1 4·5 0·4819
Eating scores‡
Restraint 9·0 5·0 6·1 3·5 0·0285
Disinhibition 7·7 3·2 8·9 3·0 0·2184
Hunger 4·8 2·9 6·4 3·2 0·0769
*Differences between UR and non-UR were tested with unpaired t tests.
† Physical activity level is calculated by dividing total energy expenditure by RMR.
‡The results of one male were missing.
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according to the DR. The ﬁnding of low reports of sweets, des-
serts and snacks is in accordance with a number of previous
studies. In a study by Livingstone et al. (1990), snacks were
named as the most onerous and irritating aspect of the recording
procedure and subjects admitted having omitted or simpliﬁed
some measurements. In a Norwegian survey, Johansson et al.
(1998) reported that under-reporters had a lower intake of
cakes, potato chips, chocolate, sweets and sugar-containing soft
drinks. Likewise, among non-obese women, Bingham et al.
(1995) found a lower intake of breakfast cereals, cakes and
sugars and confectionery in under-reporters compared with accu-
rate reporters and consumption of sugar and sweet foods was also
lower in under-reporters in two other large surveys (Rothenberg
et al. 1997; Cook et al. 2000). Based on data from a number of
studies Heitmann & Lissner (1995) concluded that snack-type
foods might preferably be forgotten or suppressed when obese
subjects omit food items in dietary reporting. This notion has
been directly substantiated in an elegant study. Poppitt et al.
(1998) covertly measured the food intake of obese and non-
obese women conﬁned to a metabolic facility and allowed ad libi-
tum food intake. Food consumed during a meal was reported
accurately, but the between-meal snack food was under-reported
by over one-third. With the exception of the study by Livingstone
et al. (1990), under-reporters were identiﬁed according to calcu-
lated EI:RMR ratios, N excretion or directly measured in a meta-
bolic facility. One strength of the present study is that we
quantiﬁed the contribution of under-reporting of sweets, desserts
and snacks to accuracy in free-living, obese subjects with the
DLW method according to both the DR and the FFQ.
Table 6. Daily intake of food and eating frequency in under-reporters (UR) and non-under-reporters
(non-UR) according to the dietary records*
(Medians and interquartile ranges)
UR (n 28) Non-UR (n 22)
Food (g/d) Median IQR Median IQR P
Fruit, berries, juice and jam 253 110–354 195 75–388 0·9680
Milk 126 0–292 127 54–370 0·5090
Bread 154 121–213 198 121–235 0·3890
Vegetables 115 75–149 103 57–158 0·8100
Boiled potatoes, rice and pasta 118 85–168 100 58–202 0·6025
Fatty meat, minced meat and sausages 52 8–121 119 38–164 0·1158
Chicken and meat with less fat 71 20–100 34 9–63 0·2033
Fish and ﬁsh products 44 0–137 47 4–122 0·7800
Oil, butter and margarine 31 17–56 40 21–79 0·2662
Fatty cheese 23 13–34 28 8–47 0·3781
Sweets, deserts and snacks 61 38–93 128 108–185 0·0002
Sugary drinks 0 0–110 167 0–335 0·0057
Eating frequency (times/d) 4·7 3·3–5·0 5·0 4·3–6·0 0·2333
IQR, interquartile range.
* Differences in reported intake of food in UR and non-UR were tested with the Mann–Whitney signed rank test.
Table 8. Multiple regression analyses of reporting accuracy of
energy according to the food-frequency questionnaire*
(Standardised regression coefﬁcients with their standard errors)
b SE P
Sweets, desserts and snacks 0·354 0·0002 0·0043
Energy density 0·031 0·0170 0·8113
Bread 0·380 0·0003 0·0163
Fatty cheese 0·093 0·0010 0·4434
Oil, butter and margarine 0·139 0·0010 0·3022
Restraint 20·079 0·0060 0·5159
*Reporting accuracy is indicated by the energy intake:total energy expendi-
ture ratio.
Table 7. Relation of accuracy according to the food-frequency questionnaire
(FFQ) and dietary records (DR) to energy density, macronutrient compo-
sition, food, eating frequency and eating scores
(Correlation coefﬁcients)
FFQ DR
EI:TEE P EI:TEE P
Energy density* 0·406 0·0034 0·537 ,0·0001
Diet composition (% energy)*
Fat 0·224 0·118 0·292 0·0414
Protein 20·438 0·0015 20·403 0·0041
Carbohydrate 0·051 0·7273 0·191 0·1882
Sucrose 0·283 0·0462 0·251 0·0824
Alcohol 0·049 0·7342 0·220 0·1283
Food (g/d)†
Fruit, berries, juice and jam 0·135 0·3445 0·040 0·7826
Milk 0·333 0·0197 0·007 0·9630
Bread 0·387 0·0067 0·262 0·0694
Vegetables 0·024 0·8690 20·005 0·9735
Boiled potatoes, rice and
pasta
0·201 0·1584 20·013 0·9286
Fatty meat, minced meat
and sausages
0·218 0·1270 0·300 0·0380
Chicken and meat with less
fat
20·093 0·5166 20·237 0·1009
Fish and ﬁsh products 0·114 0·4250 0·002 0·9917
Oil, butter and margarine 0·379 0·0080 0·256 0·0758
Fatty cheese 0·398 0·0053 0·295 0·0407
Sweets, desserts and
snacks
0·513 0·0003 0·698 ,0·0001
Sugary drinks 0·214 0·1336 0·490 0·0007
Eating frequency (times/d)† NA NA 0·360 0·0125
Eating scores*
Restraint 20·373 0·0098 20·388 0·0140
Disinhibition 0·038 0·7913 0·118 0·4203
Hunger 0·301 0·0369 0·318 0·0304
EI, energy intake; TEE, total energy expenditure, NA, not analysed.
*Correlation coefﬁcients were calculated with Pearson’s correlations.
†Correlation coefﬁcients were calculated with Spearman rank correlations.
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Despite a strong statistical association between reporting accu-
racy and sweets, desserts and snacks in the multivariate analyses,
the difference in reported intake of sweets, desserts and snacks
was only 60 g/d representing about 1MJ/d. The energy difference
between under-reporters and non-under-reporters was 4·5MJ/d,
thus less than one-quarter was accounted for. It appears that the
underestimation is more general as seen in the energy density
of the diet, at least according to the DR, and in the macronutrient
composition. The percentage energy from protein was higher but
the actual intake of protein was lower among under-reporters than
non-under-reporters. Excretion of urinary N also indicated that
protein intake was lower among under-reporters of energy (data
not shown).
The percentage of energy from protein in the diet was strongly
inversely related to the reported intake of sweets, desserts and
snacks (data not shown). This and other studies (Heitmann &
Lissner, 1995; Pryer et al. 1997; Livingstone & Black, 2003)
suggest that when sweet and fatty foods are under-reported, the
percentage of energy from protein increases. In the largest
study using urinary N and DLW methodologies, protein density
was similar for men, but slightly overestimated for women
(Subar et al. 2003). Heitmann & Lissner (1995) found a positive
association between under-reporting of protein (and total energy)
and the degree of obesity among 323 lean and obese men and
women. Compared with total energy, protein was over-reported
by the obese subjects. Other studies have reported preferential
under-reporting of fat (Bingham et al. 1995; Macdiarmid et al.
1998; Goris et al. 2000). Discrepancies between the studies
may be explained by differences between populations due to
different cultural attitudes or habits, temporal trends, chance or
other factors. What foods are considered not healthy, and thus
are under-reported, may be affected by societal expectations
and messages from the media (Blundell, 2000). In the present
study involving obese individuals with characteristics of the meta-
bolic syndrome we speculate that under-reporters may be prone to
under-report carbohydrate and fatty food used as sweets, desserts
and snacks because of the inﬂuence of ongoing debates about
low-glycaemic-index diets.
The optimal number of eating occasions to facilitate weight
reduction has been debated and it has long been believed that a
‘nibbling meal pattern’ could be beneﬁcial for the purpose of
weight reduction. However, a recent review concluded that
weight loss was not facilitated by a high meal frequency (Bellisle,
2004). An association between frequent snacking and EI was also
seen in a Swedish study among 4259 obese subjects (Berte´us
Forslund et al. 2005). Our ﬁndings tend to support these ﬁndings
since reported energy was, not surprisingly, related to the
frequency of eating occasions. However, we did not ﬁnd a statisti-
cally signiﬁcant difference between the frequency of eating
between under-reporters and non-under-reporters. The same was
also seen in a study by Livingstone et al. (1990), and may be
due to small sample size, which is also a limitation of the present
study.
Dietary restraint, the self-imposed practice of consciously
attempting to restrict EI with the purpose of preventing weight
gain or promoting weight loss, is a common determinant of accu-
racy (Bathalon et al. 2000), though some conﬂicting data have
been reported. For example, Taren et al. (1999) found no associ-
ation between restraint and reporting accuracy in overweight indi-
viduals using 3 d DR to assess reported EI. Lindroos et al. (1997)
found strong associations between EI, disinhibition and hunger,
but a weaker association between EI and restraint in obese
women. However, reporting accuracy was not considered in that
study. In the OPEN study, restrained eating predicted reporting
accuracy only when EI was assessed by the 24 h recall and only
among men (Tooze et al. 2004). Furthermore, Bingham et al.
(1995) could not differentiate restrained eating from the known
effects of obesity on reporting accuracy. In a simple comparison
of under-reporters and non-under-reporters, the present study
clearly showed that under-reporters in this population had
higher dietary restraint scores and restraint was a signiﬁcant pre-
dictor of accuracy according to the DR. Dietary restraint did not
contribute signiﬁcantly to accuracy according to the FFQ. Hunger
scores were associated with accuracy in the univariate but not
in the ﬁnal multiple analyses. Intercollinearity between several
of the measured variables may explain these observations.
Scores for restraint were inversely associated with the
consumption of bread, milk and ‘oil, butter and margarine’
according to the FFQ (data not shown). Of these variables,
bread consumption signiﬁcantly contributed to accuracy in the
multivariate analyses.
Methodological issues
When using DLW as an objective measure of EI, we assume that
the subjects were in energy balance over the period of the
measurement. The weight change during the DLW period was
minor and in accordance with the weight change seen in the
Dutch men (Goris et al. 2000). We could have adjusted for the
weight change in the calculations, but according to the Inter-
national Dietary Energy Consultancy Group (1990) the difﬁculty
of accurately estimating change in body composition over the
short period of DLW measurement is such that little advantage
is gained. We could have adjusted for the increase in weight
during the 3-month period resulting in a greater degree of under-
estimation. However, the 3-month study period that included holi-
days may not adequately represent long-term weight change.
The DLW measurement was done during 14 d and may not
measure the actual long-term energy expenditure (Livingstone
& Black, 2003).
In the calculations of the TEE, we used the individually cal-
culated FQ from the reported intakes according to the FFQ. The
under-reporting of carbohydrate could be a concern. However,
this probably does not affect the energy calculations because
of the high homogeneity of FQ. Fat and carbohydrate intake
may vary over a fairly wide range and still the variation in
FQ is small (Black et al. 1986). The mean FQ was 0·85 in
Table 9. Multiple regression analyses of reporting accuracy of energy
according to the dietary records*
(Standardised regression coefﬁcients and their standard errors)
b SE P
Sweets, desserts and snacks 0·612 0·0002 ,0·0001
Energy density 0·053 0·0130 0·6298
Sugary drinks 0·104 0·0001 0·1508
Restraint 20·212 0·0040 0·0444
Eating frequency 0·154 0·0170 0·1450
Hunger 0·005 0·0060 0·9610
*Reporting accuracy is indicated by the energy intake:total energy expenditure ratio.
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the present study, in agreement with a typically Western diet
(Black et al. 1986).
While the FFQ method is prone to under-reporting due to
difﬁculties in remembering eating occasions and estimating por-
tions sizes, under-reporting according to weighed DR may be
due both to under-eating and under-recording. We are not
able to differentiate between under-eating and under-reporting
because a 3 d food record has too short a time period to
follow weight changes. It may be that subjects with high
scores for dietary restraint actually under-eat when they
record food intake to achieve weight reduction, but it has
also been shown that restrained eaters as a group do not
report all food they consume (Bathalon et al. 2000).
Dietary restraint became less obvious in the FFQ that covers
a much longer time period including holiday seasons for almost
all the participants, and most individuals do not restrict eating
during holidays. Limitations of the present study were that
we did not collect data on the temporal distribution of eating.
Furthermore, the DR was collected for only 3 d and was done
a mean of 34 d before the DLW measurement period. We
chose the 3 d DR to minimise the burden on the participants
in accordance with the suggestion by Trabulsi & Schoeller
(2001), that in subjects deﬁned as dietary resistant and obese,
any precision gained through a long dietary recording period
is outweighed by a larger magnitude of under-reporting. To
minimise the burden of the participants was also the reason
for obtaining the DR before the DLW measurement period.
However, the results of the DR were largely in accordance
with the results of the FFQ that covered the DLW measurement
period.
In contrast to others (Johansson et al. 1998; Cook et al. 2000),
we did not ﬁnd any relationship between sex or education level
and reporting accuracy. This may be due to the limited size of
our sample or to differences between populations. Furthermore,
in our sample of obese individuals, BMI, percentage of body fat
and fat distribution did not predict reporting accuracy. This may
be due to the small variation of BMI or that BMI levels out as
a predictor for reporting accuracy of energy at BMI levels
above 35 kg/m2 as was observed in the OPEN study (Tooze
et al. 2004). The study included only non-smokers and may not
be applicable to obese smokers.
Implications
An understanding of the foods and meal patterns that are
associated with errors in self-reported data is critical. Individ-
uals often report their usual dietary intake and forget to
report extra meals and snacks or more frequent eating patterns.
These items must be particularly emphasised in dietary inter-
views. It was not our objective to determine which of the diet-
ary assessment methods showed superior accuracy in this obese
sample. However, it seems that the FFQ is less inﬂuenced by
the restraint eating behaviour, while the DR may be an import-
ant tool to achieve change in eating behaviour because of
increased attention. Because of their high risk, obese subjects
with the metabolic syndrome or risk factors for the metabolic
syndrome are prime targets for dietary advice to achieve
weight reduction. While weight-stable, individuals that report
high dietary restraint, low consumption of bread, sweets, des-
serts and snacks and a low frequency of eating may require
particular attention when a dietary assessment is conducted.
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ActiRegw is an instrument that uses combined recordings of body position and motion to calculate energy expenditure (EE) and physical activity
(PA). The aim of the study was to compare mean total energy expenditure (TEE) measured by ActiRegw and doubly labelled water (DLW) in
obese subjects. TEE was measured by the DLW method during a period of 14 d in ﬁfty obese men and women with metabolic risk factors.
During the same period ActiRegw recordings were obtained for 7 d. RMR was measured by indirect calorimetry and also estimated by standardized
equations. Because EE may be disproportionately increased in obese subjects during weight-bearing activities, we established a new set of physical
activity ratios (PAR). These ratios were based on oxygen uptake measurements during treadmill walking. The mean TEE according to the DLW was
13·94 (SD 2·47) MJ/d. Mean TEE calculated from the ActiRegw data and measured RMR was 13·39 (SD 2·26) MJ/d, an underestimation of 0·55MJ
(95% CI 0·13, 0·98; P¼0·012) or 3·9%. RMR derived from standard equations based on weight, age and sex were overestimated while the RMR
based on fat-free mass values in addition was underestimated. Despite slight underestimation ActiRegw may be used to measure TEE in obese sub-
jects on two premises: RMR should be measured, and the increased EE during weight-bearing activities in obese subjects should be considered.
Energy expenditure: Physical activity: Activity pattern
Obesity (BMI . 30 kg/m2) is associated with type 2 diabetes,
CHD, stroke, increased morbidity and early mortality. In order
to plan optimal treatment for subjects at risk, validated
methods to measure total energy expenditure (TEE) and physi-
cal activity (PA) are essential.
Although the doubly labelled water (DLW) method is clearly
the most accurate measure of TEE, its widespread use is limited
by the high cost of the labelled water and the requirement of
highly specialized and expensive equipment for analysis. The
need for precise quantiﬁcation of TEE and PA during usual
living conditions has led to the development of several
measurement methods(1). We have recently described a novel
instrument called ActiRegw, a validated position-and-move-
ment monitor(2). The ActiRegw system uses RMR combined
with calculated physical activity ratio (PAR) values as the
basis for energy and activity calculations. RMR may be
measured or estimated from predictive equations. These
equations are usually based on body weight, body height, age
and sex and/or fat-free mass (FFM)(3–6). However, the most
widely used predictive equations may not be well suited in
obese populations, because the source materials on which
they are based include very few if any obese individuals(6–9).
Choice of prediction method for the estimation of RMR may
therefore be important. To date the PAR values used by the
ActiCalc32w program to calculate EE are published reference
values for people with normal body weight(2,6). Due to the rela-
tive increase of adipose tissue mass in obese individuals, pre-
dictive equations for RMR based on body weight and
developed mainly for a normal-weight population may lead to
overestimation of RMR. Likewise the energy cost of weight-
bearing activities such as walking and standing is related to
body weight, and is therefore increased in obesity(10–14). There-
fore PAR values developed for weight-bearing activities in lean
individuals may not be appropriate for obese subjects(15). As
both these factors are the main contributors to the calculation
model, it is important to establish reliable and validated
values for obese individuals.
The aim of the present study was to calculate TEE from the
ActiRegw recordings and compare this to TEE measured by
DLW. In order to achieve this aim we established a set of
mean PAR values for obese subjects during weight-bearing
activity. Finally, we asked whether RMR could be estimated
using predictive equations rather than directly measured by
indirect calorimetry to simplify the procedure.
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Subjects and methods
Subjects
Fifty non-smoking, obese men and women (BMI $ 30·0 kg/
m2) with two or more risk factors for the metabolic syndrome
were recruited by newspaper advertisement and referral to the
Department of Preventive Cardiology at Ulleva˚l University
Hospital. The characteristics of the group are shown in
Table 1. As this was part of a broader study of subjects with
two or more risk factors for metabolic syndrome subjects
were screened via blood chemistry and a medical examination
done by a physician to assess risk factors and eligibility to the
study(16). Exclusion criteria were body weight . 135 kg, cur-
rent dieting, cigarette smoking, history of eating disorder or
chronic disease, suspected non-compliance due to abuse of
drugs or alcohol, drug- or insulin-treated diabetes mellitus,
migraine requiring intermittent medication, use of thyroxin,
diuretics or weight-reducing agents, and use of inhaled or
oral b-agonists or corticosteroids. The educational level of
each subject was determined according to the number of
years of education and categorized as completed primary
school, high school or a university degree. The Ethical Com-
mittee (region 1 in Norway) approved the protocol and all par-
ticipants gave their written informed consent. The study was
conducted between October 2001 and October 2003.
Experimental schedule
The total duration of the experiment was 4 weeks. At baseline
(week 1) the participant underwent physical examination
including measurement of height, body weight, waist–hip
ratio, sitting blood pressure, and collection of plasma and
serum samples for different blood parameters(16). During this
week lean body mass was determined by dual-energy X-ray
absorptiometry (DEXA). At week 2, RMR and energy expen-
diture (EE) during weight-bearing activities were measured.
Later in the same week the DLW measurement, which
lasted for 14 d, was initiated. At the same time the subjects
attached the ActiRegw instrument for recording for 7 consecu-
tive days, i.e. the ﬁrst 7 d of the 14 d DLW period. At week 4,
the DLW measurement was terminated and the ﬁnal urine spot
samples were delivered. A dietary assessment using a FFQ
was administered.
Methods
Height was measured with a standardized wall measuring stick
scale to the nearest 0·5 cm. Subjects were weighed (in under-
wear) with a digital weight (Seca, Germany) to the nearest
0·1 kg. Weight was measured at the screening and baseline
visits and on day 1 and day 15 of the DLW measurement
period. Weight changes during the DLW period were calcu-
lated as the difference between day 15 and day 1. Body com-
position was determined by DEXA (Lunar Expert 1116). The
measurement was done in the course of 15min. The CV for
the DEXA measurements was 3–4%. RMR was measured
with a standard portable ventilated hood system (Deltatracw
Metabolic Monitor; Datex Instrumentarium Corp., Helsinki,
Finland). The Deltatracw was calibrated by automatic standard
gas calibration at the start of each measurement. The subjects
slept at home the night before the measurement. On the day of
the measurement the subjects took a taxi to the site. The sub-
jects fasted during the last 12 h before the measurement and
were instructed not to eat or drink anything but water on the
day of the measurement. After changing clothes and mounting
the equipment, the subjects relaxed for 30min in the recum-
bent position before the head was covered with the canopy.
Measurements were done at 1min intervals for 20–25min.
A mean value of at least a 10min period at a stable level of
EE was deﬁned to be the RMR. After completion of the
RMR measurements the subjects were offered a sugar-contain-
ing drink prior to the start of a standardized treadmill test. This
was done because they all had fasted for more than 12 h. The
treadmill test consisted of walking at increasing speeds (1, 2,
3, 4, 5 and 6 km/h) at an inclination of 1% for periods of 5min
at each velocity, while their O2 uptake and CO2 output were
measured with spirometry (Jaeger Oxiconw). The treadmill
test was performed in order to obtain calibration values for
the EE related to different weight-bearing PA.
The doubly labelled water method
EE by the DLW method was measured over a period of 14 d
and used as a gold measure of habitual EE. Sample analyses
and calculation procedures have been described in detail else-
where(17). First a baseline urine sample was collected for the
determination of the background isotope enrichment (day 1).
Then a weighted mixture of deuteriated and oxygenated
water, corresponding to 0·05 g 2H2O and 0·10 g H2
18O per kg
body weight, was ingested. The percentage enrichment of
the waters was 99·9% for 2H and 10·0% for 18O. The dose
was planned to enrich body water with approximately 350 d
(delta per mill) for 2H and 60 d (delta per mill) for
18O. Urine samples were collected from the second voiding
during days 2, 3, 4, 8, 13, 14 and 15. The mean time interval
between drinking dose and the ﬁrst post-dose urine sample
was 22 (SD 3) h (range 12–30 h). The participants were
instructed to collect the urine spot, register exact voiding
Table 1. Physical characteristics of the participants
Males (n 23) Females (n 27)
Mean SD Range Mean SD Range P *
Age (years) 44·5 10·0 27·7 42·6 10·7 41·0 0·5322
Height (m) 1·82 0·07 0·30 1·69 0·06 0·24 0·0000
Weight (kg) 116·2 14·8 52·6 105·0 12·2 48·1 0·0053
BMI (kg/m2) 34·9 3·1 11·5 36·6 3·3 12·8 0·0645
*Two-sample t test assuming equal variances.
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time and freeze the samples at home. Participants were called
every voiding day to ensure compliance with the procedure.
When the samplings were completed, the urine samples were
stored at 2758C until transportation to laboratory on dry ice.
Analysis of the isotopic enrichment was determined in tripli-
cates with a Thermoquest Finnigan MAT Delta plus isotope-
ratio mass spectrometer with water/H2–CO2 equilibrating
device (Thermoquest Finnigan MAT, Bremen, Germany).
The precision deﬁned as standard error in triplicate samples
is 0·26 d for 2H and 0·10 d for 18O. Tap water was collected
and analysed for background measurements and all TEE calcu-
lations were corrected for the content of isotopes in the drink-
ing water. TEE was calculated by the multi-point method using
linear regression as suggested by the International Dietary
Energy Consultancy Group(18). All elimination curves were
checked for major or diverging residuals. The CV for the elim-
ination constants was on average 3·2% for hydrogen and 2·7%
for oxygen. We used the relationship between pool size of 2H
(Nd) and pool size of
18O (No) derived from the antilog inter-
cept on the y-axis of the elimination curves as a quality
measurement for the DLW as suggested by the International
Dietary Energy Consultancy Group(18). The mean food quoti-
ent determined from the FFQ was 0·85 (SD 0·016; range
0·81–0·89). The individual No/Nd ratio and food quotient of
the participants were used in the calculation of the energy
Table 2. Mean RMR measured by indirect calorimetry and calculated by different prediction equations
RMR (MJ/d)
Type of measurement/estimation Mean SD Difference Range 95% CI P *
Measured by indirect calorimetry 7·75 1·05 4·53
Mifﬂin et al. (4)† 7·94 1·06 20·19 4·61 20·33, 2 0·05 ,0·007
FAO/WHO/UN University(6)‡ 8·20 1·19 20·45 4·44 20·62, 2 0·29 ,0·000
Mu¨ller et al. (3)§ 8·25 1·09 20·50 4·53 20·63, 2 0·36 ,0·000
Cunningham(5), fat-free mass from DEXA{ 6·65 0·97 1·11 4·17 0·90, 1·32 ,0·000
DEXA, dual-energy X-ray absorptiometry.
* Paired samples test on the mean difference between the measured value and predicted values. Signiﬁcance level P,0·05.
†Calculation formula: RMR (kcal/d) ¼ 9·99 £ weight (kg) þ 6·25 £ height (cm) 2 4·92 £ age þ 166 £ sex (males ¼ 1; females ¼ 0) 2 161
(result converted to MJ/d by multiplication by 4·184).
‡Calculation formula: Males (age 30–60): RMR (MJ/d) ¼ 0·0485 £ weight (kg) þ 3·67; females (age 30–60): RMR (MJ/d) ¼ 0·0364 £ weight
(kg) þ 3·64.
§Calculation formula (BMI $ 30): RMR (MJ/d) ¼ 0·05 £ weight (kg) þ 1·103 £ sex (males ¼ 1; females ¼ 0) 2 0·01 586 £ age þ 2·924.
{Calculation formula: RMR (kcal/d) ¼ 370 þ 21·6 £ fat-free mass (kg) (result converted to MJ/d by multiplication by 4·184).
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Fig. 1. Treadmill walking test for the combined group of obese subjects (both
sexes, n 50). The physical activity ratio (PAR) is the measured energy
expenditure divided by RMR at each speed. Values are means with their
standard errors depicted by vertical bars. (X), Mean PAR for the combined
obese group (both sexes); (K), for comparison, table values of PAR for nor-
mal-weight subjects(6,23,24).
EE0EE0EE0
Recordings of body position and motion
VLPA
AF < 0·1
LPA
0·1 ≤ AF < 0·9
MHPA
AF ≥ 0·9
Lie: 1·0 × RMR
Sit: 1·2 × RMR
*Stand: 1·4 × RMR
Lie: 2·0 × RMR
Sit: 2·0 × RMR
*Stand: 3·5 × RMR
Lie: 6·5 × RMR
Sit: 6·5 × RMR
*Stand: 6·5 × RMR
EEAR = EE0 [1 + k (Number_of_Position_Changes)]
Fig. 2. The calculation procedure for energy expenditure based on ActiRegw
data (EEAR). In the ﬁrst step the data are distributed into the three activity
levels: Very Low Physical Activity (VLPA), Low Physical Activity (LPA) and
Moderate-High Physical Activity (MHPA)(2). The calculation within each level is
based on the estimated energy cost for the actual body position, expressed as
the RMR-factors. The result of this ﬁrst calculation step is denoted EE0. The
second step takes the number of body position changes into account by apply-
ing the algorithm shown, where EEAR is the ﬁnal result for the actual minute.
The constant k ¼ 0·025 determines the weight given to the number of body
position changes, here designated as ‘Number_of_Position_Changes’. AF,
activity factor; * Stand, standing position including the bent forward position.
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equivalence of the produced carbon dioxide as suggested by
the International Dietary Energy Consultancy Group(18). The
mean No/Nd ratio was 1·033 (SD 0·008; range 1·007–1·049).
ActiRegw
ActiRegw is an electromechanical device which records the
main body positions (stand, sit, bent forward and lie) together
with motion of the trunk and/or one leg each second(2). The
position (tilt switches) and motion sensors are ﬁxed to plastic
brackets. During registration the subjects attached the ActiR-
egw (actual size of the box is 8·5 cm £ 4·5 cm £ 1·5 cm) to a
belt while the sensors were connected to the box with thin
lines. The brackets were attached by medical tape to the sub-
ject’s chest (on sternum) and on the front of the right thigh
approximately midway between the knee and the hip. The
tilt switches were oriented so that they would be in the vertical
position when the subject was standing. A specially developed
computer program (ActiCalc32w) calculated EE and activity
pattern from the collected information and calibration data(2).
The ActiRegw system uses a combined second-to-second
recording of body position and motion to calculate EE and
PA. The apparatus has two pairs of position and motion sen-
sors connected by cables to a battery-operated storage unit
ﬁxed to a waist belt. Each pair of sensors is attached by medi-
cal tape to the chest and the front of the right thigh, respect-
ively. The collected data are transferred to a PC and
processed by a dedicated program ActiCalc32w. More details
about the method are published elsewhere(2). The calculation
model used by ActiCalc32w is based on the estimated cost
of the actual body position and activity expressed as PAR
values (i.e. EE/RMR) combined with the number of position
changes within each minute.
As described byHustvedt et al. (2) the data from the ActiRegw
was categorized into three levels of physical activity deﬁned as
Very Low Physical Activity (VLPA), Low Physical Activity
(LPA) and Moderate-High Physical Activity (MHPA). The cal-
culation within each level was based on the estimated energy
cost for the actual body position, expressed as RMR-factors
(PAR values) for subjects with normal body weight and taken
from published reference values (Annex 5 of FAO/UN Univer-
sity/WHO(6)). In the VLPA range, the following factors were
selected: lie still: 1·0 £ RMR; sit still: 1·2 £ RMR; stand
still/bent forward: 1·4 £ RMR. The LPA range extended
from moving very slowly to walking at about 3 km/h and
2·5 £ RMR is chosen as the average energy cost of standing
activities. This is the energy cost given for ‘walking around or
strolling’. The factor for sitting and lying activities, which are
non-weight-bearing activities, was set somewhat lower, at
2·0 £ RMR. The dominant activity in the MHPA range during
the daily life of most people is walking. The reported energy
cost of ‘walking: at normal pace’ is 3·2 £ RMR. In addition, a
variable amount of more energy-requiring activities is expected,
such aswalking on stairs or uphill, walkingwhile carrying loads,
and performing exercise. The factor 5·0 £ RMR was therefore
chosen as the average energy cost of all MHPA activities.
It was applied for all body positions. The treadmill experiments
performed by Hustvedt et al. (2) showed that walking will fall in
the MHPA range and that no body position changes
were recorded until the walking speed exceeded 5 km/h.
At $ 7 km/h, where the number of position changes increased,
some minutes with the body positions ‘sit’ or ‘lie’ were also
recorded. These recordings show that the state of the position
sensors as well as the movement sensors is inﬂuenced by accel-
eration forces during rapid movement, such as running, in
addition to the effect of the position angle. When walking/run-
ning speed increases a rising number of body position changes
is recorded which is used to discriminate between higher levels
of PA. The calculation procedure for EEAR (EE based on ActiR-
egw data) utilizes the combined information about PA level,
body position and the number of position changes. The EEAR
of all MHPA are therefore not calculated according to a PAR
value of 5·0 but by an increased value proportional to the
number of position changes as described by Hustvedt et al. (2).
However, for obese subjects we expected that the PAR
values (RMR-factors) for weight-bearing activities would be
Table 3. Mean total energy expenditure (TEE) from the doubly labelled water (DLW) measurements and
those calculated from the ActiRegw data based on the different RMR values and the difference between
results calculated by ActiRegw and DLW values
TEE (MJ/d) Difference (MJ)
Calculation method* Mean SD Mean SD 95% CI P †
DLW 13·94 2·47
AR-RMR-measured 13·39 2·26 20·55 1·49 20·98, 2 0·13 0·012
AR-RMR-Mifﬂin 13·73 2·32 20·21 1·65 20·68, 0·25 0·358
AR-RMR-FAO/WHO/UNU 14·18 2·59 0·24 1·78 20·26, 0·75 0·341
AR-RMR-Mu¨ller 14·26 2·42 0·32 1·71 20·17, 0·80 0·199
AR-RMR-Cunningham-FFM-DEXA 11·48 2·05 22·46 2·00 23·03, 2 1·90 0·000
AR-RMR-measured-normal-PAR 11·81 1·87 22·13 1·36 22·52, 2 1·74 0·000
DEXA, dual-energy X-ray absorptiometry; FFM, fat-free mass; PAR, physical activity ratio.
* AR-RMR-measured: calculated by ActiRegw with measured RMR. AR-RMR-Mifﬂin: calculated by ActiRegw with RMR pre-
dicted from the equation of Mifﬂin et al. (4). AR-RMR-FAO/WHO/UNU: calculated by ActiRegw with RMR predicted from
FAO/WHO/UN University equation(6). AR-RMR-Mu¨ller: calculated by ActiRegw with RMR predicted from the equation of
Mu¨ller et al. (3). AR-RMR-Cunningham-FFM-DEXA: calculated by ActiRegw with RMR predicted from the equation of Cun-
ningham, with FFM from DEXA(5). AR-RMR-measured-normal-PAR: calculated by ActiRegw with measured RMR com-
bined with calculation parameters for normal-weight subjects. For comparison, the last row gives the result obtained by
using the measured RMR values combined with PAR values for normal-weight subjects, i.e. no correction made for
increased energy expenditure during weight-bearing activities.
†Paired samples test on the mean difference between the TEE calculated from ActiRegw data and those measured by DLW.
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somewhat increased. In this investigation these PAR values
were based on mean values obtained during the treadmill
experiments.
Statistics
The agreement between the results obtained by two different
methods was tested by the method of Bland and Altman(19).
Paired two-sample t tests were used to evaluate the difference
between the groups (SPSS for Windows version 13.0.0; SPSS
Inc., Chicago, IL, USA). The signiﬁcance level was set at
P,0·05. The correlation of linear regression is given as r 2.
Results
Subject characteristics according to sex are shown in Table 1.
There was no signiﬁcant difference in mean age between
males and females.
TEE from DLW measured over 14 d was not signiﬁcantly
different from the value extracted from 7 d, and the mean
value during 14 d was chosen as a more reliable measurement
based on more data points.
Table 2 shows the mean RMR combined for both sexes
obtained by indirect calorimetry and corresponding results
using different predictive equations for RMR. The results of
all predictive methods differed signiﬁcantly from the
measured RMR value. The equation proposed by Cunningham
based on FFM signiﬁcantly underestimated RMR(5). The
equations proposed by Mu¨ller et al. (3), Mifﬂin et al. (4)
and the FAO/WHO/UN University(6) all led to overestimation
of RMR.
Figure 1 show the results of the treadmill experiments. It
will be seen that the mean PAR value for the total group
(both sexes) is increased compared to the table values of
PAR for normal-weight subjects at all walking speeds between
2 and 6 km/h. This implies that the basic PAR values used
during calculation of EEAR should be increased accordingly
during weight-bearing conditions in order to follow the same
logic as used for normal-weight subjects. The logic of the cal-
culation model is described earlier(2).
The calculation procedure established for the obese group is
shown in Fig. 2. This implies that the PAR value for the weight-
bearing body positions, i.e. standing and bent forward at LPA
(which corresponds to a walking speed of about 3 km/h) is
increased from 2·5 to 3·5, while it is increased from 5·0 to 6·5
at MHPA (corresponding to a PA of walking 4·0–5·0 km/h)
for all body positions.
The mean TEE from the DLW measurements as well as
those calculated from the ActiRegw data based on different
RMR values are presented in Table 3. There was no signiﬁcant
difference between the mean TEEDLW and those calculated
from ActiRegw data based on RMR values from the FAO/
WHO/UN University, Mifﬂin and Mu¨ller predictive equations
(Table 3). However, the difference between the mean TEEDLW
and the mean TEEAR based on RMR values measured by
indirect calorimetry was statistically signiﬁcant. The TEEAR
value calculated from RMR values based on the predictive
equation using FFM instead of body weight signiﬁcantly
underestimated the mean TEE. Also the mean TEEAR based
on measured RMR but using PAR values for ‘normal-
weight’ subjects grossly underestimated mean TEE.
Fig. 3 shows the linear correlation between TEEAR_
Measured_RMR and TEEDLW (Fig. 3 (a)) and TEEAR_Mifﬂin_RMR
and TEEDLW (Fig. 3 (b)) with r
2 0·64 (P¼0·00) and r 2 0·585
(P¼0·00), respectively.
In Figs. 4 and 5 the results are compared with
Bland–Altman plots. The difference between the calculated
TEEAR and the TEEDLW are plotted against their average
values. The limits of agreement of the mean difference (i.e.
^2 SD) are indicated by the dotted lines. Fig. 4 includes
results calculated from measured RMR, and predicted from
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Fig. 3. (a), Linear correlation between the mean total energy expenditure
measured by ActiRegw based on measured RMR (TEEAR_Measured) and
the mean total energy expenditure from doubly labelled water measur-
ements (TEEDLW). The linear regression line shows a positive correlation
(y ¼ 0·736 þ 3·122, r 2 0·64, P¼0·000). (b), Correlation between by TEEDLW
and the mean total energy expenditure from the same ActiRegw data but
here the calculations are based on predicted RMR from equations developed
by Mifﬂin et al. (4) (TEEAR_Mifﬂin). The linear regression line shows a positive
correlation (y ¼ 0·718 þ 3·704, r 2 0·585, P¼0·000). —, Linear regression
line; , 95% conﬁdence limits.
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FAO/WHO/UN University(6), Mifﬂin(4) and Mu¨ller(3) equa-
tions. For all four graphs in this ﬁgure the differences are
evenly distributed throughout the range of the measurements
and the linear regression lines are almost parallel to the x-axis.
Fig. 5 presents the corresponding results based on RMR values
calculated from FFM by the Cunningham equation(5) and
measured RMR using PAR values for normal-weight people.
The graphs in Fig. 5 show serious underestimation of mean
TEE, but also a tendency to increased underestimation
at higher levels of TEE. This is shown by the negative trend
of the linear regression line and is most pronounced when
PAR values for normal-weight people are employed.
Discussion
The present study compared measurements of TEE by ActiR-
egw and DLW in a group of obese subjects. The results show
that with the use of increased PAR values for weight-bearing
activities, mean TEE calculated from the ActiRegw data was
underestimated by less than 4% compared to DLW, a statisti-
cally signiﬁcant but minor difference for most purposes.
Despite this underestimation we propose that ActiRegw may
be used to measure TEE in obese subjects on two premises:
RMR should be measured, and the increased EE during
weight-bearing activities in obese subjects should be
considered.
The calculation model used by the ActiRegw system is
based on the product of RMR (kJ/min) and the PAR value
for each minute of the registration period, i.e. the factorial
principle. The PAR values for each speciﬁc minute is esti-
mated from the combined information of body position,
motion and number of position changes. Reliable values of
RMR and PAR values in different body positions and activity
levels are therefore a prerequisite for an optimal estimate of
EE. The results of using the prediction equations based
solely on anthropometric data, age and sex led to signiﬁcant
overestimation for this group of obese subjects (Table 2).
This is in accordance with previous reports(3,9,11,20–22). The
Schoﬁeld(8) equations which have been adopted by WHO for
general use in predicting RMR are linear in weight
(Table 2)(6). The overestimation between measured and pre-
dicted RMR may be explained in part by composition of the
database and biological factors. These equations are based
on analysis of data collected from 114 previous studies made
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Fig. 4. The results are compared in Bland–Altman plots. The difference between the calculated total energy expenditure measured by ActiRegw (TEEAR) and the
total energy expenditure from doubly labelled water measurements (TEEDLW) are plotted against the average value of them. The results are based on measured
RMR (a), and RMR predicted from the equations of the FAO/WHO/UN University(6) (b), Mifﬂin et al. (4) (c) and Mu¨ller et al. (3) (d). – – –, Mean difference; ,
limits of agreement of the mean difference (^2SD); —, zero difference and the linear regression lines.
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in persons belonging to different races. In addition, one-third
of the reference population had BMI , 20 kg/m2, but very
few were obese. Also the total distribution of body weights
within this population is quite different from the normal distri-
bution for subjects living in modern afﬂuent societies(3,9). It is
well documented that RMR increases with increased body
weight and with increasing BMI, but the increase is not
linear or directly proportional to body weight. RMR increases
more slowly at heavier weights, and to ignore this will lead to
overestimation of RMR in the obese. When the body gets
fatter, a greater ratio of fat to lean tissue is deposited and as
the metabolic rate of adipose tissue is low compared to that
of lean tissue, RMR will not increase linearly by weight(9).
Mifﬂin et al. (4) derived new prediction equations based on a
data set of 498 men and women that also incorporated a sig-
niﬁcant number of obese subjects (Table 2). More recently
Mu¨ller et al. (3) developed equations based on an actual
German database for different BMI groups of which the
equation for BMI $ 30 has been used in this paper (Table 2).
Because most of the values included in the development of
these prediction equations fell within the normal weight
range, it is reasonable that they will overestimate RMR in
the obese because they all are linear with respect to body
weight. The RMR values calculated by the general prediction
equation proposed by Cunningham(5) are based solely on the
amount of FFM (Table 2). When we apply this equation to
calculate RMR in our obese subjects this will underestimate
RMR compared to measured values.
In the present study, reliable PAR values for obese subjects
during weight-bearing activities were obtained by treadmill
walking and indirect calorimetry (Fig. 1). Based on the
mean PAR values for the whole group (both sexes) at LPA
and MHPA the PAR values in the calculation model were
set to 3·5 and 6·5, respectively, compared to 2·5 and 5·0 for
normal-weight people. The LPA level extends from moving
very slowly to walking at about 3 km/h which is equivalent
to ‘walking around or strolling’. A reasonable value for this
activity for the obese is therefore set to 3·5, a value that we
chose empirically.
Walking is the dominant activity in the MHPA range during
the daily life of most people. The reported PAR value of
‘walking at normal pace’ (4–5 km/h) is 3·2 for normal-
weight people.
In addition, there will be a variable amount of more energy-
requiring activities, such as walking on stairs or uphill, walking
while carrying loads, and performing exercise. Based on the
treadmill measurements a PAR value of 6·5 is therefore
chosen as the average energy cost of all MHPA activities.
The same PAR value is applied for all body positions, since
the body position recording may be erroneous during high
activity(2).
Comparison of the results of mean TEE from the ActiRegw
recordings based on different RMR values (measured and esti-
mated) and the DLW measurements shows that results based
on the anthropometric data age and sex are not signiﬁcantly
different from the DLW values. This is likely to be due to
overestimation of RMR and underestimation of PA by ActiR-
egw while the results based on measured RMR underestimate
TEE by 2 0·55MJ on average (Table 3). The reason for the
underestimation based on the measured RMR may be due to
variation in variables other than pure anthropometrical data.
The mean TEE values obtained by using RMR based on
FFM calculated by the Cunningham equation seriously under-
estimate TEE compared to TEEDLW.
The correlation between TEEAR_Measured_RMR and TEEDLW
(Fig. 3 (a)) and TEEAR_Mifﬂin_RMR and TEEDLW (Fig. 3 (b))
are of the same magnitude, i.e. r 2 0·645 and r 2 0·585, respect-
ively. The difference between them is small also when the
results based upon RMR values from the anthropometrical
data and measurements are compared in Bland–Altman plots
(Fig. 4). However, the limits of agreement for the measurement
based upon measured RMR are narrower than for those based
upon predicted RMR values. This is the most likely reason
why this value is different compared to DLW. It will be seen
that the mean and the standard deviation of the differences
are constant throughout the range of measurements and normal-
ity tests show that the differences are evenly distributed and the
linear regression line is almost parallel to the x-axis. A close
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Fig. 5. Bland–Altman plots comparing the calculated total energy expendi-
ture measured by ActiRegw (TEEAR) results based on RMR values calculated
from fat-free mass obtained from dual-energy X-ray absorptiometry (DEXA)
by the Cunningham(5) equation (a) and measured RMR values using physical
activity ratio (PAR) values for normal-weight people (b) with total energy
expenditure from doubly labelled water measurements (TEEDLW). – – –,
Mean difference; , limits of agreement of the mean difference (^2SD); —,
zero difference and the linear regression lines.
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look at the frequency distribution plot of the difference values
based upon the RMR value from FFM shows that these are less
evenly distributed and exhibit an increased tendency to under-
estimation as TEE increases (Fig. 5 (a)). This is also demon-
strated by the negative trend of the linear regression. The
reason for underestimation of TEE in this plot is solely due
to underestimated RMR because all other calculation par-
ameters are equal. (Measured RMR is closely correlated to
body weight also in this group (r 0·82) while the corresponding
values for RMRCunningham_DEXA is 0·50.)
In Fig. 5 (b) the calculation has been performed using the
measured RMR values but employing the calculation par-
ameters (PAR values) for normal-weight subjects. The underes-
timation can be seen clearly, and in addition this underestimation
increaseswith higher TEE. This clearly demonstrates the signiﬁ-
cant impact on TEE of the increased EE due to body weight
during weight-bearing activities which are not compensated
for when using the PAR values for normal-weight subjects.
The only difference in this calculation compared to that in
Fig. 4 (a) is the application of lower PAR values.
In conclusion, ActiRegw is a simple and cheapmethod to esti-
mate TEE compared to DLW. The present study shows ActiR-
egw to give good estimates of mean TEE in obese subjects as
validated by DLW with a mean underestimation of only
0·55MJ. The performance ofActiRegw in obese subjects is com-
parable to that previously shown in normal-weight subjects(2).
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ABSTRACT
Background: We assessed physical activity (PA) pattern and examined the association 
between cardiovascular risk factors and PA in treatment seeking obese subjects. 
Methods: Sixty-eight women and 62 men aged 24-64 years who were obese and had a high 
metabolic risk profile were referred for treatment. They recorded PA continuously with a 
position and movement recorder (ActiReg®) for a mean of 4 days. Time spent on PA 
categorized as physical activity ratios (PAR) were calculated. Blood tests were obtained for 
fasting lipids. 
Results: The subjects spent a mean±s.d. of 1065±107 min lying, standing and sitting (PAR 
1.0-1.5), 348±100 min strolling and walking (PAR 1.6-6.0), and 26±17 min brisk walking and 
jogging (PAR >6.0) daily. The time spent on brisk walking and jogging was inversely 
associated with total cholesterol (R2adj=0.056 [95%CI 0.013, 0.186], P=0.0161) and 
triglycerides (R2adj=0.080 [95%CI 0.027, 0.208], P=0.0039) after adjustment for age and sex.  
Conclusion:  Obese subjects with metabolic risk factors engaged in activities corresponding 
to brisk walking and jogging for a mean of 26 min per day, before weight loss was attempted. 
This level of PA was inversely associated with lipid concentrations. Thus higher levels of 
activity than 30 min daily may be needed to facilitate weight loss. 
2Introduction
The relation between obesity and several of its co-morbidities such as premature 
atherosclerosis and type 2 diabetes is primarily mediated by risk factors including increased 
abdominal obesity, high blood pressure, impaired glucose metabolism, and dyslipidemia.1,2
The metabolic syndrome is a cluster of these risk factors that increases the risk of 
cardiovascular disease (CVD) and all cause mortality.2, 3 One of the primary methods to 
reduce the risk associated with the metabolic syndrome is weight loss.4 Studies have shown 
that even a modest degree of weight reduction induced by change in diet and physical activity 
(PA) reduced the risk for developing type 2 diabetes.5, 6 Physically active women and men of 
all ages have a lower mortality rate compared to inactive individuals.7, 8 Moreover, increased 
leisure time PA in middle-aged men was associated with decreased risk of developing 
metabolic syndrome nearly 30 years later.9 However, obesity has been inversely associated 
with physical activity in observational studies. 10
In 2007 the American College of Sports Medicine and American Heart Association 
updated their recommendations for PA and public health. To promote and maintain health it 
was recommended that all healthy adults aged 18 to 65 years should engage in a minimum of 
30 min of moderate-intensity (endurance) physical activity on five days each week as well as 
activities that maintain and increase muscular strength and endurance a minimum of two days 
each week.11 Furthermore, for individuals that achieve this level of activity but remain 
overweight, a further increase in PA was stated to be a reasonable component of strategies to 
lose weight.11 Data from the 1999-2002 NHANES showed that only 20% of obese subjects 
that wanted to loose weight participated in moderate- to vigorous-intensity physical activity 
for more than 150 min per week. 12 Clearly, this is an area where adherence is a challenge. To
be able to design appropriate exercise prescriptions in a clinical setting, a quantified 
assessment of the activity pattern of obese individuals i.e. the amount time spent in inactivity, 
3light activity and moderate to vigorous activity is useful. However, data regarding the 
physical activity pattern of severely obese subjects is sparse.
Though PA has been assessed in numerous ways, accurate and reliable monitors for 
assessing PA are still lacking.13 ActiReg®, a portable device that records positions and 
movements 14, has been shown to give valid estimates of total energy expenditure (TEE) in 
obese subjects.15 In addition, activity patterns can be assessed from the recording by 
calculating the physical activity ratio (PAR) of different physical activities. The PAR is the 
ratio that expresses the energy expended in a particular activity, as multiples of the resting 
metabolic rate (RMR). 16
This study’s primary aim was to assess PA patterns recorded using ActiReg®, in 
treatment seeking obese women and men with a high risk of CVD due to the presence of risk 
factors for the metabolic syndrome. Furthermore, we examined the associations between 
moderate intensity PA and cardiovascular and metabolic risk factor levels. 
Methods
Subjects
Subjects were 68 women and 62 men consecutively referred to the Department of Preventive 
Medicine at Ullevål University Hospital for weight loss and cardiovascular risk reduction or 
who were seeking obesity treatment in response to newspaper advertisements. The present 
study was performed before any dietary advice or advice to increase physical activity was
given. Potential subjects were included if they had two or more components of the metabolic 
syndrome according to the National Cholesterol Education Program.17 Exclusion criteria were
body weight > 135 kg, suspected non-compliance because of drug or alcohol abuse, any major 
non-cardiac disease expected to interfere with the study, weight change of more than ± 4% 
4and/or the use of appetite suppressants or weight reducing medication within the last three 
months.  
The subjects were aged between 24 and 64 years and had a mean ± s.d. body mass 
index (BMI; kg/m2) of 36.4 ± 4.3 (range 30-50). They were screened via blood chemistry and 
a medical examination to assess risk factors and eligibility. The Ethical Committee (region 1) 
in Norway approved the protocol and all subjects provided written informed consent. The 
study was conducted between November 1998 and September 2003. 
Anthropometrics and biochemical measurements 
The subjects were weighed (in underwear) with a digital weight (Seca, Germany) to the 
nearest 0.1 kg. Height was measured with a standardized wall measuring stick scale to the 
nearest 0.5 cm. Waist circumference was measured at the umbilicus with the subject 
unclothed and in the standing position. Blood pressure was measured in the right arm with a 
digital blood pressure monitor (OMRON Hem-705 CP).  
Body composition (total fat mass, trunk fat mass and lean mass) was determined by 
dual energy X-ray absorptiometry (Lunar Expert 1116). The coefficient of variation (CV) for 
the dual energy X-ray absorptiometry measurements was 3-4%. Due to technical problems, 2  
subjects were missing data for total body fat and lean body mass. In addition, trunk fat was 
not calculated for 3 subjects.
Fasting (10 h overnight) blood samples were analyzed for serum lipids and glucose 
with conventional enzymatic methods. Values of serum triglycerides and glucose were 
missing for 1 male subject due to insufficient material for analysis.  
5Assessment of physical activity
PA was assessed continuously with ActiReg® for a mean ± s.d. of 4 ± 2 days. All days of the 
week were represented in the measurements. ActiReg® is not waterproof and the device was 
taken off when the subjects took a shower or were swimming. A few subjects experienced 
skin reactions due to the medical tape used to attach the sensors, and were allowed to take off 
the device during sleep at night.
A detailed description of the ActiReg® system has been described elsewhere. 14 In 
short, ActiReg® is an electromechanical device, which records the main body positions 
(stand, sit, bent forward and lie) together with motion of the trunk and/or one leg each second. 
During registration the subjects wear the ActiReg® monitor in a belt and two sensors are 
connected to the monitor with thin cables. The motion sensors are attached to the subject’s 
chest (on sternum) and on the front of the right thigh. A dedicated computer program 
(ActiCalc32®) calculates TEE and activity patterns from the collected information.14  The 
calculation model used by ActiCalc32® is based on the estimated cost of the actual body 
position and activity expressed as PAR values (i.e. EE/RMR) combined with the number of 
position changes within each minute. 15
We used PAR values between 1-1.5 for activities such as lying down, standing and 
sitting. As described elsewhere 15, 50 of the subjects did a treadmill test where they walked at 
increasing speeds as follows: 0.6, 1.2, 1.8, 2.4, 3.0 and 3.6 mph (1, 2, 3, 4, 5 and 6 km/h). 
According to this test, PAR values between 1.6-6.0 corresponded to strolling and walking at a 
speed of 0.6-2.7 mph (1.0-4.5 km/h) and PAR >6.0 corresponded to brisk walking at a speed 
of >2.7 mph (4.5 km/h). While the PA pattern is expressed in terms of walking at different 
speeds in correspondence to the treadmill test, the actual activity correspondent to PAR 1.6-
6.0 included light housework, gardening, vacuuming, golf, dancing and bicycling. The actual 
activity correspondent to PAR >6.0 included brisk walking, heavy yard work, snow 
6shoveling, cross-country skiing, aerobics, fast bicycling, walking uphill, climbing stairs, 
walking with loads and jogging.
TEE was calculated by summing the energy expended on the different PAR levels. 
RMR was calculated with the Mifflin formula 18 as this formula has shown good predictibility 
of RMR in obese subjects. 19, 20
RMR (kcal) = 9.99·weight (kg) + 6.25·height (cm) – 4.92·age + 166·sex (men;1, women;0) 18
To assess the overall activity during the day, we calculated the physical activity level (PAL) 
as the ratio of TEE to RMR. Compared to TEE measured with the doubly labelled method, 
the ActiReg® method has shown a small, but clinically insignificant underestimation of  
TEE.15
Statistics
Data are presented as mean ± s.d. or median (25th, 75th percentile) values. Differences 
between sexes were tested with an unpaired t-test and the Mann-Whitney two-sample rank 
test as appropriate for normally distributed and skewed variables. Associations between 
single, continuous variables were tested with Pearson’s correlation. Serum triglycerides and 
the amount of time spent at PAR >6 were log-transformed because of skewness but are 
presented as untransformed values. One female subject did not record any activity at PAR >6. 
The variable (ln (min at PAR>6 + 1 min)) was used in the analyses. Variables that were 
significantly correlated with min per day spent at PAR>6 were entered into a multiple 
regression analysis and adjusted for confounders. In these analyses min per day spent at 
PAR>6 was the dependent variable and sex and age and total cholesterol, HDL cholesterol or 
triglycerides were the independent variables. The tests were considered statistically 
7significant at P<0.05. Statistical analyses were performed using Stat View 5.0.1 (Abacus 
concepts, Berkeley, CA). 
Results
Characteristics of the subjects are shown in Table 1. The subjects had a high mean waist 
circumference, high systolic and diastolic blood pressures and high concentrations of total 
cholesterol and triglycerides. Of the total, 16 subjects (12%) had diabetes type 2 and 98 (75%)
had the full metabolic syndrome. Women had a lower mean waist circumference and lean 
body mass and higher total fat mass than men.  
Table 2 shows the levels of energy expenditure and activity pattern separated by sex. 
Women spent a median (25th, 75th percentile) of 23 (12, 32) min per day at PAR >6 while men 
spent a median (25th, 75th percentile) of 25 (16, 36) min per day at this PAR level (P= 0.3512).   
Pearson’s correlations between cardiovascular risk factors and min spent at PAR >6 
are shown in Table 3. Serum concentrations of total cholesterol (r=-0.23, P=0.002), HDL-
cholesterol (r=-0.18, P=0.042) and triglyceride (r=-0.26, P=0.003) were associated with min 
spent at PAR >6. The trends were similar in women and men (data not shown).  
In multiple regression analyses the number of min per day spent at PAR >6 was 
inversely associated with total cholesterol (R2adj=0.056 [95%CI 0.013, 0.186], P=0.0161) and 
triglycerides (R2adj=0.080 [95%CI 0.027, 0.208], P=0.0039), but not HDL-cholesterol 
R2adj=0.091 [95%CI 0.030, 0.231], P=0.0794) after adjustment for sex and age.  
Including BMI in the multivariate regression analyses did not change the model (data not 
shown).
8Discussion
Our primary finding was that obese men and women seeking treatment spent about 26 min in 
moderate intensity PA corresponding to brisk walking or jogging (PAR >6) per day. 
Futhermore, nearly 6 h were spent on strolling and walking and nearly 18 h per day lying  
down, standing and sitting. The time spent at moderate intensity PA (PAR >6) was inversely 
associated with serum total cholesterol and triglycerides explaining 6% and 8%, respectively, 
of the variation in these lipid levels after adjustment for age and sex.  
Unexpectedly, we found that these obese subjects with high risk for CVD due to 
metabolic syndrome risk factors were moderately active even before formal advice to increase 
physical activity was given as part of a weight reduction program. One-third of the subjects 
recorded more than 30 min of moderate activity per day. The mean of 26 min per day spent 
on activities such as brisk walking or jogging was close to the recommendations of the 
American College of Sports Medicine and American Heart Association. 11 Moreover, the 
mean overall PAL of 1.7 is in accordance with the mean PAL observed earlier among obese 
subjects. 21 The intensity of PAR > 6 corresponds with a walking speed above 2.7 mph, (about 
3 metabolic equivalents), and is considered to be moderate intensity PA. 11, 22 However, the 
mean time spent on moderate PA was about half of the time that may be needed to reduce 
cardiovascular risk 23 and to manage body weight. 24 In the Womens’ Health Initiative 
Observational Study 23, subjects in the highest quintile of PA walked about 60 min per day at 
a speed corresponding to a PAR >6. This amount of physical activity was associated with a 
reduction in the risk of cardiovascular disease by about 30% compared to the women in the 
lowest quintile. 23 Obese men that spent 60 min per day on brisk walking have achieved about 
a 7% reduction in body weight. 25 Likewise, the Studies of Targeted Risk Reduction 
Interventions through Defined Exercise showed that PA corresponding to 2.4-3.0 miles (4-5 
km) of daily walking had salutary effects on body weight.26 Assuming a speed of 2.7 mph 
9(4.5 km/h), our subjects would have had to walk for 60 min per day to reach this level of 
activity. Adherence to 60 min or more of PA may be a challenge. A recent study showed that 
only 12 of 202 subjects maintained a daily PA level of >60 min for 18 months. 27 However, 
moderate weight reduction of about 7-10% as suggested for treatment of the metabolic 
syndrome 4 may be achievable with individualized advice to slightly increase the level of PA 
to the minimum of 30 min of moderate intensity PA five days a week in a program including 
dietary and behavioral therapy. 
Intervention studies have shown that increased physical activity alone or in 
combination with change in diet and weight loss improves most metabolic risk factors, in 
particular those associated with the metabolic syndrome. 5, 6, 28, 29, 30, 31 A recent meta-analysis 
quantified the effect of exercise for the purpose of weight loss on diastolic blood pressure (-
0.2 mm Hg), triglycerides (-0.2 mmol/L) and fasting glucose (-2 mmol/L) but did not find an 
effect of exercise on total cholesterol and HDL cholesterol. 31 However, data on the effects of 
physical activity on metabolic risk factors in very obese individuals is sparse. 26, 31 In line with 
the meta-analysis we found inverse associations between time spent at moderate intensity PA 
(PAR >6) and serum concentrations of triglycerides. The time spent at PAR >6 were also 
inversely correlated with serum total cholesterol concentrations. Unexpectedly HDL 
cholesterol was inversely associated with time spent at PAR >6. The amount of PA in our 
study may have been insufficient to increase HDL cholesterol 29 or exercise may vary in its 
effects on lipids in very obese subjects. A relatively high heritability factor has been reported 
for the change in HDL cholesterol after endurance training. 32
The study has several limitations. The sample size was limited and may explain the 
lack of association between blood presure and serum glucose concentrations and physical 
activity. Moreover, in a cross-sectional study as the present one, causality cannot be 
determined. We measured PA for only 4 days to assure compliance. This amount of recording 
10
is consistent with the 3-5 days that are recommended for PA measurements in adults, 33
however, recording for a longer period may have given a better estimate of usual PA. The 
subjects may have changed their activity pattern during this short period of time. 
Conclusions
We observed that very obese subjects with metabolic risk factors engaged in close to the 
recommended amount of moderate physical activity before weight loss interventions were 
initiated. This activity was associated with lower lipid levels, but intervention to increase this 
level of PA may be needed to achieve weight loss.  
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Table 1 Characteristics of the subjects      
Variables    Women (N=68) Men (N=62) P1
Age (y)    44±10   48±10  0.0640 
Height (m)    1.7±0.1  1.8±0.1 <0.0001 
Weight (kg)    105.3±13.4  114.5±15.0 0.0003 
Body mass index (in; kg/m2)  37.6±4.4  35.4±3.8 0.0029 
Waist (cm)    109.8±10.3  119.1±10.2 <0.0001 
Total body fat mass (kg)  56.1±13.8  47.9±13.1 0.0008 
Trunk fat mass (kg)   29.3±7.7  29.4±8.6 0.9276 
Lean body mass (kg)    47.8±5.1  65.1±7.6 <0.0001 
Systolic blood pressure (mmHg) 133±17  139±18 0.0446 
Diastolic blood pressure (mmHg) 85±10   89±11  0.0521 
Glucose (mmol/L)    5.9±1.8  6.0±1.7 0.6681 
Total cholesterol (mmol/L)  6.1±1.1  6.1±1.1 0.8178   
HDL cholesterol (mmol/L)  1.2±0.3  1.1±0.2 0.0069 
Triglycerides (mmol/L)  2.1±0.8  2.6±1.7 0.2078 
NOTE. Values are means and standard deviations. 
1Unpaired t-test and the Mann-Whitney two sample rank test were used to examine differences 
between sexes. 
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Table 2 Energy expenditure and physical activity patterns       
Values      Women (N=68) Men (N=62)  P1
Resting metabolic rate (MJ/d)  7.2±0.7  8.5±0.8  <0.0001 
Total energy expenditure (MJ/d)  12.5±1.8  14.8±2.4  <0.0001 
Physical activity level   1.7±0.2 1.7±0.2  0.9638 
Physical activity ratio 1.0-1.5 (min/d)2 1070±113  1060±101  0.6098 
Physical activity ratio 1.6-6.0 (min/d)2  347±107  349±92  0.7779 
Physical activity ratio >6.0 (min/d)2  25±17   27±17   0.3512 
NOTE. Values are means and standard deviations. 
1 Unpaired t-test and the Mann-Whitney two sample rank test were used to examine differences 
between sexes. 
2 Physical activity ratio 1.0-1.5 corresponds to laying, standing and sitting; physical activity ratio 
1.6-6.0 corresponds to strolling and walking with a speed of  0.6-2.7 mph (1.0-4.5 km/h) and 
physical activity ratio >6.0 corresponds to brisk walking or jogging with a speed of >2.7 mph 
(4.5 km/h). 
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Table 3 Correlations between metabolic risk factors and minutes spent at physical activity 
ratio>61 in all subjects (N=130)         
Cardiovascular risk factors  Correlation coefficient2 P  95% CI 
Waist (cm)    -0.08    0.402  -0.25, 1.00 
Fat trunk (kg)    -0.03    0.782  -0.20, 0.15 
Diastolic blood pressure (mmHg) -0.11    0.214  -0.28, 0.06 
Systolic blood pressure (mmHg) -0.06    0.499  -0.23, 0.11 
Serum total cholesterol (mmol/L) -0.23    0.002  -0.42, -0.10   
Serum HDL-cholesterol (mmol/L) -0.18    0.042  -0.34, -0.07 
Serum triglycerides (mmol/L)3 -0.26    0.003  -0.41, -0.09 
Serum glucose (mmol/L)4  -0.07    0.456  -0.25, 0.12 
1Physical activity ratio >6 corresponds to brisk walking or jogging with a speed of >2.7 mph (4.5 
km/h). 
2 Pearson’s correlation. Min spent at PAR>6 and concentrations of serum triglycerides were 
skewed variables and log transformed. Because one subject did not record any min at PAR>6 the 
variable (ln (min PAR>6 + 1 min)) was used in the correlation analyses. 
3 1 man was missing value for serum triglycerides. 
4 7 women and 9 men with diabetes type 2 were excluded from the analysis. 1 man was missing 
value for serum glucose.  
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ORIGINAL ARTICLE
The effect of an increased intake of vegetables and
fruit on weight loss, blood pressure and antioxidant
defense in subjects with sleep related breathing
disorders
M Svendsen1, R Blomhoff2, I Holme3 and S Tonstad1
1Department of Preventive Cardiology, Ulleva˚l University Hospital, Oslo, Norway; 2Institute for Nutrition Research, University of Oslo,
Oslo, Norway and 3Clinic for Preventive Medicine, Ulleva˚l University Hospital, Oslo, Norway
Objective: To assess the effect of an increased consumption of vegetables and fruit on body weight, risk factors for
cardiovascular disease (CVD) and antioxidant defense in obese patients with sleep-related breathing disorders (SRBD).
Design: Randomized, controlled trial of an intervention to increase the intake of vegetables to 400g/day and fruit to 300g/day.
Dietary intake was calculated from a food frequency questionnaire. Antioxidant status was assessed with the ferric-reducing/
antioxidant power (FRAP) assay. Plasma carotenoids were biomarkers for the intake of vegetables and fruit.
Setting: A hospital clinic preventing risk factors for CVD.
Subjects: Subjects were 103 men and 35 women with a body mass index of 36.775.8 kg/m2 of which 57 (86%) in the control
and 68 (94%) in the intervention group completed the study.
Intervention: Group-based behavioral program during 3 months.
Results: The mean between group differences in body weight was 2.0% (95% CI 3.6, 0.5), Po0.0001. The mean between
group difference in systolic and diastolic blood pressure (BP) was 7.1mm Hg (95% CI: 11.6, 2.6), P¼ 0.0022 and 3.9mm
Hg (95% CI: 7.0, 0.9), P¼0.0120, respectively. The mean change in daily intake of vegetables and fruit was 12 g (95% CI:
33, 57) and 4g (95% CI: 79, 71) versus 245g (95% CI: 194, 296) and 248g (95% CI: 176, 320) in the control and
intervention groups, respectively. This was reflected in higher concentrations of a-carotene and b-carotene. No change in FRAP
was seen. In a multiple regression analysis the change in intake of vegetables was a significant contributor (Radj
2 ¼ 0.073 (95% CI:
0.019, 0.214)) to the change in weight.
Conclusion: Targeted dietary advice to increase the intake of vegetables and fruit among subjects with SRBD contributed to
weight reduction and reduced systolic and diastolic BP, but had no effect on antioxidant defense measured with FRAP.
Sponsorship: None.
European Journal of Clinical Nutrition (2007) 61, 1301–1311; doi:10.1038/sj.ejcn.1602652; published online 31 January 2007
Keywords: sleep apnea; treatment; dietary advice; risk reduction; carotenoids; FRAP (ferric reducing/antioxidant power)
Introduction
Sleep-related breathing disorders (SRBD), including habitual
snoring, increased upper airway resistance syndrome and
obstructive sleep apnea (OSA) are increasingly common
causes of morbidity and mortality among overweight and
obese individuals. It is estimated that one of five white adults
has at least mild disease and one of 15 has at least moderate
disease (Caples et al., 2005). There is a graded increase in OSA
prevalence with increasing body mass index (BMI) and waist
to hip ratio. Observational studies indicate that a decrease in
body weight of 10% is associated with improvement in the
apnea–hypoapnea index (AHI), a widely used measure of the
frequency of disordered breathing events (Peppard et al.,
2000). Thus, weight loss is universally recommended
to overweight or obese patients with SRBD. However, the
response to weight loss is variable, weight loss is difficult
to maintain long-term and SRBD may recur even after
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surgically induced weight loss (Pillar et al., 1994; Strobel
and Rosen, 1996). Furthermore, studies of weight loss are
severely deficient in regard to their design and follow-up
(Strobel and Rosen, 1996; Shneerson and Wright, 2001).
As a result, the use of continuous positive airway pressure
(CPAP), which appears to be the most effective therapy for
symptoms of OSA, has become the treatment of choice.
Treatment with CPAP may additionally cause weight loss
(Loube et al., 1997).
SRBD have been associated with hypertension and an
increased risk of cardiovascular disease (CVD) in clinical and
epidemiological reports for nearly three decades. This
association is confounded by other comorbid conditions,
most notably obesity, and to date the question of whether
SRBD independently cause CVD remains controversial
(Lavie, 2004; Stradling, 2004). Although the exact mechan-
isms of any atherogenic effects of SRBD have not been
established, a number of hypotheses have been proposed.
For example, increased sympathetic activity, endothelial
dysfunction and inflammatory processes have been sug-
gested to act as mediators of cardiovascular morbidity in
patients with SRBD and have been shown to be associated
with SRBD in clinical studies. Thus, patients with SRBD may
exhibit evidence of sympathetic overactivity and increased
oxidative stress, insulin resistance and a prothrombotic state
(Shamsuzzaman et al., 2002; Fletcher, 2003; Lavie, 2003;
Punjabi et al., 2004). Most convincing in this regard is
evidence that treatment with CPAP reduces blood pressure
(BP), at least in the short term (Becker et al., 2003).
Alhough the exact independent relation of SRBD to CVD is
still not clear, there is widespread acceptance of the idea
that patients with SRBD are at high risk of CVD because of
concomitant factors, including the pervasiveness of male
gender, age, central obesity, hypertension, diabetes and
dyslipidemia (Newman et al., 2001). Dietary modification is
a primary cornerstone of lifestyle changes that aim to
prevent CVD, even though weight reduction sufficient to
reduce the need of CPAP is probably very difficult to achieve
in the long term. A diet rich in vegetables and fruits has been
consistently associated with a reduced risk of cardiovascular
disease (Dauchet et al., 2006), and is widely recommended to
facilitate weight reduction (Krauss et al., 1996). The feasi-
bility and efficacy of such a diet with the aim of CVD risk
factor reduction in patients with SRBD has not been
previously studied, to our knowledge. The specific purpose
of this study was to test the effects of dietary advice given as
a behavioral, group session-based intervention aimed to
increase the consumption of vegetables and fruit compared
with a single session of dietary advice, in free living
overweight or obese subjects with SRBD. The primary
outcome was weight change from baseline to 3 months.
Changes in established risk factors for CVD including BP,
lipids and glucose at 3 months were secondary outcomes.
The third outcome was change in oxidative defense
measured with ferric reducing/antioxidant power (FRAP)
assays at 3 months.
Subjects and methods
Subjects
Participants included 103 men and 35 women diagnosed
with SRBD and a mean7s.d. age and BMI of 48.279.0 year
and 36.775.8 kg/m2, respectively. The Ear, Nose and Throat
department at the hospital or primary care physicians
referred the subjects to the Department of Preventive
Cardiology at Ulleva˚l University Hospital for weight reduc-
tion. The diagnosis was verified during polysomnography
in a sleep laboratory, mostly done at the Ulleva˚l University
Hospital. Of the total, 64 subjects had severe OSA (AHI 430
mean episodes per hour of sleep), 34 subjects had moderate
OSA (AHI 15–30), 23 subjects had mild OSA (AHI 5–15), five
subjects only had SRBD (AHI o5) and AHI could not be
calculated for one subject after the polysomnography owing
to technical problems, but the oxygen saturation was 85%
and the sleep pattern was in accordance with OSA. The
actual AHI measurement could not be located for 11 subjects
owing to moving of the Ear, Nose and Throat department to
another location. Of the total, 93 subjects were treated with
therapeutic or subtherapeutic continuous positive airways
pressure CPAP and eight had undergone surgical treatments.
No significant difference in AHI was seen between subjects
treated with CPAP or who had undergone surgical treatment
and subjects without treatment (32.3725.7 versus 39.87
27.7, P¼0.1640).
Study design
All participants underwent baseline examinations for elig-
ibility, including a medical history and physical examination
as well as CVD risk factor assessment (including cardiovas-
cular risk factors, BP and blood chemistry). Inclusion criteria
were men and women between the ages of 21 and 72 with
BMIX27kg/m2 and diagnosis of OSAS made during poly-
somnography in a sleep laboratory and based on standard
criteria. Exclusion criteria were suspected non-compliance
because of drug or alcohol abuse or lack of motivation,
participating in another trial, any major non-cardiac disease
expected to reduce life expectancy or interfere with the study
and the use of appetite suppressants or weight-reducing
medication within the last 3 months. The Ethical Committee
(region 1) in Norway approved the protocol and all
participants provided written informed consent. The study
was conducted between May 2000 and December 2003.
The study design was a randomized, parallel group
controlled comparison of a group-based nutritional and
cognitive-behavioral intervention aimed to increase the
intake of vegetables and fruit and simple dietary advice
given only at baseline (control). The dietitian opened sealed,
consecutively numbered, opaque envelopes containing the
randomization number and group assignment (control or
intervention). The dietitian then allocated the next available
number to each screened and eligible subject. The randomi-
zation list was based on a table of random numbers set up by
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an investigator, who had no contact with the subjects during
the study period. Before randomization, all participants were
given written individualized dietary advice aimed to achieve
a 5% weight reduction. The advice was based on the subjects’
usual diet assessed with a dietary interview based on a food
frequency questionnaire (FFQ) as described below.
The control group
After the randomization, the participants in the control
group were not given further dietary advice or counseling on
behavior change. The subjects had no further contact with
the dietitian until the 3 months examination.
The intervention group
Participants randomized to the intervention group were
consecutively assigned to six groups with 10–18 participants
in each group. Because of holidays, the meeting frequency
for each group during the 3-month period was a minimum of
six and a maximum of 10 sessions.
The primary goal of the intervention was to increase the
consumption of vegetables (to at least 400 g/day) and fruit
(to at least 300 g/day). The subjects were told the weights of
various vegetables and fruit and encouraged to use a scaled
weight at home to become familiar with the amount of
vegetables and fruit that was necessary for goal achievement.
Participants were instructed to use a plate model for hot
meals and advised to fill one-half of the plate with
vegetables, one-fourth with potatoes, rice or pasta and one-
fourth with meat, chicken, fish and/or legumes. When the
plate model was used, the amount of vegetables increased
and the portion size of meat and/or potatoes, rice and pasta
decreased. Substitution of vegetables and fruit for high-fat,
high-energy food was otherwise emphasized. The dietary
sessions focused on how to implement an increased intake
of vegetables and fruit in daily life settings and on problem
solving issues. Recipes and tips to encourage compliance
were provided.
Dietary assessments
The subjects participated in a dietary interview based on a
FFQ before randomization and at the 3-month examination.
The interview was done with a registered dietitian and lasted
between 1 and 2h. The FFQ was designed to assess the food
intake during the last 3 months and has been validated and
described in details elsewhere (Svendsen and Tonstad, 2006).
In short, the questionnaire elicited frequencies and con-
sumption of 174 food items (of these 28 vegetables and 29
fruits and berries). Portion sizes were estimated with the use
of a photographic atlas, photographs, ordinary food items
and standardized units. The FFQ was coded manually for the
calculation of total energy, energy yielding nutrients and
food items using a software program (Mat pa˚ data 3.0, 1996)
based on the Norwegian food composition table (Rimestad
et al., 1995). Two subjects in the control group and one
subject in the intervention group did not take part in the
interview at the 3-month visit but completed the other
examinations.
Use of supplements was assessed in the dietary interview.
Fifteen subjects reported daily use of low-dose multivitamin
supplements and two subjects used high-dose multivitamin
supplements at baseline. As intake of vitamins and minerals
from supplements was low, we did not include supplements
in the calculated dietary intake or in the statistical analyses.
Anthropometry and blood pressure measurements
Subjects were weighed (in underwear) with a digital weight
(Seca, Germany) to the nearest 0.1 kg. Height was measured
with a standardized wall measuring stick scale to the nearest
0.5 cm. Waist circumference was measured at the umbilicus
with the subject unclothed and in the standing position and
hip circumference was measured at the greater trochanter.
After the subjects sat quietly for 5min, BP was measured
automatically in the right arm with a digital BP monitor
(OMRON Hem-705 CP) and an appropriately sized cuff.
Laboratory measurements
Fasting (10h overnight) blood samples were collected at
baseline and after 3 months. All samples except those for the
analysis of lipids and glucose were kept frozen at 701C for
batch analyzes of the variables. Serum lipids and glucose
were analyzed with conventional enzymatic methods and
folate was analyzed with a chemoluminescence detection
technology method (Advia Centaur immunoassay, Bayer AG,
Leverkusen, Germany).
FRAP was determined as described elsewhere (Benzie and
Strain, 1999). The carotenoids lutein, zeaxanthin, b-krytpo-
xanthin, a-carotene, b-carotene and lycopene were deter-
mined in plasma by high-performance liquid chromato-
graphy. Proteins were precipitated and removed by the
addition of a 4.5 volume of isopropanol followed by
centrifugation at 3000 g at 41C for 15min. The internal
standard astaxanthin was added with the isopropanol and
25 ml of the clear supernatant were used for analysis. The
mobile phases consisted of A: 20% water and 24% acetone in
ethanol and B: acetone. The gradient conditions were as
follows: From 2 to 100% B within 20min, followed by 100%
B for 15min. Detection was performed at 453nm using a
variable wavelength detector. Plasma calibrators quantified
against the National Institute of Standards and Technology
and 968c standard reference material were used as standards.
Values of the laboratory parameters (lipids and glucose)
were missing for 1–5 in the control group and 2–4 subjects in
the intervention group. Values of carotenoids and FRAP were
missing for eight subjects and three subjects in the control
and intervention group, respectively. Values of serum folate
were missing for 13 subjects in the control group and 13
subjects in the intervention group. In all cases missing
samples were due to insufficient material for analysis.
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Statistical analysis
The results are presented as means7s.d., means (95% CI) or
median and 25th, 75th percentiles. Mean differences within
and between groups were tested with paired- and unpaired
t-tests, respectively. Differences between the groups for
skewed variables were tested with the Mann–Whitney two-
sample rank test. The w2 test was used in comparisons of
categorical variables. Changes were calculated as the differ-
ence between 3 months and baseline. Energy density was
calculated for the whole diet minus all drinks (coffee, tea,
milk, juice, soft drinks and alcoholic beverages).
The association between single, continuous variables was
explored by Pearson or Spearman correlations as appropriate
for normally distributed or skewed variables. We conducted
multiple regression analyses to identify factors that deter-
mined weight change in all subjects as follows. To test for
group homogeneity, we did a multiple regression analysis
including the exposure factor (x1), treatment variable (x2)
and the product variable of x1 and x2. When the product
variable was found to be significant in the multiple
regression analysis, the slopes of association were claimed
to be different between treatment groups. In such a case
simple regression analysis between change in weight and the
exposure factor was done within each treatment group.
Group homogeneity was tested for the presence of diabetes
or CVD, use of antihypertensive or lipid-lowering medica-
tion, smoking habits and gender. The tests for homogeneity
showed heterogeneity between the control and intervention
group only in regard to the use of antihypertensive
medication (P¼0.0165). Because of the heterogeneity, use
of antihypertensive medication was not included in the final
multiple regression analysis.
The tests were considered significant at Po0.05. Statistical
analyses were performed using the Stat View 5.0.1 software
(Abacus concepts, Berkeley, CA, USA).
Results
A total of 125 subjects participated in the 3-month
examination. There were nine dropouts in the control group
and four in the intervention group. In the control group
three subjects withdrew because of a high workload, three
subjects did not show up after three reminders, one subject
wanted another treatment, one subject was disappointed
with the treatment and one moved to another city. In the
intervention group one subject withdrew because of a
divorce, one because of a hip operation, one because of
alcohol abuse and one quit attending the group sessions and
did not show up at the 3-month examination after three
reminders.
The ranges for age and BMI were 28–72 years and 27.2–
55.4 kg/m2, respectively. Other characteristics of participants
are shown in Table 1. There was no statistically significant
difference in BMI between the groups.
At baseline, there were no statistically significant differ-
ences in weight, BP, serum concentrations of lipids, glucose
and FRAP or dietary intake of vegetables and fruit between
the groups (Tables 2 and 3). However, serum folate was
higher in the intervention group.
Outcome effects
The mean7s.d. % weight loss was 0.974.3% in the control
group and 3.074.6% in the intervention group (Po0.0001).
In the control group eight subjects (14%) achieved a weight
loss of X5% compared to 21 subjects (31%) in the
intervention group (P¼0.01).
Systolic and diastolic BP was reduced in the intervention
group (Table 2). The mean change in systolic BP was 2.7%
(95% CI: 0.3, 5.7) versus 3.2% (95% CI: 5.5, 1.0) and
the mean change in diastolic BP was 1.3% (95% CI: 1.7,
4.3) versus 3.5% (95% CI: 5.8, 1.2) in the control group
Table 1 Baseline characteristics of participants in the control and
intervention group
Control group Intervention group
(n¼57) (n¼68)
Gender
Male, n (%) 42 (74) 53 (78)
Female, n (%) 15 (26) 15 (22)
Age (years) 49.2710.3a 47.177.5
Cardiovascular disease, n (%) 7 (12) 9 (13)
Diabetes mellitus, n (%) 3 (5) 8 (12)
Hypertensiveb, n (%) 31 (54) 38 (59)
Antihypertensive medication, n (%) 18 (32) 18 (26)
Lipid lowering medication, n (%) 11 (19) 15 (22)
Smokers, n (%) 19 (33) 17 (25)
CPAPc treatment, n (%) 34 (60) 43 (63)
Height (m)
Male 1.7970.06 1.8170.06
Female 1.6670.07 1.6470.06
Weight (kg)
Male 120.0723.7 115.5717.6
Female 103.2721.5 97.2716.3
BMI (kg/m2)
Male 37.576.4 35.575.1
Female 37.677.5 36.075.5
Waist (cm)
Male 124716 119712
Female 113712 107714
Hip (cm)
Male 114712 11179
Female 114712 116711
Waist-to-hip ratio 1.170.1 1.070.1
Abbreviations: BMI, body mass index; CPAP, continuous positive airway
pressure.
aw7s.d. (all such values).
bBlood pressure X140/90mm Hg or current uses of antihypertensive
medications.
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and intervention group, respectively. The between-group
difference in BP remained significant after adjustment for
baseline BP and BMI (mean change systolic BP: 6.6mm Hg
(95% CI: 11.0, 2.2) and diastolic BP: -3.6mm Hg (95% CI:
6.4, 0.8)).
No differences in lipid or glucose concentrations in
between-group comparisons were seen, neither did we see
any statistically significant difference in antioxidant defense
measured with FRAP within or between the groups (Table 2).
Effects of intervention on diet and serum biomarkers
The intake of vegetables and fruit (including berries and
juice) was doubled in the intervention group which was a
Table 2 Intervention outcomes at baseline and at 3 months
Control group (n¼57) Pa Intervention group (n¼68) Pa Pb
Weight (kg)
Baseline 115.6724.2c — 111.5718.8 — 0.2867
3 months 114.7725.2 — 108.1718.0 — —
Change 0.974.8 0.1425 3.475.3 o0.0001 0.0074
Waist (cm)
Baseline 121716 — 116714 — 0.0601
3 months 120718 — 113714 — —
Change 1.675.5 0.0365 3.075.4 o0.0001 0.1541
Systolic blood pressure (mm Hg)
Baseline 127718 — 130714 — 0.2286
3 months 130718 — 126716 — —
Change 2.7713.0 0.1278 4.4712.1 0.0044 0.0022
Diastolic blood pressure (mm Hg)
Baseline 81710 — 8479 — 0.1692
3 months 82711 — 8079 — —
Change 0.678.6 0.5843 3.378.3 0.0019 0.0120
Total cholesterol (mmol/l)
Baseline 5.571.0 — 5.671.2 — 0.6390
3 months 5.471.1 — 5.471.2 — —
Change 0.070.8 0.7540 0.270.8 0.0660 0.3219
HDL cholesterol (mmol/l)
Baseline 1.270.2 — 1.270.2 — 0.7216
3 months 1.270.2 — 1.270.2 — —
Change 0.070.1 0.5692 0.070.1 0.1430 0.5853
Triacylglycerols (mmol/l)
Baseline 2.170.1 — 2.472.0 — 0.3394
3 months 2.271.2 — 2.071.5 — —
Change 0.171.1 0.7519 0.471.4 0.0260 0.0638
Glucose (mmol/l)
Baseline 6.171.1 — 5.972.1 — 0.6520
3 months 6.071.3 — 5.872.3 — —
Change 0.171.1 0.6587 0.271.6 0.3905 0.6887
Serum folate (nmol/l)
Baseline 12.775.5 — 16.379.1 — 0.0209
3 months 13.676.0 — 16.977.7 — —
Change 0.975.1 0.2508 0.676.2 0.4792 0.8021
FRAPd (mmol/l)
Baseline 13697209 — 13687235 — 0.9835
3 months 13477221 — 13767243 — —
Change 227111 0.1692 77203 0.7702 0.3596
aDifferences between baseline and 3 months within the control group and the intervention group (paired t-test).
bDifferences between the control group and the intervention group (unpaired t-test).
cw7s.d. (all such values).
dFRAP, ferric reducing/antioxidant power.
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significant increase compared to controls and resulted in
lower energy density of the diet, a reduction in energy
percent from total and saturated fat, higher intake of energy
percent from carbohydrate and higher intake of fiber,
potassium, magnesium, a-tocopherol, Vitamin C, folate
and b-carotene (Table 3). No significant change was seen
in the intake of calcium within the intervention group.
However, the dietary intake of diary products was decreased
(62 g (95% CI 143, 19) and 77 g (95% CI 151, 3),
P¼0.8023 in the control and intervention group,
respectively).
The increased intake of vegetables and fruit was reflected
in increased plasma concentrations of a- and b-carotene in
between-group comparisons (Table 4). The mean between-
group difference of the percentage change in serum levels
of a-carotene, b-carotene, b-cryptoxanthin, lycopene, lutein
and zeaxanthin were 166.2% (95% CI 59.5, 273.0), 61.3%
(95% CI 31.5, 91.1), 47.2% (95% CI 7.2, 87.86), 56.1% (95%
CI 29.9, 142.0), 21.0% (95% CI 7.1, 49.9) and 3.0%
(95% CI 65.7, 59.7), respectively.
Table 3 Intervention outcomes for vegetables, fruit and nutrients at
baseline and 3 months
Control group (n¼57) Intervention group
(n¼68)
Pa
Vegetables (g/day)
Baseline 2267178b 2237159 0.9717
3 months 2387144 4577240
Change 12 (33, 57)c 245 (194, 296) o0.0001
Fruit, juice and berries (g/day)
Baseline 3277266 2427199 0.0626
3 months 3227258 4867285
Change 4 (79, 71) 248 (176, 320) o0.0001
Energy (kJ/day)
Baseline 1133474220 1046173943 0.2322
3 months 987573114 898272243
Change 1563 (2216, 910) 1463 (2300, 626) 0.8499
Energy density (kJ/g)d
Baseline 6.6271.25 6.6371.48 0.8081
3 months 6.2971.43 4.9171.14
Change 0.33 (0.64, 001) 1.76 (2.08, 1.44) o0.0001
Protein (% of energy)
Baseline 16.372.8 16.772.6 0.4118
3 months 16.673.1 17.472.6
Change 0.4 (0.5, 1.3) 0.6 (0.2, 1.5) 0.6978
Fat (% of energy)
Baseline 34.075.6 33.477.0 0.5997
3 months 32.275.6 28.075.9
Change 1.8 (3.5, 0.1) 5.2 (7.1, 3.4) 0.0078
Saturated fat (% of energy)
Baseline 12.873.1 12.473.1 0.4505
3 months 11.872.9 8.972.9
Change 0.9 (1.7, 0.2) 3.4 (4.2, 2.5) o0.0001
Carbohydrate (% of energy)
Baseline 45.376.4 44.877.1 0.6682
3 months 47.376.0 49.676.3
Change 1.8 (0.2, 3.3) 4.8 (3.2, 6.4) 0.0091
Alcohol (% of energy)
Baseline 3.274.4 3.974.0 0.3717
3 months 3.073.6 3.974.5
Change 0.13 (0.93, 0.66) 0.03 (0.10, 0.63) 0.8432
Fiber (g/day)
Baseline 30712 27712 0.1762
3 months 2979 36712
Change 2 (5, 1) 9 (6, 13) o0.0001
Cholesterol (mg/day)
Baseline 3377133 3047125 0.1547
3 months 2927122 239795
Change 46 (75, 18) 65 (94, 36) 0.3631
Sodium (mg/day)
Baseline 359371674 348571278 0.6847
3 months 306571182 28017909
Change 543 (861, 225) 609 (1070, 380) 0.5208
Potassium (mg/day)
Baseline 475171591 430971477 0.1358
3 months 433971283 490471126
Change 422 (749, 95) 642 (337, 947) o0.0001
Table 3 Continued
Control group (n¼57) Intervention group
(n¼68)
Pa
Calcium (mg/day)
Baseline 11347584 10157509 0.2258
3 months 9997414 9007463
Change 138 (255, 21) 103 (221, 15) 0.6763
Magnesium (mg/day)
Baseline 4747170 4377144 0.1899
3 months 4437142 4597108
Change 35 (64, 6) 25 (5, 55) 0.0063
a-tocopherol (mg/day)
Baseline 9.573.9 8.073.3 0.0223
3 months 8.773.5 9.073.3
Change 0.9 (1.9, 0.1) 1.1 (0.1, 2.1) 0.0065
Vitamin C (mg/day)
Baseline 2157438 130776 0.1128
3 months 151783 2407107
Change 68 (190, 53) 113 (85, 141) 0.0019
Folate (mg/day)
Baseline 3037115 2727101 0.1053
3 months 2877102 3377101
Change 20 (49, 8) 71 (42, 100) o0.0001
b-Carotene (mg/day)
Baseline 299671870 303772281 0.9156
3 months 360072729 708674528
Change 588 (81, 1257) 4140 (2948, 5334) o0.0001
Abbreviation: CI, confidence interval.
aDifferences between the control group and the intervention group (unpaired
t-test).
bw7s.d. (all such values).
cw; 95% CI in parentheses (all such values).
dEnergy density was calculated for the whole diet minus tea, coffee, water and
soft drinks.
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At 3 months, nine subjects (16%) in the control group and
37 subjects (55%) in the intervention group reported an
intake of X400 g/day of vegetables (P¼0.001). Furthermore,
27 subjects (49%) in the control group and 46 subjects (69%)
in the intervention reported an intake of fruit X300g/day
(P¼0.05). Compared to controls, the increased intakes of
vegetables and fruit in the intervention group were also
reflected in higher calculated intakes of b-carotene and folate
(Table 3).
Correlation analyses
Correlation analyses conducted among all subjects showed
that changes in intake of vegetables and fruit were positively
correlated to change in body weight (rS¼0.284, P¼0.0015
and rS¼0.209, P¼0.0207, respectively) but not to changes
in systolic or diastolic BP (data not shown). Within the
intervention group, weight changes were significantly
correlated to changes in systolic BP (r¼0.304, P¼0.0137)
not to diastolic BP (r¼0.232, P¼0.0631).
Tables 5 and 6 show correlations between antioxidant
markers (lutein, zeaxanthin, b-kryptoxanthin, b-carotene, a-
carotene, lycopene and FRAP) and changes in the intake of
vegetables and fruit and the correlations between anti-
oxidant markers and the intake at 3 months in the
intervention group and among all subjects. The marker that
showed best correlation in all analyses was a-carotene (Tables
5 and 6). Changes in intake of b-carotene were significantly
correlated to changes in serum concentrations of b-carotene
(rS¼0.234, P¼0.0135).
To explore the most important factor for weight reduction
during the intervention we included change in the intake of
vegetables, change in the intake of fruit and treatment group
in a multiple regression analysis. As shown in Table 7 change
in the intake of vegetables was the only significant factor in
the model (Radj
2 ¼0.073 (95% CI 0.019, 0.214)). Including
CPAP did not improve the model (Radj
2 ¼0.062 (95% CI
0.018, 0.210)) nor did the inclusion of age, gender and BMI
at baseline (Radj
2 ¼0.051 (95% CI 0.020, 0.216)).
Discussion
Our main finding was that an B500 g increase in the total
consumption of vegetables and fruit resulted in weight loss
and BP reduction in the intervention group, but did not
Table 4 Changes in plasma carotenoid values from baseline to 3 months in the control and intervention group
Control group (n¼49) Intervention group (n¼65) Pa
Lutein (mM) 0.017 (0.039, 0.005)b 0.005 (0.013, 0.023) 0.0555
Zeaxanthin (mM) 0.010 (0.020, 0.005) 0.002 (0.062, 0.058) 0.0844
b-Cryptoxanthin (mM) 0.026 (0.004, 0.056) 0.055 (0.021, 0.089) 0.0516
a-Carotene (mM) 0.002 (0.016, 0.020) 0.046 (0.026, 0.066) 0.0023
b-Carotene (mM) 0.029 (0.077, 0.019) 0.086 (0.036, 0.150) 0.0031
Lycopene (mM) 0.014 (0.004, 0.068) 0.073 (0.009, 0.137) 0.3015
Abbreviation: CI, confidence interval.
aDifferences between groups (the Mann–Whitney two sample rank test).
bw; 95% CI in parentheses (all such values). Eight subjects in the control group and three in the intervention group were missing values.
Table 5 Correlations between antioxidant markers and change in intakes of vegetables and fruit between baseline and 3 months and intakes at 3
months in the intervention group
Changes in intake (n¼64)a Intake at 3 mo (n¼65)b
Vegetables Fruit Vegetables Fruit
Rc P r P r P r P
Lutein 0.190 0.1318 0.094 0.4569 0.001 0.9971 0.045 0.7208
Zeaxanthin 0.096 0.9609 0.023 0.8532 0.127 0.3105 0.016 0.8996
b-Kryptoxanthin 0.108 0.3926 0.041 0.7442 0.203 0.1038 0.270 0.0308
b-Carotene 0.072 0.5688 0.018 0.8887 0.160 0.2010 0.233 0.0620
a-Carotene 0.323 0.0103 0.153 0.2238 0.213 0.0887 0.426 0.0006
Lycopene 0.038 0.7626 0.004 0.9722 0.085 0.4973 0.124 0.3219
FRAPd 0.135 0.2831 0.060 0.6322 0.083 0.5092 0.001 0.9933
aOne subject was missing dietary data and three subjects were missing serum values for carotenoids and FRAP.
bOne subject was missing dietary data and two subjects were missing serum values for carotenoids and FRAP.
cSpearmann correlations (all such values).
dFRAP, the ferric reducing/antioxidant power.
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influence antioxidant defense measured with FRAP. Com-
pared to the control group, the intervention group reported
a doubled intake of vegetables and fruit, a reduced intake
of saturated fat and increased intake of fiber, vitamins and
minerals known to lower BP.
The effects that we observed in these obese subjects with
SRBD were achieved with dietary advice to increase the
intake of vegetables and fruit primarily. Even though no food
was provided in our study, more than 50% of the participant
reported achieving the dietary goals. A design with no food
provided was also used in the PREMIER clinical trial (Appel
et al., 2003). The study lasted for 6 months and tested the
effect of established recommendations for BP reduction
(weight loss, sodium restriction, increased physical activity
and limited alcohol intake) compared to the effect of these
recommendations plus the DASH diet among adults with
above optimal levels of BP. As in our study the achieved
weight reduction was about 1 kg per month and the
reduction in systolic and diastolic BP was 4 and 3mm Hg,
respectively. In comparison, the DASH study, which was a
feeding study, showed that a diet that was high in vegetables
and fruit, low-fat dairy product, nuts, fish and otherwise low
in total and saturated fat was associated with highly
significant reductions of 6 and 3mm Hg in systolic and
diastolic BP, respectively, after 8 weeks (Appel et al., 1997).
Furthermore, Nowson et al. (2005) showed that specific
targets to increase the foods used in the DASH diet resulted
in a greater decrease in BP than did an ordinary low-fat diet
without dietary targets (Nowson et al., 2005). As in the study
by Nowson et al. (2005), we had specific targets for the intake
of vegetables and fruit. Even more than seven servings of
vegetables and fruit as we used in our study have been used
to achieve BP reductions. For example, in the Optimal
Macronutrient Intake Trial to Prevent Heart Disease trial the
total servings of vegetables and fruit were nine to 11 servings
per day (Appel et al., 2005). However, this regimen may be
difficult to achieve (Weinberger, 2005). In a daily life setting
in which persons have to plan, purchase and prepare their
own meals, a more moderate intake of vegetables and fruit
will probably be more realistic and feasible.
In contrast to the DASH study (Appel et al., 1997), the
primary aim of our study which was performed in obese
subjects with SRBD was to study the effect of increased
intake of vegetables and fruit on weight reduction. We did
not emphasize increasing the intake of low-fat diary
products. Vegetables and fruit were recommended in
exchange for other food groups. Therefore, in contrast to
the DASH study we observed a small reduction in the intake
of diary products in the intervention group.
The clinical relevance of the weight loss achieved in these
obese subjects with SRBD is reflected in the BP reduction.
In a study conducted in general practice among nearly 300
hypertensive subjects, prompt sheets for high fruit, vegeta-
ble, fiber and low fat resulted in a weight reduction of 1.2 kg
during 6 months, but did not reduce blood pressure (Little
et al., 2004). In our study, despite a 2% difference in body
weight we did not see any difference in serum concentra-
tions of lipids or glucose between the groups. Both the
weight reduction and the reduced intake of total and
saturated fat are expected to act favorably on concentrations
of total and LDL cholesterol. In a recent controlled feeding
study, the reduction in LDL cholesterol concentrations
decreased as the percentage of body fat, BMI and insulin
concentrations increased (Lefevre et al., 2005). Because our
Table 6 Correlations between antioxidant markers and change in intakes of vegetables and fruit between baseline and 3 months and intakes at 3
months in all subjects
Changes in intake (n¼112)a Intake at 3 months (n¼114)b
Vegetables Fruit Vegetables Fruit
rc P r P r P r P
Lutein 0.255 0.0073 0.121 0.2016 0.270 0.0041 0.156 0.0965
Zeaxanthin 0.103 0.2776 0.138 0.1490 0.126 0.1812 0.123 0.1911
b-Kryptoxanthin 0.112 0.2366 0.067 0.4775 0.233 0.0133 0.319 0.0008
b-Carotene 0.229 0.0159 0.134 0.1581 0.315 0.0008 0.235 0.0126
a-Carotene 0.422 o0.0001 0.221 0.0198 0.399 o0.0001 0.349 0.0002
Lycopene 0.117 0.2176 0.119 0.2115 0.207 0.0280 0.054 0.5693
FRAPd 0.030 0.7484 0.046 0.6270 0.063 0.5005 0.069 0.4631
Abbreviation: FRAP, the ferric reducing/antioxidant power.
aThree subjects were missing dietary data and 10 subjects were missing serum values for carotenoids and FRAP.
bThree subjects were missing dietary data and eight subjects were missing serum values for carotenoids and FRAP.
cSpearmann correlations (all such values).
Table 7 Multiple regression analysis of change in weight in all
participants (n¼122)a
Standardized regression coefficients P
Changes in intake of vegetables 0.213 0.0443
Changes in intake of fruit 0.106 0.2813
Treatment 0.063 0.5565
aDietary data were missing for three subjects.
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subjects were obese, this observation may partly explain the
lack of effect of weight reduction on lipids in our study.
Furthermore, the amount of weight loss needed to influence
lipids or glucose concentrations are thought to be at least
5% (World Health Organization (1997)).
Obese subjects and subjects with SRBD may exhibit
increased oxidative stress (Schultz et al., 2000; Dandona
et al., 2001; Dyugovskaya et al., 2002), though a recent study
questioned this notion (Svatikova et al., 2005). After dietary
restriction and weight loss a decrease in reactive oxygen
species generation by leukocytes and oxidative damage to
lipids, protein and amino acids has been shown (Dandona
et al., 2001). We measured fasting serum FRAP as a measure of
antioxidant defense but this parameter was largely unaffected
by our intervention. Similar findings were reported in a
recent dietary study by Dragsted et al. (2004). This study
showed that markers of oxidative damage, oxidative capacity
or antioxidant defense were largely unaffected by an increase
in vegetables and fruit. However, the diet was not based on
vegetables and fruit known to have high FRAP values. For
example, blue grapes, berries, dog roses, pomegranates,
Brussels sprouts, kale, red cabbage, herbs, green tea, dark
chocolate, seeds, nuts and oils have high FRAP values
(Halvorsen et al., 2002; Dragland et al., 2003). This may also
have been the case in our study. The participants chose their
own vegetables and fruit based on preferences and primarily
consumed carrots, tomatoes, apples and bananas (data not
shown), which are not particularly high in FRAP. In contrast,
increased levels of FRAP were demonstrated in 12 obese,
hypertensive subjects that followed the DASH diet (Lopes
et al., 2003). A limitation of our study was that we did not
measure postprandial FRAP. It has been proposed that food
items with very high amounts of specific plant phenols may
have postprandial effects (Dragsted et al., 2004). In contrast
to a number of other studies we did not include a depletion
period and this may have minimized the effects of the diet.
Furthermore, baseline concentrations of FRAP were high
compared to other studies (Lopes et al., 2003; Dragsted et al.,
2004). Indeed, we observed a small trend toward an increase
in FRAP in the intervention group, but based on these small
changes, we would require approximately 500 participants
in each group to achieve statistical significance (data not
shown) and the clinical significance of such a small change
has not been proven.
Study limitations
We included all subjects in the analyses and did not separate
subjects using CPAP and subjects not using CPAP due to
reduced sample size and power. However, in the multiple
regression analysis, CPAP treatment was not a significant
contributor to the weight change observed.
In the multivariate analysis, changes in intake of vegeta-
bles only explained 7% of the variation in weight loss. This
may be owing to weight reduction, which also depends on
other factors such as motivation to reach goal weight and
participants expectations of weight loss (Foster et al., 1997).
These factors were not considered in the multivariate model.
Because the intervention only lasted for 3 months the data
do not address the feasibility and efficacy of the dietary
advice for a longer time period. Another limitation is
underreporting of energy, as commonly noted in dietary
studies, particularly among obese individuals (Tooze et al.,
2004). Despite a greater weight loss in the intervention
group, there was no statistically significant difference in
reported energy intake at 3 months between the control and
the intervention groups. The intervention group may have
been more aware of their dietary intake and reported more
accurately. However, the primary goal of our intervention
was to increase the consumption of vegetables and fruit.
Over-reporting of vegetables and fruit may have occurred
in the intervention group because of social desirability bias
(Tooze et al., 2004) and because of the large number of
vegetables, fruit and berries that were included in the FFQ
(about 50). The reported difference in the intake of these
items was highly statistically significant between the groups
and was mirrored in increased serum concentrations of
lutein, b-kryptoxanthin, a-carotene and b-carotene in the
intervention group. The relatively small correlation coeffi-
cients seen may be explained by the homogeneous popula-
tion, the emphasis on all vegetables and fruit (not all
vegetables and fruit are high in carotenoids) and the fact
that concentration biomarkers often shows low correlation
coefficients with reported dietary intake (Al-Delaimy et al.,
2005).
We did not include specific targets to increase the intake
of low-fat diary products in our intervention. In the
DASH study a more beneficial effect was seen in the group
that ate more low-fat diary products compared to the
group that only increased the intake of vegetables and
fruit. However, the subjects in the DASH study had a low
baseline intake of calcium (Appel et al., 1997). Our subjects
had a high baseline intake of calcium. Further studies would
be needed in obese subjects with SRBD to examine the
effect of increasing low-fat diary products in the dietary
intervention.
A minor limitation is that we did not exclude subjects
taking high doses of multivitamin supplements; however,
only two subjects in the intervention group took such doses
at baseline. This may be reflected in the difference in serum
folate between the groups at baseline. These subjects stopped
taking the supplements during the study. We have no
reasons to believe that this has influenced our results.
Implications
We have shown that simple dietary advice to increase intake
of vegetable and fruit in a group session based behavior
treatment was effective for moderate weight reduction and
in reducing systolic and diastolic BP in a population of
symptomatically treated subjects with SRBD. Vegetables and
fruit are water-rich foods that are low in energy density and
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hence allow big portion sizes while reducing energy intake. A
behavioral program with targeted goals to increase the intake
of vegetables appears to be important for weight loss and BP
reduction. If no advice is given about the specific choice of
food items known to be high in FRAP, antioxidant defense
does not appear to be affected.
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Effect of Orlistat on Eating Behavior Among 
Participants in a 3-year Weight Maintenance Trial
Mette Svendsen1, Aila Rissanen2, Bjørn Richelsen3, Stephan Rössner4,  
Fredrik Hansson5 and Serena Tonstad1
Objective: To examine the effect of orlistat on dietary restraint, disinhibition, hunger, and binge eating and to 
understand the relation between changes in eating behavior and weight maintenance.
Methods and Procedures: Subjects were 306 women and men (age: 19–45 years; BMI: 37.5 ± 4.1 kg/m2) included in 
the Scandinavian Multicenter study of Obese subjects with the Metabolic Syndrome, a 3-year clinical trial of orlistat 
or placebo following an 8-week very low energy diet (VLED). Outcomes were changes in weight and in the Three 
Factor Eating Questionnaire (TFEQ) and Binge Eating Scale (BES) between screening and 17 and 33 months after 
randomization. As reported previously, weight gain following VLED was lower in subjects treated with orlistat than with 
placebo.
Results: Compared to screening results, dietary restraint was increased and disinhibition, hunger, and binge eating 
were decreased in both groups. These changes were similar in both groups with the exception of the hunger score at 
month 33 that was reduced more in the placebo than in the orlistat group (difference between groups −1.1 (95% CI 
(−2.0, −0.2)) P = 0.014). In multivariate analyses, scores for restraint, disinhibition and binge eating were associated 
with weight loss after adjustment for BMI, gender, age, and treatment (all P ≤ 0.002, model R2 = 0.12–0.17).
Discussion: Orlistat did not affect eating behavior differently in any substantial way than the placebo did in this  
long-term weight maintenance trial. The results indicate that increased restraint and decreased disinhibition and  
binge eating are important for sustained weight maintenance in obese subjects with the metabolic syndrome.
Obesity (2008) 16, 327–333. doi:10.1038/oby.2007.82
INTRODUCTION
The relation between obesity and several of its comorbidities 
such as type 2 diabetes and premature atherosclerosis seems to 
be mediated by risk factors characterized by the metabolic syn-
drome (1,2). The metabolic syndrome is closely associated with 
abdominal obesity (3,4). Weight loss achieved by changes in 
eating behavior, diet and physical activity are the cornerstones 
in the treatment of the metabolic syndrome. However, weight 
control methods often produce short-term success, while sus-
tained weight maintenance is difficult to achieve (5,6). Thus, 
pharmacological therapy has been proposed as an adjunct 
to diet and lifestyle changes to improve the maintenance of 
weight loss. Orlistat is a pancreatic lipase inhibitor that reduces 
the intestinal absorption of fat (7,8). Because gastrointestinal 
symptoms may occur after the intake of fatty food, orlistat is 
thought to act as a policing influence in daily food choices.
Psychological and behavioral factors including dietary 
restraint, disinhibition, hunger, and binge eating may also influ-
ence dietary intake and body weight. Dietary restraint is defined as 
the tendency to consciously restrict food intake either to prevent 
weight gain or to promote weight loss by control over energy 
intake and types of food eaten (9). Disinhibition is the tendency 
to overeat in the presence of palatable foods or other disinhibi-
tors such as emotional distress (10). Hunger has been defined 
as the susceptibility to perceived body symptoms that signal 
the need for food (10). The Three Factor Eating Questionnaire 
(TFEQ) (11) and the Binge Eating Scale (BES) (12) are recog-
nized instruments for assessing these eating behaviors.
Increasing dietary restraint, and decreasing disinhibition 
and hunger are important for improved weight maintenance 
(13–17). A better understanding of how eating behaviors influ-
ence weight maintenance during treatment with orlistat, a drug 
that may influence daily food choices, could be helpful in the 
clinical management of obesity.
We recently reported the results of the Scandinavian 
Multicenter study of Obese subjects with the Metabolic 
Syndrome, a placebo-controlled clinical trial aimed at  inves-
tigating the efficacy of orlistat in the maintenance of weight 
loss following a very low energy diet (VLED) in 309 abdomi-
nally obese women and men. The VLED initiated a weight loss 
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of 14.4 kg. After 18 months the maintained weight loss was 
11.7 kg in the orlistat group and 9.6 kg in the placebo group 
and after 3 years the maintained weight loss was 9.4 kg and 
7.2 kg respectively, in the orlistat and placebo groups (all P < 
0.05). Thus, the gain in body weight after VLED at month 36 
was less in the orlistat group compared to the placebo group 
(4.6 kg vs. 7.0 kg, P < 0.02) (18).
The objective of this study was to examine the effect of orlistat 
on dietary restraint, disinhibition, hunger and binge eating 
at month 17 and month 33 after an initial weight loss and to 
understand the relation between eating behavior and weight 
maintenance in subjects participating in the Scandinavian 
Multicenter study of Obese subjects with the Metabolic 
Syndrome trial.
METHODS AND PROCEDURES
Subjects
Subjects were recruited at nine clinical research centers in Scandinavia 
(Denmark, Finland, Norway, and Sweden) to participate in the 
Scandinavian Multicenter study of Obese subjects with the Metabolic 
Syndrome as described elsewhere (18). Men and women were eligible 
for the trial if they met the following criteria: (i) abdominal obesity 
(waist circumference >92 cm for females and >102 cm for males) (ii) at 
least one of the following metabolic risk factors: impaired fasting glu-
cose (>6.1 mmol/l and <7.1 mmol/l), diet treated type II diabetes, dys-
lipidemia (HDL cholesterol <1.1 mmol/l for females and 0.9 mmol/l for 
males) and/or triglycerides >2.0 mmol/l. Subjects were excluded if they 
had clinically relevant conditions that might affect the outcome of the 
trial (i.e., weight change of more than ±4% for the previous 2 months 
before inclusion, women of child-bearing potential who were not on 
any accepted method of birth control or were lactating, uncontrolled 
hypertension (systolic >180 mm Hg, diastolic >115 mm Hg), significant 
cardiac, respiratory, renal, neurological, gastrointestinal, or endocrine 
disease, pre-existing cholelithiasis, pancreatic disease, history of gas-
trointestinal surgery for weight loss purposes, active gastrointestinal 
disease, drug treated diabetes mellitus, HbA1c >10%, serum triglycer-
ides ≥10 mmol/l, serum creatinine >150 μmol/l, psychiatric disorders 
requiring medication that may impact upon the requirements of the pro-
tocol, history or presence of carcinoma, history or presence of bulimia 
or laxative abuse, clinical symptoms of fat soluble vitamin deficiencies, 
use/dependence of any substance of abuse, unable or unwilling to com-
ply with the demands of the protocol, or subjects who had received any 
investigational drug within the previous 2 months). All participants 
gave their written informed consent. The study was conducted accord-
ing to the Helsinki Declaration and the Ethical Committee in each of 
the four countries approved the protocol. The study was conducted 
between November 1998 and October 2002.
Study design
Before randomization the participants followed a VLED for 8 weeks 
with the aim of achieving a weight loss of r5%. The VLED provided 
2.5–3.3 MJ (600–800 kcal) per day. One of two liquid protein prepara-
tions depending on commercial availability (Modifast; Novartis, Basel, 
Switzerland or Nutrilett; Nycomed Pharma, Oslo, Norway) was used 
in the study, provided free of charge. Of 383 participants, 309 achieved 
a r5% weight loss and were randomly assigned to 36 months of treat-
ment with orlistat capsules (120 mg three times daily) or matching pla-
cebo capsules. Of these, 306 completed screening assessments of eating 
behavior and were eligible for this study, while three subjects refused to 
fill in the questionnaires.
After the VLED, participants were instructed to follow a diet reduced 
in energy by 2.5 MJ (600 kcal), mostly focused on reducing the fat content 
and following as closely as possible the prescription of 30% of total kcal 
from fat, 50% from carbohydrate, and 20% from protein. The energy 
deficit was individually determined and subtracted from an estimate of 
total energy expenditure based on the WHO formula (19) for calculating 
resting metabolic rate and was corrected for the physical activity level. 
Resting metabolic rate was estimated based on the subjects’ weight after 
the VLED prior to randomization. According to the protocol a physical 
activity level of 1.3 or 1.5 was used for middle to moderate or heavy daily 
activity, respectively. A dietitian helped the participants to plan a diet at 
the appropriate energy level according to the abovementioned recom-
mendations and the food preferences of the subjects. To standardize the 
dietary counseling, the 20 dietitians involved in the study were trained at 
two investigator meetings prior to the study. Based on individual prefer-
ences, the counseling was provided individually or in groups in sessions 
lasting 30 min. A dietitian who was blind to the drug assignment moni-
tored patients every month for the first 18 months and then at 3-month 
intervals. The behavioral treatment was based on a structured program 
that included assignments to be completed at home (20). The subjects 
assessed problematic eating habits and were then given opportunities 
to suggest behavioral changes that were discussed with the dietitian or 
group participants. If the patients did not have suggestions for behav-
ioral changes themselves, the dietitians suggested changes. The behav-
ioral changes concerned food choices and the organization of meals as 
well as dealing with emotional states or specific situations and eating 
occasions.
Assessments
The body weight, waist circumference, and blood pressure were mea-
sured by standardized techniques (18). Fasting (10 hour overnight) 
blood samples were collected according to the protocol of the trial and 
laboratory parameters were analyzed centrally (Medilab, Copenhagen, 
Denmark).
Eating behavior was assessed with the TFEQ and the BES at screen-
ing (i.e., before VLED treatment) and at month 1, month 8, month 17, 
month 21, and month 33 after randomization. The TFEQ is a 51-item 
instrument, which contains three subscales measuring dietary restraint, 
disinhibition, and hunger. It consists of 36 closed questions with a forced, 
false/true answer format and 15 with a 4-point “Likert” scale (11). Dietary 
restraint is measured with questions like:
How frequently do you avoid “stocking up” on tempting foods? Using a 
Likert scale, the participants are asked to respond to the most appropri-
ate alternative of almost never, seldom, usually or almost always.
Disinhibition is measured using a false/true format including items 
such as:
When I feel anxious, I find myself eating.
Hunger is measured using a false/true format, including items such as:
I am usually so hungry that I eat more than three times a day.
The BES consists of 16 sets of 3–4 statements relating to binge eat-
ing behavior and the subject is asked to endorse the one item from 
each set which best describes the eating behavior. Scores were calcu-
lated and the ranges for possible scores were 0–21 for dietary restraint, 
0–16 for disinhibition 0–14 for hunger and 0–46 for BES (12). Higher 
scores reflect a greater tendency to exhibit the particular eating behavior 
characteristics.
Statistical analyses
Descriptive statistics are presented as means ± s.d. and means (95% CI). 
Scores for eating behavior were calculated at screening time (i.e., before 
VLED treatment) and at months 1, 8, 17, 21, and month 33. Analyses 
of variance using least square means with changes in weight as covari-
ates was done to test the possible difference between the orlistat and 
placebo group with regard to changes in scores for eating behavior at 
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the measured time-points. Changes were calculated as the difference in 
scores between screening and subsequent measurements at months 1, 
8, 17, 21, and 33. To test the interaction effect between treatment and 
gender, F-tests from ANCOVA were used. Student’s t-test was used to 
test differences between gender and the Chi squared test was used in 
comparisons of categorical variables.
Pearson’s correlations were done between changes in weight and 
changes in the scores for eating behavior within each treatment group 
at month 17 and month 33. To test the association between eating 
behavior and change in weight at month 33, we conducted multiple 
regression analyses with change in weight as the dependent variable and 
BMI at screening, age, gender, treatment, and the changes in scores for 
restraint, disinhibition, hunger, and binge eating, respectively, as four 
separate independent variables. Analyses were done using the observed 
values (for which the data are shown), last observation carried forward 
(from month 8) values and for the completers. The statistician (Fredrik 
 Hansson) chose to use month 8 from screening (month 6 from rand-
omization) because a reasonable test of the study medication required 
that it had to be taken for a relatively long period of time. The tests were 
considered significant at P < 0.05. Statistical analyses were performed 
using SAS software (version 9.1.3; SAS Institute, Cary, NC).
Power calculations was based on the main hypothesis of the study 
that the proportion of subjects with a maintained weight loss of at least 
5% after the VLED was greater with orlistat than placebo treatment. The 
sample size calculation was performed using a formula from Lachin (21) 
N = (Zα + Zβ)
2 4 · P(1 − P)/(Pc − Pe)
2 where Zα is the significance level set 
to be 0.05, Zβ is the power of the study set to be 90%, Pc is the proportion 
of treatment success in the orlistat group set to be 0.60, Pe is the propor-
tion of treatment success in the placebo group set to be 0.35 and P is the 
overall treatment success rate. With this, the total number of subjects 
needed would be 168. With a drop out rate of 40% the number of subjects 
required would be 280. The statistical power of the study to achieve this 
goal was 92%.
RESULTS
Of the 306 subjects whose eating behavior was assessed at 
screening, 251 (82.0%) and 197 (64.4%) subjects remained 
in the trial and completed eating behavior assessments at 
months 17 and 33, respectively. Within each group, 1 subject 
was unwilling to complete the BES following screening. The 
last observation carried forward population consisted of 140 
subjects in the orlistat group and 137 subjects in the placebo 
group and the completer population included 103 subjects 
and 98 subjects in the orlistat and placebo group, respectively. 
Table 1 shows the subject characteristics. These were similar in 
the orlistat and placebo groups.
Eating behavior
Table 2 shows the eating behavior scores at screening and the 
changes in eating behaviors at month 1, 8, 17, 21, and 33 in the 
orlistat and placebo groups. No difference was seen between 
the groups before weight reduction. The mean scores from the 
BES tended to be low.
The main changes in eating behavior occurred between 
screening and month 1 and remained quite stable thereafter 
(Table 2). There was no significant difference between genders 
with regard to change in dietary restraint, disinhibition and 
binge eating (data not shown). Dietary restraint increased, 
while disinhibition, hunger, and binge eating decreased with 
no between-group differences with the exception of the score 
for hunger. The scores for hunger were reduced more in the 
placebo than in the orlistat group at month 33 and this was 
statistically significant in men (between-group difference 
−1.1 (95% CI −1.2, 0) P = 0.0493). This tendency was similar 
in women in numerical terms but did not achieve statistical 
significance (between-group difference −1.0 (95% CI −2.2, 
0.3) P = 0.1395). There was no statistically significant interac-
tion effect between treatment and gender (Table 2). However, 
scores for restraint increased more in men than in women 
(7.0 (95% CI 6.3, 7.8) vs. 5.0 (95% CI 4.3, 5.7), respectively; 
P = 0.0002) but there was no difference between the genders 
at month 33 (5.8 (95% CI 4.9, 6.6) vs. 5.0 (95% CI 4.2, 5.8), 
P = 0.2).
Change in weight was significantly associated with change 
in restraint, disinhibition and binge eating at month 17 and 
Table 1 Characteristics of the participants in the orlistat and 
placebo groups before weight reduction (screening)
Orlistat  
(N = 153)
Placebo  
(N = 156) P valuea
Female, N (%) 77 (50.3) 80 (51.3) 0.8666
Age, y 47.2 ± 8.6b 46.7 ± 9.4 0.5998
Smokers, n (%) 33 (21.6) 40 (25.6) 0.3991
Weight (kg)
 Female 101.6 ± 13.5 104.1 ± 12.7 0.2294
 Male 119.1 ± 19.8 119.6 ± 15.3 0.8552
Height (m)
 Female 1.64 ± 0.06 1.65 ± 0.06 0.5599
 Male 1.79 ± 0.07 1.80 ± 0.06 0.3386
BMI (kg/m2)
 Female 37.6 ± 3.8 38.4 ± 4.2 0.2456
 Male 37.1 ± 4.3 36.8 ± 3.9 0.6689
Waist (cm)
 Female 114 ± 12 115 ± 10 0.6436
 Male 123 ± 11 124 ± 10 0.8603
Hip (cm)
 Female 123 ± 10 124 ± 10 0.3351
 Male 117 ± 10 118 ± 10 0.6548
Waist-to-hip ratio 1.0 ± 0.1 1.0 ± 0.1 0.6957
Diastolic blood 
pressure (mm Hg)
91 ± 12 91 ± 10 0.9235
Systolic blood 
pressure (mm Hg)
144 ± 19 144 ± 17 0.8872
Glucose (mmol/l) 6.44 ± 1.83 6.27 ± 1.54 0.4046
Total cholesterol 
(mmol/l)
5.91 ± 1.26 6.02 ± 1.08 0.3760
HDL cholesterol 
(mmol/l)
1.13 ± 0.26 1.15 ± 0.26 0.5473
Triacylglycerols 
(mmol/l)
2.36 ± 1.24 2.50 ± 1.41 0.3406
aDifferences between the orlistat and placebo group were tested with the 
 Student’s t-test for all variables except from gender and smoking that was tested 
with the Chi square test.
bMean ± s.d. and all such values.
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33 and with hunger at month 17 (all P < 0.01), but not with 
hunger at month 33 (P = 0.09). The same trends were seen 
in the last observation carried forward analyses and in the 
analyses of completers (data not shown).
Table 3 shows the correlations between change in weight 
and eating behavior within each group in the observed popu-
lation. In the orlistat group, change in weight was inversely 
correlated to change in restraint and positively correlated 
to change in disinhibition and binge eating. In the placebo 
group, change in weight was inversely correlated to change 
in restraint. In addition change in hunger and binge eating 
was positively correlated to change in weight at month 17. The 
correlations observed in the completer analyses as well as the 
last observation carried forward analyses were very similar. 
The results of the multiple linear regression analyses for 
restraint, disinhibition, hunger and binge eating, each adjusted 
for treatment, BMI at screening, gender, and age are shown in 
Table 4. Changes in restraint, disinhibition, and binge eating 
were significantly associated with weight loss (all P ≤ 0.002), 
explaining 12–17% of the variation in weight predicted for 
month 33. Changes in hunger tended to be associated with 
weight loss (P = 0.0534) explaining 9% of the variation. We also 
included smoking as an independent variable, but smoking was 
not a significant predictor in the models (data not shown).
DISCUSSION
In this 3-year, placebo-controlled clinical trial of weight main-
tenance following a VLED we found no substantial differences 
Table 2 Scores before weight reduction (screening) and changes in eating behavior in the orlistat and placebo group; the 
observed population
Orlistat Placebo
Between-group 
difference Pa
Pa treatment 
sexN N
Restraint
 Before weight reduction (screening) 151 8.0 ± 4.0b 155 7.8 ± 4.2
 Difference: month 1 after randomization—screening 150 6.9 (6.2, 7.6)c 152 7.2 (6.4, 8.0) 0.3 (−0.7, 1.3) 0.576 0.715
 Difference: month 8 after randomization—screening 140 6.0 (5.4, 6.7) 137 6.5 (5.7, 7.3) 0.6 (−0.4, 1.6) 0.240 0.984
 Difference: month 17 after randomization—screening 128 5.9 (5.2, 6.6) 122 6.2 (5.3, 7.0) 0.6 (−0.5, 1.6) 0.297 0.985
 Difference: month 21 after randomization—screening 121 5.6 (4.8, 6.3) 109 5.9 (5.1, 6.7) 0.9 (−0.2, 2.0) 0.103 0.920
 Difference: month 33 after randomization—screening 104 5.2 (4.4, 6.1) 93 5.4 (4.5, 6.3) 0.5 (−0.7, 1.7) 0.407 0.457
Disinhibition
 Before weight reduction (screening) 151 9.1 ± 3.4 155 9.2 ± 3.1
 Difference: month 1 after randomization—screening 150 −2.8 (−3.3, −2.3) 152 −2.8 (−3.3, −2.3) 0.3 (−0.7, 1.3) 0.576 0.715
 Difference: month 8 after randomization—screening 140 −2.3 (−2.8, −1.8) 137 −2.5 (−3.0, −2.0) 0.6 (−0.4, 1.6) 0.240 0.984
 Difference: month 17 after randomization—screening 128 −2.4 (−2.9, −1.8) 122 −2.1 (−2.6, −1.5) 0.0 (−0.7, 0.8) 0.929 0.348
 Difference: month 21 after randomization—screening 121 −2.3 (−2.8, −1.8) 109 −2.4 (−3.0, −1.8) 0.9 (−0.2, 2.0) 0.103 0.920
 Difference: month 33 after randomization—screening 104 −2.3 (−2.9, −1.7) 93 −2.6 (−3.2, −2.0) −0.5 (−1.3, 0.4) 0.289 0.419
Hunger
 Before weight reduction (screening) 151 6.3 ± 3.3 155 6.8 ± 3.4
 Difference: month 1 after randomization—screening 150 −2.4 (−2.9, −2.0) 152 −2.9 (−3.4, −2.3) 0.3 (−0.7, 1.3) 0.576 0.715
 Difference: month 8 after randomization—screening 140 −2.0 (−2.4, −1.5) 137 −2.7 (−3.2, −2.1) 0.6 (−0.4, 1.6) 0.240 0.984
 Difference: month 17 after randomization—screening 128 −2.1 (−2.6, −1.7) 122 −2.5 (−3.1, −1.9) −0.5 (−1.3, 0.2) 0.160 0.445
 Difference: month 21 after randomization—screening 121 −1.4 (−2.1, −0.7) 109 −2.8 (−3.4, −2.1) 0.9 (−0.2, 2.0) 0.103 0.920
 Difference: month 33 after randomization—screening 104 −1.8 (−2.4, −1.3) 93 −2.9 (−3.6, −2.2) −1.1 (−2.0, −0.2) 0.014 0.921
Binge eating
 Before weight reduction (screening) 150 14.7 ± 7.8 154 14.8 ± 7.2
 Difference: month 1 after randomization—screening 149 −4.8 (−5.8, −3.8) 151 −5.7 (−6.8, −4.6) 0.3 (−0.7, 1.3) 0.576 0.715
 Difference: month 8 after randomization—screening 139 −4.8 (−5.8, −3.7) 136 −5.3 (−6.5, −4.1) 0.6 (−0.4, 1.6) 0.240 0.984
 Difference: month 17 after randomization—screening 127 −4.6 (−5.7, −3.5) 122 −5.3 (−6.5, −4.1) −1.2 (−2.7, 0.3) 0.123 0.871
 Difference: month 21 after randomization—screening 121 −4.4 (−5.5, −3.4) 109 −6.1 (−7.4, −4.8) 0.9 (−0.2, 2.0) 0.103 0.920
 Difference: month 33 after randomization—screening 104 −4.5 (−5.7, −3.3) 93 −5.1 (−6.5, −3.7) −0.9 (−2.7, 1.0) 0.358 0.615
aDifferences between the groups before weight reduction was tested with Students t-test. Differences in changes between the groups were covariance analyses with 
weight reduction as covariate. F-tests from ANCOVA were used to test the interaction effect between treatment and gender.
bMean ± s.d. and all such values.
cMean (95% CI) and all such values.
OBESITY | VOLUME 16 NUMBER 2 | FEBRUARY 2008 331
ARTICLES
INTERVENTION AND PREVENTION
between the effect of orlistat or placebo on eating behavior 
measured with the TFEQ and BES. Increased restraint and 
decreased disinhibition and binge eating were predictors of 
sustained weight maintenance in these participants; the partic-
ipants were obese men and women with metabolic syndrome 
risk factors. Thus, changes in eating behavior in the orlistat 
group are mostly due to quantified eating behavior similar 
to the way the placebo operates. We are not aware of previ-
ous reports that have examined the effect of long-term orlistat 
treatment on eating behavior following a VLED.
Compared to scores at screening, dietary restraint was 
increased and disinhibition, hunger and binge eating were 
decreased in both the orlistat and placebo groups. An 
improvement in restraint, disinhibition and hunger has been 
shown in other trials of obese subjects taking sibutramine, an 
obesity drug that influences appetite (22,23). In the study by 
Hainer et al. 80 women were followed for 1 year and a drop in 
the disinhibition score was the most important factor associ-
ated with the decrease in BMI (22). In the study by Bauer et al., 
the improvement in eating behavior was mostly attributed to 
the cognitive weight loss program (23). This may have been the 
case in our study, too, as all the subjects took part in a dietitian-
managed behavioral program.
We found no differences between the treatment with orli-
stat or with the placebo with regard to restraint, disinhibition 
and binge eating. Thus, this form of drug treatment appears to 
be safe with regard to eating behavior amongst obese adults. 
Notably the placebo group showed a greater reduction in hun-
ger scores than the orlistat group at 33 months. This difference 
may be due to chance or to the greater degree of weight loss in 
orlistat-treated subjects though a ~2 kg difference between the 
groups seems unlikely to affect regulators of appetite. Energy 
balance and appetite regulation are controlled by a number of 
hormones and peptides (24). Decreased levels of leptin may 
increase the release of orexigenic signals and thereby induce 
hunger (25). Unfortunately, we did not measure leptin levels 
in this study. The difference in hunger between the orlistat and 
the placebo group may be of minor clinical relevance given the 
overall reduction in hunger.
Increase in dietary restraint was inversely correlated to 
weight maintenance in both groups. However, the associa-
tions between change in weight and other eating behaviors 
Table 3 Correlations between change in weight and eating behavior in the orlistat and placebo group (observed population)
Orlistat Placebo
N Correlation coefficient Pa N Correlation coefficient P
Restraint
 Changes month 17 126 −0.1888 0.0342 119 −0.3017 0.0009
 Changes month 33 103 −0.2983 0.0022 92 −0.3536 0.0005
Disinhibition
 Changes month 17 126 0.2994 0.0007 119 0.1444 0.1171
 Changes month 33 103 0.3888 <0.0001 92 0.0473 0.6541
Hunger
 Changes month 17 126 0.0733 0.4145 119 0.2653 0.0035
 Changes month 33 103 0.1188 0.2319 92 0.1402 0.1826
Binge eating
 Changes month 17 125 0.3898 <0.0001 119 0.2980 0.0010
 Changes month 33 103 0.3157 0.0012 92 0.1179 0.2630
aCorrelation were calculated with Pearson’s correlation.
Table 4 Multiple regression analyses of change in eating 
behavior scores as predictors for weight change at month 33 
in 197 subjects in the observed population
Correlation 
coefficient
s.e. P R2 (95% CI)
Restraint −0.603 0.128 <0.0001 0.168 (0.075, 0.261)
 Treatment −2.476 1.116 0.0276
 Gender 1.772 1.135 0.1199
 BMI −0.423 0.143 0.0035
 Age 0.065 0.064 0.3062
Disinhibition 0.591 0.187 0.0018 0.117 (0.035, 0.199)
 Treatment −2.571 1.150 0.0266
 Gender 2.326 1.161 0.0465
 BMI −0.421 0.147 0.0048
 Age 0.059 0.066 0.3672
Hunger 0.372 0.194 0.0534 0.088 (0.015, 0.162)
 Treatment −2.794 1.185 0.0194
 Gender 2.264 1.182 0.0568
 BMI −0.453 0.150 0.0029
 Age 0.052 0.067 0.4372
Binge eating 0.304 0.088 0.0007 0.125 (0.041, 0.209)
 Treatment −2.592 1.145 0.0248
 Gender 2.558 1.156 0.0282
 BMI −0.480 0.147 0.0013
 Age 0.049 0.065 0.4557
332 VOLUME 16 NUMBER 2 | FEBRUARY 2008 | www.obesityjournal.org
ARTICLES
INTERVENTION AND PREVENTION
differed somewhat within the orlistat and placebo groups. 
Lower scores for disinhibition and binge eating were associ-
ated with changes in weight only in the orlistat group. High 
scores for disinhibition and hunger have been associated with 
a high intake of fatty foods (26) and with a greater binge eat-
ing severity (14,27,28). During binge eating the energy intake 
per episode may be of several thousand kJ and highly palat-
able, fatty foods are preferred (29). Participants taking orlistat 
may have experienced gastric side effects when eating palat-
able and fatty food, consistent with its mechanism of action. 
Though the overall percentage of energy from fat did not differ 
between the groups (18,30), a subgroup of participants may 
have reduced the intake of energy yielding fatty foods and 
improved their weight maintenance because of that. Indeed, 
better weight loss and reduced binge eating has been reported 
in obese binge eaters treated with orlistat (31). Other contrib-
utors to weight loss maintenance than those measured here 
could be significant predictors of success. Despite the blinded 
design of the study, some participants may have guessed that 
they received the placebo. This may have increased their moti-
vation to reach weight goals or maintain a certain amount of 
weight loss (32).
We further sought to understand the role of eating behavior 
in long-term weight maintenance. After adjustment, increase 
in restraint and decrease in disinhibition and binge eating were 
all associated with improved weight maintenance, as expected, 
given that any dietary treatment of obesity implies increased 
restraint. Obese individuals who are not in treatment tend to 
score similarly to non-obese individuals as regards cognitive 
restraint; however, their scores increase during treatment (33). 
Likewise, obese subjects score higher than non-obese subjects 
with regard to disinhibition but their scores fall during treat-
ment (13). Moreover, scores for disinhibition have been shown 
to correlate with the severity of binge eating (34). The rela-
tive importance of restraint, disinhibition, hunger, and binge 
eating as predictors for weight maintenance has been shown 
in a number of other studies (16,17,27,35,36). In the study 
of Pekkarinen et al. obese subjects were followed for 2 years 
after a weight loss program of 17 sessions including an 8-week 
VLED (16). Subjects that maintained an increase in restraint 
and decreases in disinhibition and hunger also were most suc-
cessful with their weight reduction (16). Among subjects who 
were followed for 1 year after a VLED-induced initial weight 
loss, success was associated with increased dietary restraint 
and lesser feelings of hunger (17). In a study by Westenhoefer 
et al. 7407 men and women participated in a computer-based 
weight loss program. Successful weight reduction was associ-
ated with higher baseline scores for restraint that increased 
further during treatment and a lower baseline score of disinhi-
bition that was further reduced (36). Changes in BES were not 
measured in these studies.
During weight maintenance it may be of special importance 
to focus on increasing dietary restraint and reducing disinhibi-
tion. This is challenging in an environment where there is an 
abundance of fatty foods and snacks, but inter-personal group 
approaches for dealing with stimuli control and disinhibitors 
such as lack of time, social eating, stress, anxiety, distress, and 
loneliness may be helpful (11).
Our study has several strengths. With over three hundred 
obese individuals and about equal numbers of men and 
women, its statistical power was good. The subjects were fol-
lowed for 3 years in a placebo-controlled trial and the com-
pletion rate was relatively high. We were able to prospectively 
measure changes in eating behavior at several time-points. One 
of the limitations is that we did not perform the assessments of 
eating behavior at randomization, after the end of the VLED. 
It was not considered to be clinically relevant to measure eat-
ing behavior in subjects at the end of a VLED fast before a nor-
mal diet was restarted. Thus, we were unable to assess changes 
during the VLED. However, the changes in restraint, disinhi-
bition and hunger were in accordance with others (16,17,35). 
Moreover, no difference in weight loss was seen between the 
orlistat and placebo groups after VLED (18).
In conclusion, our novel finding was that, in a long-term 
weight maintenance trial, orlistat did not affect eating behavior 
in a substantially different way than did the placebo. These find-
ings indicate that orlistat does not impair the effect of a behav-
ioral program and that changes in eating behavior seem to be 
important determinants of success during drug treatment.
ACKNOWLEDGMENTS
We thank the subjects for participating and the staff who were involved 
in this study. Hoffman La Roche financed the trial. Serena Tonstad has 
received honoraria for lectures from Hoffman La Roche, the manufacturer 
of orlistat.
DISCLOSURE
Serena Tonstad has received honoraria for lectures from Hoffman La Roche, 
the manufacturer of orlistat.
© 2008 The Obesity Society
REFERENCES
1. Laaksonen DE, Lakka HM, Niskanen LK et al. Metabolic syndrome and 
development of diabetes mellitus: application and validation of recently 
suggested definitions of the metabolic syndrome in a prospective cohort 
study. Am J Epidemiol 2002;156:1070–1077.
2. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and 
total and cardiovascular disease mortality in middle-aged men. JAMA 
2002;288:2709–2716.
3. Lemieux I, Pascot A, Couillard C et al. Hypertriglyceridemic waist: a marker 
of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; 
small, dense LDL) in men? Circulation 2000;102:179–184.
4. Tanko LB, Bruun JM, Alexandersen P et al. Novel associations between 
bioavailable estradiol and adipokines in elderly women with different 
phenotypes of obesity: implications for atherogenesis. Circulation 
2004;110:2246–2252.
5. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a 
systematic review of studies published between 1931 and 1999. Obes Rev 
2000;1:113–119.
6. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for  
long-term weight control. Obes Res 2004;12(Suppl):151S–162S.
7. Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled 
trial of orlistat for weight loss and prevention of weight regain in obese 
patients. European Multicentre Orlistat Study Group. Lancet 
1998;352:167–172.
8. Hill JO, Hauptman J, Anderson JW et al. Orlistat, a lipase inhibitor, for 
weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 
1999;69:1108–1116.
9. Pirke KM, Laessle RG. Restrained eating. In: Stunkard AJ, Wadden TA (eds). 
Obesity: Theory and Therapy, 2nd edn. Raven Press: New York, 1993,  
pp 151–162.
OBESITY | VOLUME 16 NUMBER 2 | FEBRUARY 2008 333
ARTICLES
INTERVENTION AND PREVENTION
10. Lowe MR, Maycock B. Restraint, disinhibition, hunger and negative affect 
eating. Addict Behav 1988;105:145–150.
11. Stunkard AJ, Messicks S. The Three Factor Eating Questionnaire to measure 
dietary restraint, disinhibition and hunger. J Psychosom Res 1985;29:71–83.
12. Gormally J, Black S, Daston S, Bardin D. The assessment of binge eating 
severity among obese persons. Addict behav 1982;7:47–55.
13. Clark M, Marcus V, Pera V, Niaura R. Changes in Eating Inventory scores 
following obesity treatment. Int J Eat Dis 1994;15:401–405.
14. Foster GD, Wadden TA, Swain RM, Stunkard AJ, Platte P, Vogt RA.  
The eating inventory in obese women: clinical correlates and relationship to 
weight loss. Int J Obes 1998;22:778–785.
15. Cooper Z, Hawker DM, Fairrburn CG. Cognitive-behavioral Treatment  
of Obesity: A Clinician’s Guide. The Guilford Press: New York, 2003.
16. Pekkarinen T, Takala I, Mustajoki P. Two year maintenance of weight loss 
after a VLCD and behavioural therapy for obesity: correlation to the scores of 
questionnaires measuring eating behaviour. Int J Obes 1996;20:332–337.
17. Vogels N, Westerterp-Plantenga MS. Categorical strategies based on 
subject characteristics of dietary restraint and physical activity, for weight 
maintenance. Int J Obes 2005;29:849–857.
18. Richelsen B, Tonstad S, Rössner S et al. Effect of orlistat on weight regain 
and on cardiovascular risk factors following a very-low-calorie diet in 
abdominally obese patients. A three-year-randomized placebo controlled 
study. Diabetes Care 2007;30:27–32.
19. FAO/WHO/UNU. Energy and Protein Requirements. Geneva: World Health 
Organization, 1985.
20. Melin I, Rössner S. Practical clinical behavioral treatment of obesity. Patient 
Educ Counc 2003;49:75–83.
21. Lachin JM. Introduction to sample size determination and power analysis for 
clinical trials. Control Clin Trials 1981;93:93–113.
22. Hainer V, Kunesova M, Bellisle F et al. Psychobehavioral and nutritional 
predictors of weight loss in obese women treated with sibutramine.  
Int J Obes 2005;29:208–216.
23. Bauer C, Fischer A, Keller U. Effect of sibutramine and cognitive-behavioral 
weight loss therapy in obesity and subclinical eating disorders. Diab Obes 
Metab 2006;8:289–295.
24. Huda MSB, Wilding JPH, Pinkney JH. Appetite regulatory peptides.  
Gut peptides and the regulation of appetite. Obes Rev 2006;7:163–182.
25. Blundell JE. Perspective on the central control of appetite. Obesity 
2006;14(Suppl 4):160S–163S.
26. Lindroos AK, Lissner L, Mathiassen ME et al. Dietary intake in relation to 
restrained eating, disinhibition, and hunger in obese and nonobese Swedish 
women. Obes Res 1997;5:175–182.
27. Marcus MD, Wing RR, Lamparski DM. Binge eating and dietary restraint in 
obese patients. Addict behav 1985;10:163–168.
28. Wadden TA, Foster GD, Letizia KA, Wilk JE. Metabolic, anthropometric  
and psychological characteristics of binge eaters. Int J Eat Disorder 
1993;14:17–25.
29. Marcus MD. Binge eating in obesity. In: Fairburn CG, Wilson GT (eds).  
Binge Eating: Nature, Assessment and Treatment. Guilford Press: New York, 
1993, pp 77–96.
30. Svendsen M, Helgeland M, Tonstad S. Does long-term treatment with 
orlistat influence dietary fat intake in obese subjects with metabolic 
syndrome risk factors? (Abstract) Int J Obes Relat Metab Disord 
2003;27(Suppl 1):S123.
31. Golay A, Laurent-Jaccard A, Habicht F et al. Effect of orlistat in obese 
patients with binge eating disorder. Obes Res 2005;13:1701–1708.
32. Foster GD, Wadden TA, Voght RA, Brewer G. What is a reasonable 
weight loss? Patients’ expectations and evaluations of obesity treatment 
outcomes? J Consult Clin Psychol 1997;65:79–85.
33. Björvell H, Rössner S, Stunkard AJ. Obesity, weight loss and dietary 
restraint. Int J Eat Dis 1986;5:727–734.
34. Lawson OJ, Williamson DA, Champagne CM et al. The associations of body 
weight, dietary intake and energy expenditure with dietary restraint and 
disinhibition. Obes Res 1995;3:153–161.
35. Lejeune MPGM, Hukshorn CJ, Saris WHM, Westerterp-Plantenga MS. 
Effect of dietary restraint during and following pegylated recombinant  
leptin (PEG-OB) treatment of overweight men. Int J Obes  
2003;27:1494–1499.
36. Westenhoefer J, Stunkard AJ, Pudel V. Validation of the flexible and rigid 
control dimensions of dietary restraint. Int J Eat Dis 1999;26:53–64.

VI

The long-term influence of orlistat on dietary intake in obese subjects with 
components of metabolic syndrome
Svendsen M1, Helgeland M1, Tonstad S1. 
1Department of Preventive Cardiology, Ullevål University Hospital, Oslo, Norway. 
Abstract
Background Orlistat is a lipase inhibitor that reduces the intestinal absorption of fat and may 
enhance the effects of dietary and behavioural therapy on weight loss and maintenance. This 
study examined the effect of orlistat on dietary intake, especially fat intake, during long-term 
weight maintenance.  
Methods Subjects were 44 men and women (age: 18-63 years; BMI: 37.5 ± 4.3 kg m-2) 
included in the Scandinavian Multicenter study of Obese subjects with the Metabolic 
Syndrome, a three-year clinical trial of orlistat or placebo following an eight-week very low 
energy diet (VLED). Two months after the end of the trial when the use of orlistat was 
optional, 33 subjects remained in the study. A dietary interview based on a validated food 
frequency questionnaire was conducted before the VLED, after one year of treatment with 
orlistat or placebo and two months after the end of the trial.  
Results At one year, dietary intake did not differ between the orlistat and placebo group. 
Energy percent (E%) fat was reduced and E% carbohydrate was increased within both 
groups. Two months after the end of the trial, E% fat was 32.6% (SD 6.2%) in subjects that 
chose to take orlistat and 27.7% (SD 5.5%) in subjects not taking orlistat (between group 
difference -5.0% [95%CI -9.2 to -0.7]; P=0.021).  
Conclusion Use of orlistat compared with placebo in a lifestyle modification program does 
not appear to influence dietary intake. Subjects that chose to take orlistat after the end of the 
program did not comply with dietary recommendations and this may hamper the effect of the 
drug.
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Introduction
Given the worldwide increase in obesity and its health consequences, efficient strategies for 
its prevention and treatment are important. It has been recommended that weight reduction 
programs focus on achieving a modest weight loss of 7% to 10% of the initial weight 
(Grundy, 2005). Behavioural and dietary therapies are the cornerstones of weight reducing 
programs. However, long-term adherence to the diet is difficult and pharmacological therapy 
has been proposed as an adjunct to diet and lifestyle changes to improve treatment outcomes.    
Orlistat has been shown to improve weight loss compared to placebo in behavioural 
treatment programs (Rucker et al., 2007). The drug is a pancreatic lipase inhibitor that 
reduces the intestinal absorption of fat. About 30% of dietary fat is not metabolised, but 
excreted in the faeces (Guerciolini, 1997). If the dietary intake of fat is higher than 
recommended, abdominal symptoms including oily spotting, faecal incontinency and flatus 
ensue. As part of a dietary and behavioural treatment program, orlistat may promote weight 
loss in two ways: 1) by the loss of energy as fat in the stools due to the pharmacological 
effect of the drug and 2) by improving adherence to a low fat diet. Because gastrointestinal 
symptoms may occur after the intake of fatty food, orlistat is thought to act as a policing 
influence in daily food choices. However, this notion has not been substantiated in studies 
conducted to date (Franson & Rössner, 2000; Krempf et al., 2003).  
The effect of anti-obesity drugs is likely to be counteracted by compensatory changes 
in food intake and energy expenditure to maintain a stable body weight over time, unless 
changes in lifestyle are made simultaneously (Speakman, 2004). However, the motivation to 
maintain lifestyle changes may be attenuated by the use of a drug (or its placebo) for weight 
reduction. For example, studies have shown only minor weight reductions in the placebo arm 
of recent studies of anti-obesity drugs (Pi-Sunyer et al., 2006). Subjects that are taking an 
active, effective drug may be less likely to comply with dietary advice than subjects taking 
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placebo. Moreover, data is sparse with regard to the dietary intake of individuals that take 
anti-obesity drugs for weight maintenance compared to those that choose not to use such 
drugs.  
The results of the Scandinavian Multicenter study of obese subjects with the 
Metabolic Syndrome (SMOMS) have been reported elsewhere (Richelsen et al., 2007). In 
short, the study was a double-blinded, randomized clinical trial comparing the effects of 
orlistat and placebo on weight maintenance after weight loss following an eight-week very 
low energy diet (VLED) in subjects with components of metabolic syndrome. After the 
VLED, the subjects were randomized to orlistat or placebo for three years. During weight 
maintenance, all the subjects participated in a dietary and behavioural treatment program and 
special emphasis was given to the reduction of fat intake. The main result of the study was 
that after three years, participants receiving orlistat maintained 2 kg more of their weight loss 
compared with participants receiving placebo (Richelsen et al., 2007). The present study 
included all subjects that participated in SMOMS at the Oslo centre.  
The aims of the study were to: 
1. Examine whether there were differences in dietary intake, in particular fat intake, 
among subjects treated with orlistat or placebo one year after randomization.  
2. Examine whether there were differences in dietary intake among participants that 
chose to take or not to take orlistat two months after the end of the trial when the use 
of orlistat was optional.  
 
Subjects and methods 
Subjects with a body mass index (BMI) >30 kg m-2 were recruited to take part in a placebo-
controlled, multi-centre trial of orlistat for weight maintenance following a VLED. Subjects 
were eligible for the trial if they met the following criteria for the metabolic syndrome: 
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abdominal obesity (waist circumference > 92 cm for females and > 102 cm for males) and at 
least one or more metabolic risk factor including an impaired fasting glucose (> 6.1 mmol L-1 
and < 7.1 mmol L-1) or diet treated type 2 diabetes and/or dyslipidaemia (HDL-cholesterol 
<1.1 mmol L-1 for females and 0.9 mmol L-1 for males) and/or triglycerides >2.0 mmol L-1. 
The study was initiated before the National Cholesterol Education Program (NCEP) proposed 
definitions of the metabolic syndrome in 2001 (Expert Panel, 2001). In the NCEP definition 
at least three of the metabolic risk factors have to be present to define the metabolic 
syndrome. Thus, some of the subjects in this study did not have the full metabolic syndrome 
according to the NCEP criteria. Therefore the phrase “components of the metabolic 
syndrome” is used. Subjects were excluded if they had clinically relevant conditions that 
might affect the outcome of the trial. The Ethical Committee (region 1 in Norway) approved 
the protocol and all participants gave written informed consent. The study was conducted 
between November 1998 and January 2003. 
Study design 
After the screening visit, all subjects initiated a VLED (800 kcal [3.4 MJ] day-1) for eight 
weeks. Immediately following the VLED subjects were randomized to orlistat 120 mg three 
times day-1 or to matching placebo three times day-1 for three years. Subjects were scheduled 
to attend 24 clinical visits during the first 18 months and every third month during the next 18 
months for a total of 30 visits. Weight was monitored, tablets were counted and adverse 
events were reported at every visit. At the last visit in the trial, subjects chose to take or not to 
take orlistat as treatment to facilitate weight maintenance after the end of the trial. 
At every visit the participants met with a registered dietitian. For the first 18 months 
the dietary behaviour program consisted of scheduled group sessions for four to six subjects. 
Individual sessions were offered only when subjects were unable to attend the scheduled 
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visits. For the last 18 months of the study, only individual sessions were offered. Each of the 
individual and group sessions lasted for about 30 min. 
During the dietary and behavioural treatment program, the subjects were instructed to 
follow a diet consisting of <30% of energy from fat and to decrease the intake of saturated fat 
to <10% of energy while allowing for a small amount of unsaturated fat from fatty fish and 
plant sources. The subjects were to increase the intake of fibre from vegetables, legumes, 
fruits and whole meal bread, to choose low fat diary products and lean meat or chicken in 
stead of minced meat and sausages, and to reduce the intake of cakes/biscuits, ice cream, 
chocolate, sugar containing beverages and alcohol to achieve a energy deficit of 600 kcal (2.5 
MJ) day-1 giving the possibility for further weight reduction when the subjects were highly 
motivated. Subsequently the subjects increased the energy intake. 
In the group session’s exhibitions were used to illustrate the amount of fat in foods.  
Subjects were taught to read food labels, make a plan for mealtimes and plan menus. Subjects 
were instructed to use a plate model for hot meals and advised to fill one-half of the plate 
with vegetables, one-fourth with potatoes, rice or pasta and one-fourth with meat, chicken, 
fish and/or legumes. The plate model was recommended at occasions such as eating with 
friends, at parties and at restaurants. The subjects were given exercises to assess eating 
behaviour and to plan specific strategies to avoid pitfalls (Melin & Rössner, 2003). The 
behavioural program otherwise included features such as goal setting, stimulus control and 
cognitive restructuring. 
 
Dietary assessment 
The dietician assessed dietary intake by an interview based on a food frequency questionnaire 
(FFQ)(Andersen et al., 1999; Lindroos et al., 1993). The first dietary interview was 
conducted immediately before the VLED period. The second dietary interview was 
 6
conducted 11 ± 2 months after randomization to orlistat or placebo. The third dietary 
interview was conducted 10 ± 4 weeks after the end of the trial. Dietary data was missing for 
two subjects at the one-year examination. As a supplementary check of dietary compliance a 
24 h dietary recall was conducted in 33 subjects (15 subjects in the placebo group and 18 in 
the orlistat group) one year after randomization. 
The dietary interview was conducted by a registered dietician and lasted between one 
and two hours. The FFQ was designed to assess habitual food intake during the last three 
months. The questionnaire elicited frequencies and consumption of 174 individual food items 
or constellations of items grouped together according to the typical Norwegian meal pattern. 
Particular attention was given to extra layers of bread-spread, food eaten during meal 
preparation, fat used in frying and extra portions of dinner and dinner leftovers. The between 
meal intake of sweet baked goods, cookies, cakes, ice cream, desserts, sweets, chocolate and 
snacks as nuts, potato crisp and popcorn was specifically queried. An atlas of food portions as 
well as photographs, household measurements and ordinary models of sweets and snacks was 
used to estimate portion sizes. The FFQ was coded manually for the calculation of energy 
intake (EI), energy yielding nutrients and food items using a software program (Mat på data 
3.0, Landsforeningen for kosthold og helse, Oslo, Norway, 1996) based on the Norwegian 
food composition table (Rimestad et al., 1995). The FFQ has been validated against doubly 
labelled water (Svendsen & Tonstad, 2006). Despite underestimation of energy intake the 
FFQ method showed better reporting accuracy assessed by the ratio of EI to total energy 
expenditure (TEE) compared to three days of dietary records (EI/TEE = 0.824 according to 
the FFQ and EI/TEE = 0.704 according to the dietary records, P<0.001). 
Because underreporting may impair the validity of dietary reports (Subar et al., 2003) 
total energy expenditure was measured to validate the dietary intake data. Physical activity 
was recorded for three consecutive days by ActiReg®, an electromechanical device which 
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records the main body positions (standing, sitting, bent forward and lying down) together 
with motion of the trunk and/or one leg each second. The ActiReg® method uses a 
combination of position changes and movements not acceleration, to estimate the energy cost 
of the activity. An especially developed computer program (ActiCalc®) was used to calculate 
total energy expenditure. The calculation model is based on the estimated energy cost of the 
body position and activity expressed as physical activity ratios (the ratio of energy 
expenditure to resting metabolic rate) combined with the number of position changes each 
minute. Total energy expenditure was calculated by summarizing the calculated energy 
expenditure for each minute of the measurement period (Hustvedt et al., 2004). Total energy 
expenditure calculated by the ActiReg® system has shown valid estimates in obese subjects 
compared to total energy expenditure measured by the doubly labelled water method 
(Hustvedt et al., 2008). The resting metabolic rates were calculated with the Mifflin formula 
(Mifflin et al., 1990) as this equation has shown valid estimates of resting metabolic rate in 
obese subjects (Frankenfield et al., 2005; Tooze et al., 2007). The physical activity level was 
calculated as the ratio of total energy expenditure to resting metabolic rate. In weight stable 
subjects energy intake equals energy expenditure (i.e. EI/TEE = 1). The EI/TEE was 
calculated before the VLED, at one year after randomization and at the final assessment. 
The ActiReg® recording was missing for four subjects before weight reduction due to 
technical problems. At one year and at the final visit, five and six subjects, respectively, were 
unwilling to take part in the procedure.  
Anthropometrics and biochemical measurements 
Participants were weighed wearing light indoor clothing and no shoes with a digital scale at 
every visit. The average of two measurements was recorded. Height was measured once 
using a standard scale. Blood pressure was measured automatically with a digital blood 
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pressure monitor (OMRON Hem-705 CP) in sitting position. Waist was measured midway 
between lower costa and crista while the participant was unclothed and standing and hip 
circumference was measured at the level of the greater trochanter. 
Fasting (10 hour overnight) blood samples were collected according to the protocol of 
the SMOMS trial and laboratory parameters (serum total cholesterol, high density lipoprotein 
cholesterol, triglycerides, and glucose) were analyzed centrally in the SMOMS trial 
(Medilab, Copenhagen, Denmark).  
Statistical analysis 
Descriptive statistics were performed and presented as means (SD), means (95% CI), median 
(25th.,75th. percentile). For normally distributed variables mean differences within and 
between groups were tested with paired- and unpaired t-tests, respectively. For skewed 
variables differences within each group were tested with the Wilcoxon signed rank test and 
differences between groups were tested with the Mann-Whitney two-sample rank test. The 
Chi squared test was used in comparisons of categorical variables. Pearson’s correlation 
coefficient was used to test agreement between the dietary methods. The tests were 
considered significant at P<0.05. Statistical analyses were performed using Stat View 5.0.1 
(Abacus concepts, Berkeley, CA, USA). 
 
Results 
Fifty-two subjects were randomized after the VLED period to orlistat or placebo. Six subjects 
dropped out before one year. One subject refused to participate in the dietary assessment and 
one subject had received formal dietary counselling just before entering the trial and was 
excluded. Thus 44 subjects were available at one year. There were 10 further dropouts 
leaving 34 subjects at the end of the trial. At this time-point nine of 17 subjects in the orlistat 
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group chose to continue with orlistat and five of 16 subjects in the placebo group started 
orlistat giving a total of 14 subjects who were taking orlistat two months after the end of the 
trial. Eleven subjects in the placebo group continued without orlistat and eight subjects in the 
orlistat group stopped treatment giving a total of 19 subjects who were not taking orlistat 
after the end of the trial. One final subject chose sibutramine and was excluded from the end 
of trial population. Table 1 shows the characteristics of the subjects before starting the 
VLED.   
 
Dietary intake before the VLED and one year after randomization  
The placebo and orlistat groups achieved almost similar dietary changes with no differences 
between the groups. The energy percent from fat and sucrose decreased and the energy 
percent from carbohydrate increased. The reduction in energy percent from fat was 9.6% 
(95% CI –12.6 to -6.6) in the orlistat group and 10.2% (95% CI -13.0 to -7.4) in the placebo 
group (P = 0.8 between the groups). The energy percent from fat ranged from 19.7% to 
39.9% in the orlistat group and from 14.6% to 37.9% in the placebo group. The between 
group change in energy percent from fat was -0.6% (95% CI - 4.9 to 3.7). This was 
confirmed by the 24 h dietary recall as showed that the energy percent from fat was 30.6% 
(SD 9.1%) in the orlistat group and 29.4% (SD 9.1%) in the placebo group (P = 0.5). Energy 
percent from fat calculated by the two methods showed significant correlations (r = 0.513, P 
= 0.010). EI/TEE ratio was similar in both groups (Table 2) as were the intakes of fat-soluble 
vitamins, fibre and cholesterol (data not shown). The intake of butter and cream was higher in 
the orlistat group than in the placebo group (Table 3).  
 
Dietary intake two months after the end of the placebo controlled trial  
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Subjects that did take orlistat reported a higher percent of energy from fat than subjects that 
did not take orlistat two months after the end of the trial (Table 4). In subjects that took 
orlistat the energy percent from fat was 32.6% (SD 6.2%) and in subjects that did not take 
orlistat the energy percent from fat was 27.7% (SD 5.5%) (mean between group difference -
5.0% [95% CI -9.2 to -0.7]; P = 0.021). The energy percent from fat ranged from 25.1% to 
46.3% among subjects taken orlistat and from 16.9% to 40.8% among subject not taking 
orlistat. The EI/TEE ratio was similar in both groups (Table 4) as were the intakes of fat-
soluble vitamins, fibre and cholesterol (data not shown). The reported intake of food items 
between the groups did not differ significantly (data not shown).  
 
Change in weight during the placebo controlled trial  
The eight-week VLED resulted in a weight loss of 13% (SD 3%) with no difference between 
the orlistat or placebo groups (-13.0% in the orlistat group vs. –12.7% in the placebo group, 
P=0.8). At one year the mean weight had increased by 2% (SD 7%) in the orlistat group 
versus 3% (SD 7%) in the placebo (P = 0.5). The overall weight reduction during the study 
was 7.2 kg (SD 8.1 kg) in the orlistat group and 3.9 kg (SD 7.4 kg) in the placebo group (P = 
0.2).    
 
Adverse events  
The tablet counting showed that one subject in the placebo group and one subject in the 
orlistat group reported less than 60% compliance with the study drug. The results are shown 
for the intent-to-treat population, but very similar trends were seen when the non-compliant 
subjects were excluded from the analyses with one exception. The difference in reported 
intake of butter and cream only achieved borderline significance (P=0.053). Sixteen subjects 
(16/21) in the placebo group and 20 (20/23) in the orlistat group (P = 0.4) reported adverse 
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events possibly or probably related to the drug once or more during the trial. Both groups 
reported abdominal pain, increased defecation, decreased defecation, soft stool, liquid stool, 
faecal urgency and flatulence. Subjects in the placebo group were the only ones that reported 
nausea and faecal incontinency, while subjects in the orlistat group were the only ones that 
reported frequent stool, vomiting, fatty evacuation and oily spotting (data not shown).  
Discussion
In obese subjects with metabolic risk factors the use of orlistat did not change dietary intake 
during long-term weight maintenance compared to placebo. After the end of the study, 
dietary intake of fat was higher in subjects taking orlistat compared to subjects that did not 
choose to take orlistat. During the entire study the subjects participated in a behavioural 
treatment program and were monitored in a clinical trial. The physical activity level did not 
differ between the groups. Hence any differences in weight maintenance between the orlistat 
and placebo groups were potentially due to orlistat and/or the diet. The findings of this study 
suggest that orlistat did not reduce dietary fat intake beyond that due to the structured 
behavioural treatment programme for weight reduction and maintenance. The novel finding 
of this study was that dietary intake of fat was higher than recommended in subjects that 
chose to take orlistat when it’s use was optional compared to subjects not taking orlistat.  
In the first part of the study the group randomised to orlistat did not achieve further 
reduction in fat intake compared to subjects randomised to placebo. The mean intake of 
dietary fat in both the orlistat and placebo groups was reduced to well below the 
recommended limit of 30% of energy from fat after one year, a reduction of about 10% 
compared to the subjects’ habitual diet prior to the VLED. Intakes above this level are likely 
to increase the gastrointestinal adverse events according to the manufacturer (Summary of 
Product Characteristics, 2005). Indeed, a reduced intake of fat was seen in the orlistat group 
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compared to the placebo group in binge eaters eating a high fat diet (Golay et al., 2005). The 
present study confirmed the finding of Hill et al. showing no difference between the orlistat 
and placebo group when dietary intake of fat was low (Hill et al., 1999). It seems like 
subjects taking orlistat did not need a further reduction in fat intake to avoid gastrointestinal 
events.  
In the second part of the study, the dietary intakes of subjects who chose to take 
orlistat were compared to the dietary intake of the subjects that did not take orlistat after the 
end of the trial. Subjects who chose to take orlistat after the end of the trial appeared not to 
comply with the dietary recommendations. They reported a higher energy percent from total 
fat compared to those that did not take the drug. The total fat intake was within the limits of 
25% to 35% that is generally recommended for weight maintenance (McManus et al., 2001; 
Wing RR et al., 2005; Schoeller & Bucholz, 2005). However, increasing fat intake has been 
associated with a lesser efficacy of orlistat (Ulrich et al., 2003). The mean intake of saturated 
fat was above the recommended level, reflecting a lack of compliance with the dietary 
instruction that was given. It can be hypothesised that subjects who chose to take orlistat may 
have been less likely than subjects that did not choose orlistat to follow dietary instructions 
because of awareness of the action of orlistat on fat loss in the stools. Furthermore, the 
subjects may have chosen to take orlistat because of non-compliance with the diet.  
   The dietary methods used in this study were retrospective and the subjects may not 
have remembered foods and estimated portion sizes accurately. However, in previous studies, 
the FFQ showed better agreement with energy expenditure measured with the doubly labelled 
water method when compared to dietary records (Svendsen & Tonstad, 2006). Nevertheless, 
underreporting of energy intake was obvious in both groups. This is in accordance with 
numerous other studies showing that obesity accentuates this phenomenon (Hill & Davies, 
2001; Livingstone and Black, 2003; Subar et al., 2003; Svendsen & Tonstad, 2006) and that 
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the obese selectively underreport sweets and fatty foods (Goris et al., 2000; Svendsen & 
Tonstad, 2006).  In the present study underreporting was assessed by estimating total energy 
expenditure based on a recording of physical activity with ActiReg®. This method has shown 
good agreement with total energy expenditure measured by the doubly labelled water method 
in obese subjects with metabolic syndrome (Hustvedt et al., 2008). However, total energy 
expenditure may be slightly underestimated by the ActiReg® method. Thus, the actual intake 
of fatty foods may have been higher than reported in this study. Despite an obvious 
underreporting of dietary intake, the diet deteriorated during long-term weight maintenance 
therapy.  
Limitations of the study were the small sample size and the number of dropouts. High 
dropout rates are typical of long-term studies of obesity (Pi-Sunyer et al., 2006; Richelsen et
al., 2007). The overall maintained weight loss during the three-year trial was about 4 kg in 
the placebo group and 7 kg in the orlistat group (NS). In the entire study population, the 
difference between the groups was statistically significant (Richelsen et al., 2007), but was 
not statistically significant at the Norwegian centre, due to the small sample size. Total 
energy expenditure was reduced in the orlistat group compared to the placebo group. This 
may be explained by a reduction in resting metabolic rate due to lower body weight and a 
slightly reduction (not statistically significant) in physical activity level. More research is 
needed on dietary intake of subjects that chose to take an anti-obesity drug for long-term 
weight maintenance after weight loss.  
The use of the VLED may be questioned. However, the method has been 
recommended for weight loss purposes, providing the diet is followed by a 1-2 years 
integrated weight maintenance programme consisting of lifestyle interventions involving 
dietary change, nutrition education and behavioural therapy (Astrup & Rössner, 2000) as was 
given in the SMOMS trial (Richelsen et al., 2007). Given the overall result of the SMOMS 
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trial, the method seems safe and effective and improvement in weight maintenance may be 
achieved with the use of orlistat.   
 
Conclusion
The use of orlistat did not lead to a lower fat intake compared to placebo in obese subjects 
participating in a structured program for weight loss and maintenance. The drug did not show 
a policing effect on daily food choices in subjects consuming a low fat diet. Subjects that 
chose to take orlistat did not comply with dietary fat recommendations and this may hamper 
the effect of the drug. 
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Table 1 Characteristics of the participants before weight loss. 
        ____________________  
Orlistat group  Placebo group 
        ____________________ 
Male/female, n    11/12   10/11  
Age (years)     49.1 (8.2)  46.6 (10.9)†  
Cigarette smokers, n     5    5  
BMI (kg m-2)     37.0 (4.0)   38.1 (4.6) 
Waist (cm)        
Male     122.8 (7.7)  122.4 (10.6) 
 Female    106.4 (8.9)*  115.4 (9.1) 
Waist-to-hip ratio    1.0 (0.1)  1.0 (0.1) 
Systolic blood pressure (mmHg)  141 (20)  140 (15) 
Diastolic blood pressure (mmHg)  86 (11)  85 (10) 
Total cholesterol (mmol L-1)   6.0 (1.3)  6.3 (0.8) 
HDL cholesterol (mmol L-1)   1.1 (0.3)  1.1 (0.2) 
Triglycerides (mmol L-1)   2.2 (0.8)  2.9 (2.2) 
Glucose (mmol L-1)    6.4 (2.0)  7.1 (3.0) 
        ____________________ 
† Mean (SD) and all such values.  
* p<0.05; Difference between the orlistat group and the placebo group (unpaired t-test).
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Appendix 1 

11
Matvaner og matvarevalg 
Navn:
Har du endret matvanene dine i løpet av de siste tre månedene?
Begrenser du matinntaket for øyeblikket?
1. MÅLTIDSRYTME
Med mellommåltid mener vi et lite måltid som f.eks. kake, frukt, sjokolade eller snacks etc. Drikke uten tilbehør regnes ikke 
som måltid. 
Gang per måned    Gang per uke    Klokkeslett  
0 <1 1 2 3  1 2 3 4-5 6-7 
Frokost        _______ 
Mellommåltid formiddag   _______
Lunsj        _______
Mellommåltid ettermiddag   _______
Middag        _______
Mellommåltid kveld     _______
Kveldsmat       _______
Nattmat        _______
Hvordan fordeler du maten i løpet av døgnet? 
Jevnt fordelt på måltider   Mest til middag   Mest til lunsj Mest utover kvelden/natten 
2. HVOR MYE BRØD PLEIER DU Å SPISE?
Legg sammen det du bruker til alle måltider  (1/2 rundstykke = 1 skive) 
           antall skiver x antall dager per uke      Sum 
Frokost  Lunsj  Middag  Kvelds  
Fint brød        
(loff, baguett, pita, fine rundstkykker)
Mellomgrøvt brød       
(helkorn, kneip, lys hjembakt, kneiprundstykker) 
Grovt brød         
(fiberkneip, grovt hjembakt, grove rundstykker)
Lyst knekkebrød    
(kavring)
Grovt knekkebrød      
(skonrokk)
Flatbrød   
Smørbrødkjeks      
Sum antall skiver/enheter per uke: ________________________________________________
Hvor tykke brødskiver skjærer du?   Bilde _________________________________________  
22
3. SMØREFETT
Hvor mye smør/margarin bruker du per skive? Bilde ______________________________________    
Hva pleier du å smøre på brødet?
Smør   antall   Vita-lett    antall     
Bremyk   antall   Soft light     antall     
Brelett    antall   Olivero     antall     
Soya soft    antall   Omega 3     antall     
Vita     antall   Annet _______   antall
4. PÅLEGG
Tenk deg din brødmat i løpet av en uke. Hvor mange skiver har du med følgende pålegg?
Antall skiver per uke            Kommentar
0    ½ 1 2-3 3-5 6-7 8-10  11-14 15-21 21-28 29-35 
Brun ost; helfet     ______________
Brun ost; halvfet, prim   ______________ 
Hvit ost > 27% fett     ______________
Hvit ost; 27% fett     ______________
Hvit ost; 16% fett     ______________
Magerost; <10% fett   ______________
Kjøttpålegg >20% fett   ______________
Kjøttpålegg 10%-20% fett   ______________ 
Kjøttpålegg <10% fett    ______________
Leverpostei      ______________
Lett-leverpostei     ______________
Kaviar, rognleverpostei   ______________ 
Fet fisk som pålegg    ______________ 
Røkt, gravet fisk     ______________ 
Reker, krabbe      ______________
Fiskepudding, crabstick   ______________
Syltetøy, marmelade   ______________
Lett-syltetøy, frysetøy   ______________
Honning, sirup     ______________
Sjokoladepålegg   ______________
Peanøttsmør   ______________
Grønnsaker som pålegg   ______________
Frukt som pålegg     ______________
Majonessalat   ______________
Lett-majonessalat etc.   ______________
Majones over/under   ______________
Lett-majones over/under   ______________
Ikke noe pålegg     ______________
Pålegg spist uten brød i forbindelse med tillaging, ekstra lag, pynt osv.
33
Antall skiver per uke            Kommentar
0    ½ 1 2-3 3-5 6-7 8-10  11-14 15-21 21-28 29-35 
Brun ost; helfet     ______________
Brun ost; halvfet, prim   ______________ 
Hvit ost > 27% fett     ______________
Hvit ost; 27% fett     ______________
Hvit ost; 16% fett     ______________
Magerost; <10% fett   ______________
Kjøttpålegg >20% fett   ______________
Kjøttpålegg 10%-20% fett   ______________ 
Kjøttpålegg <10% fett    ______________
Leverpostei      ______________
Lett-leverpostei     ______________
Kaviar, rognleverpostei   ______________ 
Fet fisk som pålegg    ______________ 
Røkt, gravet fisk     ______________ 
Reker, krabbe      ______________
Fiskepudding, crabstick   ______________
Syltetøy, marmelade   ______________
Lett-syltetøy, frysetøy   ______________
Honning, sirup     ______________
Sjokoladepålegg   ______________
Peanøttsmør   ______________
Grønnsaker som pålegg   ______________
Frukt som pålegg     ______________
Majonessalat   ______________
Lett-majonessalat etc.   ______________
Annet      ______________
5. EGG
Hvor ofte spiser du egg? Stekt, kokt, eggerøre, omelett etc.    
Antall per måned    Antall  per uke    Antall per dag  
0 <1 1 2 3  1 2 3-4 5-6 7   1 2 3 4 5 6 
   
6. GRYN, FLAK OG KORNBLANDINGER MED TILBEHØR OG YOGHURT
Hvor ofte spiser du gryn flak, kornblandinger? 
Gang per måned    Gang per uke      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    
    
Hvor ofte spiser du havregrøt?
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  Bilde  1 2 3 4 5 6 
    
Hvor ofte spiser du havregryn, usøtet müsli, Go´dag, Bran flakes? 
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde  1 2 3 4 5 6 
    
Hvor ofte spiser du søt müsli f.eks Tropisk müsli, Solfrokost?
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde  1 2 3 4 5 6 
    
Hvor ofte spiser du Cornflakes, havrenøtter, japansk ris, kavring?
44
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde  1 2 3 4 5 6 
    
Sukker til frokostkorn, gryn og grøt
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  ss   1 2 3 4 5 6 
    
Syltetøy til frokostkorn, gryn og grøt
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  ss   1 2 3 4 5 6 
    
Helmelk, kefir       
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  dl   1 2 3 4 5 6 
    
Lettmelk, Cultura, Drikkeyoghurt, Biola melk
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  dl   1 2 3 4 5 6 
    
Ekstra lett lettmelk       
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  dl   1 2 3 4 5 6 
    
Skummet melk,  Skummet kultur
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  dl   1 2 3 4 5 6 
    
Yoghurt, naturell og frukt
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  dl  1 2 3 4 5 6 
    
Lettyoghurt
Gang per måned    Gang per uke    Mengde 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  dl  1 2 3 4 5 6 
    
7. KAFFE, TE OG KAKAO
Antall kopper per uke   Antall kopper per dag 
1 2 3 4 5 6  1 2 3-4 5-6 7-8 9-10 11-12 
Kaffe, kokt          
Kaffe, trakte/filter    
Cappucino     
Te             
Grønn te      
Iste       
Kakao           
Tilbehør:    Antall per kopp     Kopper per uke   Kopper per dag  
½ 1 2 3 4 5  1 2 3 4 5 6  1 2 3-4 5-6 7-8
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Sukker til kaffe (ts)
Sukker til te   (ts)
Fløte i kaffe   (ss)
Helmelk i kaffe/te (ss)
Lettmelk i kaffe/te  (ss)
Skummet melk i kaffe/t (ss)
Krem i kakao   (ss)
Suketter    (stk) 
Sitron i te   
8. DRIKKE 
Helmelk, kefir   
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Lettmelk, Cultura, Milkshake, Sjokomelk, Biola melk    
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Skummet melk, skummet kultur  
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Ekstra lett lettmelk       
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Vann     
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Grønnsakjuice, tomatjuice, gulrot juice       
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Appelsinjuice   
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Grapefruktjuice, druejuice  
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Eplenektar, tropisk m.m.   
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Saft
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
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2 dl
Lettsaft
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Brus   
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Lettbrus
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Farris
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2 dl
Alkoholfritt øl, lettøl, vørterøl
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
3.3 dl
Pils
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8+  glass 1/2 1 2 3 4 5 6 7 	8
0.5 l 
Rødvin
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
1.2 dl
Hvitvin
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
1.2 dl
Likør 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
2.5 cl
Sprit (brennevin, konjakk, snaps, whisky, rusbrus)
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  glass 1/2 1 2 3 4 5 6 7 	8
4.0 cl
9. VARMRETTER, SMÅRETTER OG MIDDAGSRETTER
Hvor ofte spiser du varmretter, småretter og middagsretter?
Gang per måned    Gang per uke     Gang per dag 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10   1 2 3 4 5 6 
   
Hvor ofte spiser du varmrett på kafé/kantine?
Gang per måned    Gang per uke     Gang per dag 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10   1 2 3 4 5 6 
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Hvor ofte spiser du på restaurant? 
Gang per måned    Gang per uke      Gang per dag 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6 
    
Hvor ofte spiser du fast food som wienerpølse, hamburger, kebab fra gatekjøkken etc.?
Gang per måned    Gang per uke      Stk. 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2  Stor Brød Kommentar: ________ 
    Liten Lompe 
Hvor ofte spiser du pølser, kjøttpudding, farsekaker?    Medium 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
  stk.  
Hvor ofte spiser du lett-pølser, kalkun- og lette kjøttprodukter?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
  stk.  
Hvor ofte spiser du hamburger, karbonadekaker, kjøttkaker, kjøttboller, løvbiff m.m?
Gang per måned    Gang per uke    Mengde       Karbonadedeig 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 Viltkarbonade 
    
Hvor ofte spiser du kjøttsaus, gryterett, Lasagne m.m.?
Gang per måned    Gang per uke    Mengde       
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 kjøttdeig 
    karbonadedeig
Hvor ofte spiser du bacon, flesk?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  g  10 20 30 40 50 60 
    
Hvor ofte spiser du nakkekotlett, ribbe, entrecote, T-bone steak, Flintstek, spekeskinke etc.? 
Gang per måned    Gang per uke    Mengde          Med fett 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6    Uten fett 
     Ant. g _____ 
Hvor ofte spiser du biff, stek, skinke, lam, vilt? 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
     Ant. g _____ 
Hvor ofte spiser du lever? 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
     Ant. g _____ 
Hvor ofte spiser du gryterett med renskåret rent kjøtt, lapskaus, kjøttsuppe?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du snitzel, steaklets, vårull m.m.? 
Gang per måned    Gang per uke    Mengde       Egenpanering 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
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  stk.  
Hvor ofte spiser du kylling, kalkun, høne?     
Gang per måned    Gang per uke    Mengde      Uten skinn 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1/4 1/2 3/4 1/1  Med skinn    
    Gryte 
Hvor ofte spiser du torsk, sei, kolje?
Gang per måned    Gang per uke    Mengde        Kokt 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  Gryte 
    Stekt
Hvor ofte spiser du fiskekaker, -boller, -grateng, -pudding?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du skalldyr, sushi m.m.? 
Gang per måned    Gang per uke    Mengde med skall
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  hg  1 2 3 4 5 6 
    
Hvor ofte spiser du makrell, sild, kveite, laks, ørret? 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  Gryte 
    Stekt
Hvor ofte spiser du panert fisk, fiskepinner?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du pizza? 
Gang per måned    Gang per uke    Mengde        Med skinke 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  Med kjøttdeig 
    Vegetar
Hvor ofte spiser du risgrøt/melkegrøt?
Gang per måned    Gang per uke    Mengde        Smørøye 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  Sukker 
    Kommentar:_______
Hvor ofte spiser du pannekaker?
Gang per måned    Gang per uke    Mengde        Syltetøy 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  stk  1 2 3 4 5 6  Sukker 
    Kommentar:________
Hvor ofte spiser du suppe?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  dl  1-2 3-4 5-6 7-8 9-10 10+  Med grønnsaker 
    
Type:________________________________________________________________________
Hvor ofte spiser du salat som hovedrett til middag?
Gang per måned    Gang per uke    Mengde       
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Type: ____________________________________________________________________ 
Hvor ofte spiser du salat til lunsj?
Gang per måned    Gang per uke    Mengde       
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
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Type: ____________________________________________________________________ 
Hvor ofte spiser du vegetarretter til middag?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Type: ______________________________________________________________________ 
10. POTETER, RIS OG PASTA
Hvor ofte spiser du kokte poteter?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  stk.  1 2 3 4 5 6 
       Str. ______ 
Hvor ofte spiser du kokt ris?     
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du makaroni, spaghetti og pasta? 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du pommes frites?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 gatekjøkken 
    uten fett
Hvor ofte spiser du stekte poteter? 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du potetmos? 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du fløtegratinerte poteter/grønnsaker?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du potetsalat?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
11. ROTFRUKTER, GRØNNSAKER OG BELGFRUKTER
Hvor ofte spiser du grønnsaker?
Gang per måned    Gang per uke      Gang per dag 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6 
    
Hvor ofte spiser rå gulrot? 1 stk.
Gang per måned    Gang per uke      Gang per dag     Stor 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6  Middels 
    Liten
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Hvor ofte spiser kokte gulrøtter?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du grønnsakblanding?
Gang per måned    Gang per uke    Mengde       Hermetisk 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 Frossen 
    Kommentar:________
Hvor ofte spiser du tomater? 
Gang per måned    Gang per uke    Mengde       Pålegg  Stor
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde ¼ ½ 1 2 3 4 I salat Middels  
    Stekt Liten  
Hvor ofte spiser du salat?
Gang per måned    Gang per uke    Mengde        Issalat Rosso
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  Kinakål 
    Bladsalat 
Hvor ofte spiser du råkost av grovere grønnsaker som kålrot, gulrot, hodekål?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du brokkoli?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  I salat Rå
    Kokt I gryter 
Hvor ofte spiser du rosenkål?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du spinat?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  I salat Rå
    Kokt I gryter 
Hvor ofte spiser du blomkål? 
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  I salat Rå
    Kokt I gryter 
Hvor ofte spiser du hodekål?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  Stuing Surkål
    Kokt I gryter 
Hvor ofte spiser du kålrot?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  Rotmos Rå
    Kokt I gryter 
Hvor ofte spiser du aspargesbønner, asparges, sukkererter?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  I salat Rå
    Kokt I gryter 
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Hvor ofte spiser du squash?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  I salat Rå
    Stekt I gryter 
Hvor ofte spiser du aubergine?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  I salat Rå
    Stekt I gryter 
Hvor ofte spiser du løk, hvitløk, purre?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  I salat Rå
    Stekt I gryter 
Hvor ofte spiser du sopp?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6  I salat Rå
    Stekt I gryter 
Hvor ofte spiser du paprika?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 I salat Pålegg 
    I gryter 
Hvor ofte spiser du mais?
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 I salat Frisk
    Hermetisk 
Hvor ofte spiser du avocado? 
Gang per måned    Gang per uke    Mengde        
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 I salat Egen rett 
    Pålegg 
Hvor ofte spiser du tomatbønner, bønner, linser, tørkede erter?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du tyttebær, sylteagurk, rødbet?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  ss  1 2 3 4 5 6 
    
Hvor ofte spiser du andre grønnsaker? 
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
       Type:
_____________
12. TILBEHØR
Hvor ofte spiser du seterrømme, creme fraiche?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du lettrømme?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
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Hvor ofte spiser du oljebasert dressing/remulade m.m.?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    Type: _____________ 
Hvor ofte spiser du fløtesaus?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
Hvor ofte spiser du smørbaserte sauser og smeltet smør/margarin?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
      Type: _____________
Hvor ofte spiser du tomatbaserte sauser, tomatpure, tomatketchup?
Gang per måned    Gang per uke    Mengde
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  bilde 1 2 3 4 5 6 
    
13. MATLAGNINGSFETT
I løpet av 1 uke, hvor ofte tilbereder du:
kokt, microbølget, bakt?  stekt/ fett i tillagningen Wok’et/ lite fett i tilagningen  
Når du steker/bruker fett i matlagningen, hvor mye fett bruker du? Bilde
Hvilke type fett bruker du i matlagningen?
Olivenolje Maisolje  Soyaolje  Olivero  Vita  Soya Bremyk Smør Melange  Flytende  
Rapsolje  Solsikkeolje                  margarin
                 
14. FRUKT OG BÆR
Hvor ofte spiser du frukt?
Gang per måned    Gang per uke    Gang per dag 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
Hvor ofte spiser du sitrusfrukter (appelsiner, klementiner, grapefrukt)?
Gang per måned    Gang per uke      Gang per dag     Stor 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6  Middels 
    Liten
Hvor ofte spiser du epler?
Gang per måned    Gang per uke      Gang per dag     Stor 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6  Middels 
    Liten
Hvor ofte spiser du pærer?
Gang per måned    Gang per uke      Gang per dag     Stor 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6  Middels 
    Liten
Hvor ofte spiser du bananer? 
Gang per måned    Gang per uke      Gang per dag     Stor 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6  Middels 
    Liten
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Hvor ofte spiser du druer?    
Gang per måned    Gang per uke    Bilde      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du plommer?
Gang per måned    Gang per uke    Stk per gang      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du moreller/kirsebær?
Gang per måned    Gang per uke    Stk per gang      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du melon?   
Gang per måned    Gang per uke    Skiver per gang    Kantaluppmelon     
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6  Vannmelon  
Honningmelon    
Hvor ofte spiser du fersken/nektariner?
Gang per måned    Gang per uke    Stk per gang      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du eksotiske frukter (papaya, mango, sharon, ananas, pasjonsfrukt, litchi, guawa, 
kumquat, granateple)?
Gang per måned    Gang per uke    Stk per gang      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
Type: ________    
Hvor ofte spiser du kiwi?
Gang per måned    Gang per uke    Stk per gang      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser jordbær, bringebær, rips, molter m.m.
Gang per måned    Gang per uke    Bilde     Sukker       
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 Fløte 
      
Hvor ofte spiser du tørket frukt (rosin, aprikos, fiken, banan, eple)?
Gang per måned    Gang per uke    Stk per gang      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
Type: ________    
15. DESSERT          
Hvor ofte spiser du fruktsalat, fruktgrøt, hermetisk frukt, gele?
Gang per måned    Gang per uke    Bilde      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
Kommentar: ____    
Hvor ofte spiser du iskrem?           
Gang per måned    Gang per uke    Bilde     Kroneis       
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 Softis 
Ispinne       
Hvor ofte spiser du yoghurtis/lettis?       
Gang per måned    Gang per uke    Bilde     Saftis      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
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14
Hvor ofte spiser du dessertpudding f.eks sjokolade-, karamell-, mandelkjernepudding m.m.?
Gang per måned    Gang per uke    Bilde      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du vaniljesaus?
Gang per måned    Gang per uke    Bilde      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du kremfløte?    
Gang per måned    Gang per uke    Bilde     Pisket       
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
16. KAKER OG KAFFEMAT
Hvor ofte spiser du kaker/kjeks?
Gang per måned    Gang per uke    Gang per dag 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
Hvor ofte spiser du wienerbrød? 
Gang per måned    Gang per uke    Gang per dag     Stort 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6  Middels 
Lite
Hvor ofte spiser du kremkake, bløtkake, Napoleonskake?      
Gang per måned    Gang per uke    Bilde      Marsipankake     
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du sjokoladekake, nøttekake, formkake, eplekake m.m.?
Gang per måned    Gang per uke    Bilde      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du søt gjærbakst som boller, kringle, julekake, skolebrød?
Gang per måned    Gang per uke    Stk per gang     Stor       
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6  Middels 
Liten       
Hvor ofte spiser du småkaker, kransekake, søte kjeks? 
Gang per måned    Gang per uke    Stk. per gang
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6  Fylt kjeks Sjokolade
Enkel kjeks 
Hvor ofte spiser du vafler? 
Gang per måned    Gang per uke    Plate
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6  Smør Syltetøy 
Lettrømme Brunost 
Hvor ofte spiser du lefser, lomper etc.? 
Gang per måned    Gang per uke    Stk.
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6  Fylt 
   
           
17. GODTERI OG SNACKS
Hvor ofte spiser du søtsaker og sjokolade?
Gang per måned    Gang per uke     Gang per dag 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10   1 2 3 4 5 6 
15
15
   
Hvor mange små sjokolader (<50g) spiser du?
Gang per måned    Gang per uke    Stk.      Ren Kjeks
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 Sukkerfyll 
Nøttefyll      
Hvor mange normalstore (50-100g) sjokolader spiser du?
Gang per måned    Gang per uke    Stk.      Ren Kjeks
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 Sukkerfyll 
Nøttefyll      
Hvor mange store sjokoladeplater (100-200g) spiser du?
Gang per måned    Gang per uke    Stk.      Ren Kjeks
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 Sukkerfyll 
Nøttefyll      
Hvor mange konfektbiter/småsjokolader spiser du?
Gang per måned    Gang per uke    Stk.      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor mye marsipan spiser du? 
Gang per måned    Gang per uke    Stk. á 50 g    Marsipanbrød       
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 Sjokoladetrekk 
      
Hvor mye søtsaker som karameller, lakris, vingummi, seimenn etc. spiser du?
Gang per måned    Gang per uke    Pose á 300g      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1/4 1/3 1/2 3/4 1/1 1,5 2
      
Hvor mye drops/pastiller spiser du?
Gang per måned    Gang per uke    Eske     Sukkerfri      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor ofte spiser du snacks og nøtter?
Gang per måned    Gang per uke    Stk.      
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1 2 3 4 5 6 
      
Hvor mye potetgull spiser du?
Gang per måned    Gang per uke    Stor pose
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1/4 1/2 3/4 1/1 1,5 2 
Hvor mye ostepop, popcorn o.l. spiser du? 
Gang per måned    Gang per uke    Pose
0 <1 1 2 3  1 2-3 4-5 6-7 8-10   1/4 1/2 3/4 1/1 1,5 2 
Hvor mye nøtter (peanøtter, mandler, hasselnøtter, valnøtter, cashewnøtter, pistasjnøtter)  
spiser du? 
Gang per måned    Gang per uke    Pose      saltet 
0 <1 1 2 3  1 2-3 4-5 6-7 8-10   1/4 1/2 3/4 1/1 1,5 2 
16
16
Stk.
1-5 6-10  10-15 15-20 20-30 30+ 
Hvor mye oliven spiser du? 
Gang per måned    Gang per uke    Stk.    
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  1-5 6-10  10-15 15-20 20-30 30+ 
18. TILSKUDD 
Hvor ofte tar du tran? 
Gang per måned    Gang per uke    Mengde       vinter
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  ss  1/2 1 2 3 4 5 periodevis 
  stk  kommentar: __________ 
Hvor ofte tar du omega-3 tilskudd? 
Gang per måned    Gang per uke    Mengde       vinter
0 <1 1 2 3  1 2-3 4-5 6-7 8-10  ss  1/2 1 2 3 4 5 periodevis 
  stk  kommentar: __________
Hvor ofte tar du multivitamintabletter? 
Gang per måned    Gang per uke    Mengde       vinter
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6 periodevis 
  stk.  kommentar: __________
Hvor ofte tar du vitamintabletter? 
Gang per måned    Gang per uke    Mengde       vinter
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6 periodevis 
  stk.  kommentar: __________
Hvor ofte tar du mineraltilskudd? 
Gang per måned    Gang per uke    Mengde       vinter
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6 periodevis 
  stk.  kommentar: __________
Hvor ofte spiser du soyaproteinpulver? 
Gang per måned    Gang per uke    Mengde       vinter
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6 periodevis 
  ss  kommentar: __________
Hvor ofte spiser du Nutribars? 
Gang per måned    Gang per uke    Mengde       vinter
0 <1 1 2 3  1 2-3 4-5 6-7 8-10    1 2 3 4 5 6 periodevis 
  stk.  kommentar: __________
20. PERSONALIA
Vekt:    Dato:      Antall personer i husstanden:
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